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Tuberculosis (TB) remains a global health burden, with an estimated 1.3 
million people dying from the disease in 2012. Protective immunity against TB 
is thought to depend on specific T cells. However, exactly which T cell 
characteristics are required for immunological protection is unknown. To gain 
a better understanding of M. tuberculosis (M.tb)-specific memory T cell 
immunity, we studied longevity and function of M.tb-specific memory T cells. 
We reasoned that such knowledge would facilitate rational vaccine design of a 
TB vaccine. 
We designed and developed a set of new HLA class II tetramers to perform 
in-depth studies of M.tb-specific CD4 T cell responses. We studied persons 
vaccinated with a novel TB vaccine, MVA85A, as well as persons naturally 
infected with M.tb.  Antigen-specific CD4 T cells were detected with HLA class 
II tetramers and functional and phenotypic attributes of these T lymphocytes 
characterised by standard flow cytometric techniques. Comprehensive 
transcriptional analyses of M.tb-specific CD4 T cells, which were also sorted 
by FACS, were performed by microfluidic quantitative real-time PCR.  
Early after intradermal vaccination with MVA85A a large proportion of Ag85A-
specific CD4 T cells were highly activated, expressed skin homing markers 
and displayed an effector T cell phenotype. This effector response waned 
rapidly and gave way to antigen-specific central memory CD4 T cells with high 
proliferative potential, which we proposed may be desirable for protection. 
However, recent results from the first efficacy trial of MVA85A in infants 
suggested that these cells are not sufficient to enhance protection beyond that 
induced by BCG vaccination at birth.   
Further, we characterised surface marker expression and transcriptional 
signatures of a newly detected and described population of M.tb-specific CD4 
T cells, that displayed a CD45RA+CCR7+CD27+ naïve-like T cell phenotype. 
We hypothesised that these unique M.tb-specific naïve-like CD4 T cells had a 
transcriptional profile distinct from truly naïve, central memory and effector 
bulk CD4 T cells, as well as other M.tb-specific memory CD4 T cell subsets.  
Gene expression of CFP10-specific naïve-like CD4 T cells reflected an mRNA 
profile that was very distinct from truly naïve bulk CD4 T cells. Rather, naïve-




analysis methods such as hierarchical clustering and principle component 
analyses. Further analyses revealed that naïve-like CFP10-specific  CD4 cells 
expressed mRNAs coding for effector cytokines, cytotoxic molecules and 
chemokine receptors consistent with effector memory T cells. However, the 
overall transcriptional profile was more similar to CFP10-specific central 
memory CD4 T cells than that of the effector CD4 T cells.  
We concluded that M.tb-specific naïve-like CD4 T cells may possess an ability 
to traffic to sites of infection or inflammation, where they may contribute to 
effector function. These hypotheses need confirmation on a protein level. 
 
The HLA class II tetramers developed in this thesis are valuabe tools for 
assessing direct ex vivo M.tb-specific CD4 T cell responses without activation 
and cell perturbation. Our findings contribute to a more comprehensive 
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Tuberculosis (TB) is an infectious disease, primarily of the lungs.  TB is 
caused by the bacterium, Mycobacterium tuberculosis (M.tb). However this 
bacterium can spread from the lung to other sites of the body and cause 
pathology, this is known as TB dissemination.  
 
1.1.1. Epidemiology 
One third of the world’s population is estimated to be infected with 
Mycobacterium tuberculosis (M.tb), the underlying cause of tuberculosis (TB) 
disease. South Africa ranks among the 22 countries with the highest 
incidence rates per capita of TB in 2013 in the world, with an estimated 1003 
incident cases per 100 000 people (WHO Global Tuberculosis Report 2013) 
as shown in Figure 1. It is estimated that 1.3 million people died from TB in 
2012 (WHO Global Tuberculosis Report 2013).  
Figure 1: The global distribution of new TB cases per 100 000 population, 
demonstrating how developing countries are most affected. (Adapted from the WHO 
Global Tuberculosis Report, 2013)!
!
An effective TB vaccine to prevent development of disease, in combination 
with improved diagnostic tests as well as improved drugs, would be the most 




et al. 2010; Abu-Raddad et al. 2009). The rational development of better TB 
vaccines and diagnostic tests is hampered by our incomplete knowledge of 
immunity to mycobacterial infection and how immunological protection can be 
achieved by vaccination (Dye 2012). 
 
1.1.2 Tuberculosis pathogenesis 
M.tb is an intracellular pathogen, which enters the host through inhalation of 
aerosolised micro droplets containing the bacilli. These bacilli are deposited in 
the lower airways of the lung where they are recognised as foreign and are 
engulfed by alveolar macrophages as well as dendritic cells (DCs) (Kaufmann 
& McMichael 2005). Macrophages recognise bacilli via pathogen associated 
molecular patterns, phagocytose the bacilli and, upon activation, can kill M.tb. 
M.tb has developed mechanisms to manipulate the immune system to its 
advantage. M.tb has been shown to modulate the maturation of the 
phagosomal compartment in the macrophage, preventing it from fusing with 
lysosomes, and thereby creating an environment in which it can survive and 
multiply (Sturgill-Koszycki et al. 1994). This allows persistence and 
establishment of infection, which can last for decades. M.tb has also been 
shown to inhibit host cell apoptosis (J. L. Miller et al. 2010; Velmurugan et al. 
2007), allowing prolonged survival in the cells. Exactly how these 
mechanisms are regulated remains elusive and is currently being studied in 
depth. 
 
DCs that have phagocytosed M.tb become activated and traffic to draining 
lymph nodes, where M.tb antigens are processed and presented by Human 
leukocyte antigens (HLA) molecules to naïve T cells (Reiley et al. 2008). 
These T cells are primed as explained in depth in section 1.3.2, undergo 
clonal expansion, and differentiate into effector cells that traffic back to the 
site of infection, the lung. Here, antigen-specific T cells release pro-
inflammatory cytokines, such as interferon gamma (IFN-") and tumor necrosis 
factor alpha (TNF-#) which activate macrophages, as well as releasing 
chemokines, which in turn recruit other cells to the site of infection. CD4 T 




and TNF-# production to become mycobactericidal. It has been suggested 
that some individuals have the capacity to completely clear the infection at 
this point, yet the mechanism has not yet been described and it is unknown 
how often this occurs. However, this is likely not the case for the majority of 
individuals who inhale M.tb.  Individuals with persisting bacilli are said to have 
latent TB infection (LTBI) or to have asymptomatic disease. The current 
methods used to test for M.tb infection cannot distinguish between a person 
who may have had infection and cleared it and those truly infected. These 
tests are proxies for infection and test for immunological sensitisation to 
mycobacterial antigens (Robertson et al. 2012). Latently infected individuals 
are asymptomatic but have a risk of progressing to TB disease. Latency is 
now seen as a spectrum of infection, varying from people who may have 
completely cleared the infection to those with varying degrees of bacterial 
loads. By definition, these persons present with absence of clinical symptoms 
but may have subclinical active disease (Barry et al. 2009).  
 
Infected macrophages may differentiate into several different morphotypes, 
including multi-nucleated giant cells and epitheloid cells. These cells 
aggregate, to form a structure known as a granuloma, which forms around the 
infected cells. The granuloma gains structure further, with macrophages 
containing bacilli in the center surrounded by lymphocytes, neutrophils and 
DCs forming a wall-like structure. This structure functions to contain the bacilli 
within this confined environment (Russell et al. 2009). T cells continue to 
produce cytokines such as TNF-# to maintain the structure of the granuloma 
(Russell et al. 2009). 
 
It is postulated that the failure to form, or a breakdown in the structure of 
granulomas, which may be due to immune compromise either immediately or 
at a later stage, can lead to unsuccessful containment of the bacilli, local 
dissemination and subsequently, progression or reactivation of TB disease.  
However, the precise role of the granuloma remains in question. Some hold 
the view that it is a crucial host protective structure essential to pathogen 




granulomas can also facilitate local spread of the infection (Rubin 2009). 
Recent studies have suggested that the granuloma may be an environment 
that promotes survival and spread of the bacilli. Ramakrishnan et al., have 
shown that intracellular mycobacteria, in the zebrafish model, recruited 
macrophages into the early granuloma where these macrophages become 
infected and then leave the granuloma again. The authors suggested that 
mycobacteria may use the host to facilitate spread of the bacilli (Davis & 
Ramakrishnan 2009; Ramakrishnan 2012).  
 
 
Figure 2: The possible outcomes upon inhalation of M.tb bacilli. (i) Upon infection it is 
postulated that some individuals may have the capacity to spontaneously clear the 
infection without developing any symptoms, (ii) Approximately 90% of individuals 
who become infected have the ability to contain the bacteria within a granuloma due 
to a well-orchestrated immune system, (iii) The other 10% of those who are infected 
develop disease during their lifetime, and this likelihood is increased by secondary 
infection. Risk of disease is highest in the first 2 years after infection and wanes, but 
reinfection increases the risk again. (Adapted from Kaufmann et al., Nature reviews 
2005). 
 
Studies of non-human primates (NHP) infected with M.tb and that go on to 
develop disease, have shown these NHP develop a spectrum of lung 
granulomas, similar to those observed in humans. Using [18F]-D-




tomography (CT) imaging, Lin et al., were able to show that the size and 
metabolic activity of granulomas within an individual NHP, and even within a 
lung varied. At necropsy, some of the lesions within a NHP were found to be 
sterile, while others had viable bacilli showing the dynamic within the 
granulomas and the variable levels of inflammation (Lin et al. 2013).  
 
Studies have shown heterogeneity within TB lesions in latently infected 
individuals at post-mortem (Vandiviere et al. 1956). Furthermore, the recovery 
of viable M.tb bacilli in these lesions is highly variable (Vandiviere et al. 1956). 
This heterogeneity has been suggested to reflect the immune response at 
different stages of infection of disease. The recent advances in imaging 
technology have allowed scrutiny of TB lesions in humans. High resolution CT 
provides structural data on the lung and lymph nodes as well as a spatial map 
of the granulomas within these tissues. CT scans of individuals with LTBI 
have shown a wide range of findings, some of which are characteristic of 
patients with active disease, though the individual shows no symptoms of 
disease (Goo et al. 2000). It is clear that this spectrum of disease or infection 
is hard to define, but advancements in technology have proven to be very 
informative in helping to begin to understand this. 
 
Due to the complexity of host-pathogen interaction, rational designs of 
interventions remain a challenge. 
 
1.2 Vaccines 
Vaccines are designed to induce immunological memory that protects for 
prolonged periods of time.  
 
1.2.1 Types of vaccines 
It is now known that a vaccine should contain parts of or all of the pathogen it 
is designed to protect against, so that the host’s immune system can 
recognise and respond to the pathogen upon challenge (Plotkin 2005). 
Vaccines can be categorized into 3 general groups; live attenuated vaccines, 





Live attenuated vaccines are made from wild or disease-causing organisms, 
either viral or bacterial, which have been modified or attenuated to weaken or 
remove pathogenic factors (Plotkin 2003). Attenuated organisms used for 
such vaccines have the ability to grow or replicate within the human host but 
are unable to cause severe disease (Plotkin 2003). Live vaccines often induce 
mild disease-like symptoms and adverse events, however they have been 
shown to efficiently prime the immune response for exposure to the actual 
pathogen and confer protection, as seen with live attenuated measles vaccine 
(Sudfeld et al. 2010). Live attenuated vaccines can generate humoral (B cells) 
and cellular (T cells) immune responses that confer protection. Many live 
attenuated vaccines, such as those against measles (Sudfeld et al. 2010); 
poliovirus (Grassly et al. 2007) and yellow fever (Pulendran et al. 2013), are 
administered worldwide and are remarkably effective. 
 
Inactivated or killed vaccines are comprised of completely inactivated 
pathogen, where a virus or bacterium is grown and then killed either by heat 
or with formalin. The organism therefore does not have the capacity to grow 
or replicate (Plotkin 2003). Usually these types of vaccines are not as 
effective as a live attenuated vaccine and may require repeated 
administrations. Most inactivated vaccines, such as inactivated polio vaccine 
(IPV), confer protection by inducing a humoral response, which may need 
boosting later in life due to diminishing memory responses (Murdin et al. 
1996).  
Sub-unit vaccines are made from parts of the pathogen, whether inactivated 
toxins, DNA, proteins or any component of the pathogen, but not the whole 
pathogen. Many novel candidate vaccines currently under development are 
sub-unit vaccines. Sub-unit vaccines currently licensed include those for 
Hepatitis B, diphtheria and tetanus toxoid (Plotkin 2005).  
 
Vaccines that stimulate the humoral response have proven the most 
successful against pathogens (Plotkin 2005). It is postulated that a vaccine 
against TB should induce cellular immunity, as the role of T cells is likely to be 
crucial in the control of TB infection and disease (Kaufmann 2012; O'Garra et 




remains elusive and debatable (O'Garra et al. 2013; Maglione & Chan 2009). 
However, more recently it is thought that a vaccine that can induce both T cell 
and B cell responses may be better to prevent M.tb infection (Kaufmann 
2012). 
 
 1.2.2. Vaccine strategies 
Many variables need to be considered when designing vaccines. An important 
consideration in design of vaccines is whether the vaccine is to be given to i) 
prevent infection, ii) prevent progression of infection to disease or iii) to 
modulate disease, as shown in Figure 3 below (Kaufmann et al. 2010; 
Kaufmann 2010).  
 
To have the greatest cost benefit, a vaccine should ideally be given once and 
protect for a lifetime. However this has not been achieved for many diseases 
and more than one dose of many vaccines is required. A tremendous effort 
has gone into studying the timing and type of vaccination requirements to 
optimally induce long-lived protection with multiple vaccinations. Researchers 
have proposed multiple strategies. 
 
One such strategy is known as homologous boosting. Homologous boosting 
enhances a vaccine response after the initial vaccination, known as the prime, 
with the same vaccine.  A second strategy is known as the heterologous 
prime-boost strategy in which a different vaccine is given to boost the primed 
immune response (McShane 2009; Kaufmann 2010). The timing between the 






Figure 3: Vaccination strategies against TB. Graphs depict possible prime-boost 
strategies that have been explored, and others that may be implemented in vaccine 
design and clinical trials in the future. The possible predicted outcomes of disease 
severity or progression to disease are also shown (Kaufmann et al. 2010). The blue 
line represents the vaccinated population and the red line the unvaccinated 
population. (A) pre-exposure vaccination with BCG protects against early childhood 
tuberculosis but does not eradicate TB disease. This is the current vaccination 
strategy. (B) Priming with BCG at birth or early childhood followed by a pre-exposure 
boost with subunit vaccine to delay or prevent the onset of TB in adulthood; (C) 
Boosting of the immune response post-exposure with a subunit vaccine in adults who 
had been primed with BCG; (D) Priming with a superior BCG replacement to prevent 
TB for a lifetime; (E) vaccination of patients with active TB disease who are being 
treated with drugs with a therapeutic vaccine; (F) heterologous prime-boost strategy 
where BCG is replaced with a superior BCG  and a subunit vaccine is used as a 
booster, which may result in sterility or complete eradication; (G) Vaccination of LTBI 
individuals with a superior replacement BCG prime and boosting with a subunit 
vaccine to prevent TB disease and (H) pre-exposure vaccination to prevent stable 




1.2.3. Bacillus Calmette-Guérin  
The only currently available vaccine against TB is Bacillus Calmette-Guérin 
(BCG). BCG is widely administered and generally safe in immunocompetent 
individuals, however, it affords highly variable and mostly poor protection 
against pulmonary TB! (Colditz et al. 1994)! (Fine 1995). The efficacy of BCG 
has been reported to vary with geographical location, and this may be due to 
the environment and the population genetics in that region. However, BCG 
has been shown to protect infants against disseminated disease, such as 
miliary TB and TB meningitis (Rodrigues et al. 1993). The protection afforded 
by BCG against miliary and disseminated TB is reported to be as high as 80% 
(Fine 1995). Current opinions in the field include that a new TB vaccine 
should either boost BCG induced immunity or completely replace BCG. 
 
The idea of not replacing BCG is to rather boost the BCG induced immunity in 
a heterologous prime-boost strategy. BCG is given first and then at a pre-
determined interval, a different vaccine is given. This is particularly aimed at 
pre-exposure to M.tb, not only in infants but in adolescents and adults 
(McShane 2009).  
 
1.2.4. Current candidate TB Vaccines 
Current TB vaccine candidates are being designed to either induce an M.tb-
specific T cell response that will be sufficient to prevent TB infection, or to 
prevent progression to disease, for immunotherapeutic purposes.  
 
Live mycobacterial candidates being explored as potential TB vaccines are 
mostly based on improving BCG by adding or removing specific genes. One 
such vaccine is a recombinant BCG (rBCG) with a deletion of the gene 
encoding urease and integration of a gene encoding listeriolysin (Grode et al. 
2005). Listeriolysin mediates lysis of the endosomal compartment within 
infected cells, allowing enhanced MHC-I antigen presentation, thought to 
result in greater induction of CD8 T cell responses. Other live attenuated 
vaccines are strains of M.tb, which have had virulence factors disrupted, such 
as the transcriptional regulator gene phoP disrupted (MTBVAC), which is 





The majority of candidates currently in clinical trials are subunit vaccines 
containing antigens that are proteins secreted by M.tb in its active state or are 
expressed when M.tb has transformed into its latent state, where it is less 
metabolically active. Antigens included in these vaccines were mostly chosen 
because they induced immunodominant responses in T cell assays that 
measure Th1 cytokine production in the blood of latently infected or previously 
diseased individuals (Brennan & Thole 2012). 
 
Viral vectors expressing selected M.tb antigens are also being tested as 
potential vaccine candidates. Antigens included in these vectors are also 
selected based on immunodominant responses in T cell assays that measure 
Th1 cytokine production. 
 
As mentioned earlier, these vaccine candidates are identified for prime-boost 
heterologous vaccination strategies with BCG, or as immunotherapeutic 














Table 1: TB vaccine candidates in various stages of clinical trials, as at 
October 2013 (www.pipelinereport.org). Shown are the proposed vaccination 
strategy, the composition of the vaccine, the sponsors, as well as the clinical 
trial phase they are in. 
 
 
The vaccine candidate, MVA85A, is one of the most advanced in the clinical 
development process. MVA85A is a modified vaccinia Ankara, which is a 
replication deficient pox virus (Blanchard et al. 1998), and expresses the 
immunodominant mycobacterial protein antigen 85A (Ag85A). Ag85 is a 
complex of three secreted proteins with mycoltransferase activity, which is 
important in maintaining the cell wall integrity of the bacterium. Ag85 is also 




1992). Ag85A, B and C are expressed by most mycobacterium species, 
including M.tb and BCG.  
 
Some of the work in this thesis is based on T cell responses induced by 
MVA85A. At the South African Tuberculosis Vaccine Initiative (SATVI), we 
have completed five clinical trials of the MVA85A vaccine. MVA85A was 
shown to be very well tolerated and immunogenic in adults (Hawkridge et al. 
2008; Scriba et al. 2012), adolescents and children (Scriba et al. 2010), and 
infants from a TB endemic area!(Tameris et al. 2013; Scriba et al. 2011). In a 
recently completed phase IIb study in infants, MVA85A was shown to be 
immunogenic and safe, but had no protective efficacy against M.tb infection or 
TB disease (Tameris et al. 2013). Despite this disappointing result, we used 
MVA85A as a model vaccine for studying T cell immunity and generating new 
knowledge that is important for vaccine design. 
 
1.3. Immunity to TB 
1.3.1. Innate immunity 
The body’s first line of defense against pathogens that have permeated the 
skin or endothelial barrier is known as the innate immune response. This is a 
rapid response launched to kill or to contain the pathogen and restrict its 
spread.  
 
Upon inhalation of M.tb bacilli, resident cells such as the macrophages and 
neutrophils are the first to recognise the bacilli through pattern recognition 
receptors (PRR). These cells have the ability to recognise molecules known 
as pathogen associated molecular patterns (PAMPs) on the surface of the 
bacilli as foreign. Recognition is through PRRs such as complement receptor, 
C-type lectins such as dendritic cell-specific intercellular adhesion molecule-3-
grabbing non-integrin (DC SIGN) and through toll like receptors (TLR) (Ernst 
1998; Tailleux et al. 2003). This recognition results in uptake of the bacilli by 
macrophages, as well as recruited dendritic cells and neutrophils. Each one of 
these cells has a specialised function to eliminate and control the 





Macrophages play a pivotal role immediately after inhalation of the bacilli. 
Macrophages phagocytose the bacteria and sequester the bacilli into the 
phagosome, which when fused with lysosomes, facilitates acidification of the 
phagolysosome resulting in death of the bacilli (van Crevel et al. 2002). 
Macrophages can also use autophagy to sequester M.tb bacilli in the 
cytoplasm, into a double membrane autophagosome, which when activated 
increases the acidification of the phagosome and leads to killing of the 
mycobacteria (Kundu & Thompson 2008; Gutierrez et al. 2004). However 
more and more studies have shown that M.tb has the ability to stop 
phagosome-lysosome fusion, survive, and replicate within the macrophage. 
 
Neutrophils have been shown to play multiple roles in controlling M.tb 
infection. Neutrophils are highly efficient at phagocytosis after which they 
undergo apoptosis forming debris which is taken up by macrophages to 
control spread of the bacterium (Morel et al. 2008). Neutrophils are able to kill 
M.tb through production of antimicrobial peptides such as cathelicidin 
(Martineau et al. 2007). Studies in the mouse have shown that neutrophils 
may play a role in the recruitment of other cells, such as T cells, through a 
chemoattractant mechanism (Seiler et al. 2003). M.tb has been shown to 
subvert immune control mechanisms, and one way is by preventing the 
apoptosis of neutrophils, promoting its survival (Blomgran et al. 2012). 
 
On its own, the innate response is not sufficient to effectively control or 
eliminate M.tb, and efficient control of M.tb is dependent on induction of an 
adaptive immune response. Dendritic cells are the professional antigen 
presenting cells (APC) that initiate priming of T cells (Banchereau & Steinman 
1998). DCs thus act as a link between the innate and adaptive immune 
system. After M.tb infection, DCs are recruited to the lung by activated 
macrophages that secrete chemokines. In the lung, DCs take up M.tb bacilli 
and upregulate expression of cell surface markers involved in migration to 
lymph nodes and co-stimulation of T and B cells, such as CCR7, CD80, 
CD86, and CD40. These DCs then mature and traffic to draining lymph nodes 
where they present M.tb antigen in the context of HLA molecules to prime T 






1.3.2. Adaptive Immunity: T cell subsets and functions 
Upon exposure to antigen, naïve T cells to differentiate into different T cell 
subsets, which have a wide range of functions and produce multiple cytokines. 
This differentiation is influenced by the cytokine milieu present when the cells 
experience antigen for the first time, as well as the nature of the antigen 
(Mosmann & Coffman 1989). The cytokine milieu is largely influenced by 
cytokines being secreted by DCs that are delivering and presenting antigen to 
the naive cells. 
 
A few CD4 T cell subsets have been characterised in depth and belong to well 
defined differentiation lineages. This sub-setting was based on patterns of 
cytokine expression in effector T cells as well as lineage specific transcription 
factors, as shown in Figure 4. These transcription factors regulate the 
generation, function and cytokine production, as well as the inhibition of 
differentiation of other lineages of helper T cells (Oestreich & Weinmann 
2012). The most characterised helper T cell lineages to date are Th1, Th2, 
Th17 and Tregs. 
 
Th1 cells are required and essential for clearance or control of intracellular 
pathogens such as bacteria and viruses (Fietta & Delsante 2009). Th1 cells 
are generated when naïve T cells are primed in the presence of IL-12, 
resulting in expression of the transcription factor, T-Bet (Szabo et al. 2000). 
This induces the typical Th1 effector cytokine, IFN-γ. Th1 cells predominantly 
produce IFN-γ, IL-2 and TNF-α (O'Garra et al. 1998), cytokines shown to be 
very important in orchestrating immune responses. IL-2 promotes T cell 
proliferation and maintenance of T cell populations. IL-2 has also been 
implicated in the generation of CD8 T cell memory, ensuring a robust 
secondary response upon antigen encounter (Williams et al. 2006). IFN-γ 
activates macrophages resulting in killing of bacteria, as well as further IL-12 
production by DCs, resulting in a positive feedback loop that drives expansion 





Th2 cells play a major role in fighting extracellular parasites, like worms, and 
are also involved in allergic diseases (Romagnani 1994; De Carli et al. 1994). 
Th2 cells are induced by priming of naïve T cells in the presence of IL-4, 
inducing the expression of the transcription factor, GATA-3, which induces 
production of the cytokines IL-4, IL-5 and IL-13 (Zheng & Flavell 1997; 
Lantelme et al. 2001; Seder & Paul 1994; O'Garra et al. 1998).  
 
Th1 and Th2 inhibit each other’s function and differentiation, and have 
traditionally been seen as mutually exclusive T cell subsets. However, some 
data suggests otherwise, since T cell clones that co-produce IFN-γ and IL-4 
have been described (Murphy & Reiner 2002). This suggests plasticity in T 
cell lineages, and that cells are not definitively committed to a lineage and can 
switch upon particular cues (Murphy & Reiner 2002). 
 
Th17 cells are largely involved in the immune response against extracellular 
bacteria and fungi. Differentiation of Th17 cells require multiple cytokines, 
such as various combination of IL-6, TGF-β, IL-1β, IL-21 and IL-23 (Moseley 
et al. 2003; Korn et al. 2007; Veldhoen et al. 2006; Zhou et al. 2007). Priming 
of naïve T cells in the presence of these cytokines, results in the expression of 
RORγt, the master regulator of the T cell lineage. However, several other 
transcription factors have been implicated in the complete differentiation and 
lineage commitment of these Th17 cells, as a deficiency in RORγT does not 
lead to complete interruption of Th17 cytokine expression (Yang et al. 2008). 
Th17 cells mostly produce the effector cytokines IL-17A, IL-17F and IL-21, 
which act in an autocrine manner. IL-17 mediates recruitment of neutrophils to 
sites of infection, and promotes inflammation. (Moseley et al. 2003; Laan et al. 
1999). IL-17 is an important effector molecule in chronic inflammatory 
diseases such as psoriasis (Chiricozzi & Krueger 2013). 
 
Another class of T cells that have been well studied and characterised are the 
regulatory T cells (Tregs). Two subsets of Tregs have been described. Thymic 




thymus, and peripheral Tregs (pTregs) (Abbas et al. 2013), previously known 
as induced Tregs, are derived in the periphery from naïve CD4 T cells (Abbas 
et al. 2013; Bluestone & Abbas 2003). Priming of naïve T cells in the 
presence of TGF-β and absence of inflammatory cytokines drives 
differentiation of naïve cells to Tregs. These cells can be identified by the 
expression of the transcription factor, FOXP3 as well as high expression of 
the IL-2 receptor, CD25 (Sakaguchi et al. 1995). Tregs regulate the immune 
response by regulating inflammation and effector responses and by 
maintaining tolerance to self-antigens (Sakaguchi 2005). Tregs produce 
immunomodulatory or suppressive cytokines such as IL-10, IL-35 and TGF-! 
(Collison et al. 2007; Rubtsov et al. 2008). 
 
Recently, additional subsets, distinct from Th1, Th2 and Th17 subsets, have 
been identified. These subsets such as Th9 and Th22 are not as well 
characterised and defined. The Th9 subset is induced by priming of naïve T 
cells in the presence of IL-4 and TGF-β (Veldhoen et al. 2008; Putheti et al. 
2010), and is characterised by production of the effector cytokine IL-9, and not 
IL-4, IFN-γ or IL-17. Th9 cells primarily express the transcription factor PU.1 
upon priming, although IRF4 expression has also been shown to be induced. 
These IL-9 producing cells have been implicated in allergic asthma and 
autoimmunity. Surface markers that will allow the isolation of human Th9 cells 






Figure 4: Transcription factors specific to each T cell lineage induce cytokine 
production. Naïve T cells can be primed to differentiate into multiple T cell subsets in 
the presence of different cytokines. Cytokines influencing the differentiation of naïve 
T cells to specific lineages are shown adjacent to the arrows. Transcription factors 
specific to T cell linages are shown, as well as the effector cytokines produced by 




1.3.3. The adaptive immune response: CD4 and CD8 T cells in mycobacterial 
infection. 
CD4 and CD8 T cells comprise well-described subsets of T cells known to 
play important roles in control of mycobacterial infection. These cells are the 
main focus of this project.  
 
Although comprising only 30-70% of the lymphocytes in the lung as measured 
in broncheoalveolar lavage (BAL) (Walrath & Silver 2010; Kalsdorf et al. 2009) 
in healthy infected individuals, CD4 T cells are critical components of 
granuloma formation and control the replication of M.tb bacilli. Mice deficient 
in CD4 T cells are unable to control bacterial numbers and have more 
disseminated M.tb with higher bacterial burdens in the lung, liver and spleen 
when challenged intravenously with M.tb, compared with wild-type control 
mice! (Caruso et al. 1999). In addition, depletion of CD4 T cells during 
persistent M.tb infection results in increased replication of M.tb and 
breakdown in the granuloma structure, implying that CD4 T cells are also 
important for maintaining granuloma integrity (Caruso et al. 1999). 
 
The importance of CD4 cells for control of M.tb in humans is illustrated by the 
observation that HIV-infected individuals have a significantly increased risk of 
developing TB, compared with HIV negative individuals (Lawn et al. 2002). 
Ongoing viral replication within CD4 T cells is one of the most important 
parameters driving the massive, systemic depletion of memory CD4 T cells 
during acute immunodeficiency virus infection (Mattapallil et al. 2005). A 
recent study showed that M.tb-specific CD4 T cells are more rapidly and 
preferentially infected and depleted by HIV infection (Geldmacher et al. 2010), 
compared with cytomegalovirus (CMV) specific T cells. HIV infected 
individuals have reduced frequencies of M.tb-specific CD4 T cells in their 
lungs, and the function of these T cells is impaired (Kalsdorf et al. 2009). This 
loss and impairment in the function of M.tb-specific T cells is likely to be a 
contributor to the increased risk of TB in HIV infected individuals. This is 
further corroborated by a study in cynomologous macaques with latent M.tb 
infection. When infected with Simian immunodeficiency virus (SIV), these 




risk of progression to disease, further confirming the importance of CD4 T 
cells in containment and control of M.tb (Diedrich et al. 2010). 
 
CD4 T cells mediate their protective functions by secreting effector cytokines, 
such as the Th1 cytokines, IFN-", IL-2 and TNF-# (Hanekom et al. 2007), 
which regulate other immune cells. IFN-" is essential for activating 
macrophages. The importance of IFN-" in human immunity against 
mycobacteria is illustrated by individuals with gene mutations in the IFN-" 
pathway, such as the IFN-" receptor and IL-12, who are at high risk of 
developing severe mycobacterial disease (Ottenhoff et al. 2000). TNF-# is 
pivotal in cell recruitment, particularly of macrophages to enable granuloma 
formation and maintenance (Algood et al. 2005). The importance of TNF-# is 
further demonstrated in studies where the anti-TNF antibody, Infliximab/ was 
used to treat rheumatoid arthritis and Crohn’s disease in individuals latently 
infected with M.tb. In these studies, it was noted that many of these 
individuals developed TB disease within a short period of receiving anti-TNF 
treatment (Keane et al. 2001; Wallis et al. 2004). IL-2 was shown to be 
important in the development of long term T cell memory, which is essential 
for long-lived immunological protection (Ottenhoff et al. 1998). 
 
CD4 T cells are also necessary for development of functional cytotoxic CD8 T 
cells. Mice deficient in CD4 T cells had impaired CD8 T cell cytotoxic activity 
in their lungs in an acute model of M.tb infection (Serbina et al. 2001). CD4 T 
cells may also have cytotoxic capacity, as they express cytotoxic molecules, 
which have the ability to restrict M.tb growth in vivo (Bastian et al. 2008; 
Canaday et al. 2001; Mutis et al. 1993).  
 
CD8 T cells are also important for immunity to M.tb. CD8 T cells share some 
functions with CD4 T cells since they also express IFN-" and TNF-#. However, 
the best-described role of CD8 T cells in controlling infections is via their 
cytotoxic capacity. Cytotoxic CD8 T cells can induce apoptosis of infected 
macrophages by releasing cytolytic granules containing perforin (a pore-




granulysin, when secreted with perforin, can lead to direct intracellular killing 
of M.tb (Stenger et al. 1999; Mohagheghpour et al. 1998). The importance of 
CD8 T cells in humans has recently been shown in patients suffering from 
autoimmune diseases, who were treated with anti-TNF therapy and presented 
with increased susceptibility to developing TB. These patients had a reduction 
in CD8 T cells with the ability to kill M.tb infected monocytes in vitro (Bruns et 
al. 2009). 
 
Multiple other T cell subsets may be important in the control of M.tb. In mice, 
Th17 cells induced by a novel TB vaccination were shown to mediate 
protective effects through the recruitment of Th1 cells to the lung upon M.tb 
challenge (Khader et al. 2007). "$T cells (Spencer et al. 2008) and T cells 
restricted by non-classical molecules such as CD1 and HLA-E may also have 
roles in protection (Van Rhijn et al. 2009). 
 
In order to identify correlates of protection against TB disease, many studies 
in humans have assessed anti-mycobacterial T cell immunity, particularly 
focusing on cytokine expression or T cell phenotype. Studies done by our 
group have shown that the frequency, as well the cytokine expression profile 
of T cells in infants vaccinated with BCG and followed up for a period of 2 
years, did not correlate with risk of TB disease (Kagina et al. 2010).  Our 
group has also measured cytotoxic markers such as granulysin and perforin in 
CD4 and CD8 T cells and found no correlation with risk of disease (Keyser et 
al., unpublished). It is important to recognise that the outcomes measured in 
the above mentioned studies might not correlate with inhibition of 
mycobacterial growth or even killing of the pathogen. To address this, several 
investigators have developed in vitro assays aimed at measuring inhibition of 
mycobacterial growth (Worku & Hoft 2003; Wallis et al. 2001; Kampmann et 
al. 2000).  
 
1.4 Immunological memory 
Immunological memory refers to the maintenance of antigen-experienced, 




able to proliferate to large numbers of effector T cells upon secondary antigen 
encounter (Sallusto et al. 2004; Sallusto et al. 2010). The induction of long-
lived memory T cells forms the basis for adaptive immunity and vaccination.  
 
Antigen-experienced memory T cells can be categorised into distinct memory 
subsets according to their function and the expression of specific phenotypic 
markers. A large number of phenotypic markers have been used to classify T 
cells into different memory subsets. These include, but are not limited to 
CD45RA, CCR7, CCR4, IL7-R#, CD27, CD28 and CD62L, CCR2 and CCR5 
(Figure 5, below) (H. H. Zhang et al. 2010; Sallusto et al. 1999; Fritsch et al. 
2005; Kaech et al. 2003). 
 
1.4.1. Defining Memory  
Naïve T cells are antigen-inexperienced T lymphocytes that recirculate 
between secondary lymphoid organs in search of antigen presented by 
dendritic cells. Naïve T cells have a high threshold for antigen stimulation and 
require co-stimulation in order to be activated. The first phenotypic markers 
that allowed distinction between naïve, long-lived central memory (TCM) and 
short-lived effector memory (TEM) cells were CCR7 and/or CD62L in 
combination with either CD45RA or CD45RO (Sallusto et al. 2000). This 
classification system defines cells that co-express CD45RA and CCR7, a 
chemokine receptor that controls T cell homing to secondary lymphoid organs, 
as naïve T cells. Naïve T cells lose CD45RA expression and up regulate 
CD45RO upon antigen experience, and differentiate into central memory, 
effector and effector memory T cells (Sallusto et al. 2000). 
 
TCM cells, which are CD45RA-negative (or CD45RO-positive) but have 
retained expression of CCR7, are long-lived antigen-experienced cells. TCM 
cells mainly produce IL-2 and have high proliferative potential upon antigen 
encounter. TCM usually recirculate between secondary lymphoid organs. TCM 
have a lower antigen stimulation threshold than naïve T cells and do not 
require co-stimulation for activation. These cells may differentiate into effector 




bearing a TCM phenotype is thought to be important to induce long lived 
protection (Sallusto et al. 2000; Lanzavecchia & Sallusto 2005).  
 
Effector memory T cells do not express CCR7 or CD45RA but express 
chemokine receptors, such as CXCR3, and adhesion molecules, such as 
#4!1, #4!7 and #E!7, required for homing to inflamed tissues. Thus effector 
memory T cells are predominantly found at sites of infection and in the 
periphery. Both CD4 and CD8 effector memory cells produce large amounts 
of effector cytokines such as IFN-" within minutes or hours of antigenic 
stimulation and display immediate cytotoxic function. Unlike TCM, TEM may be 
short-lived, have limited proliferative capacity and are more prone to 
apoptosis upon antigen stimulation (Sallusto et al. 1999; Lanzavecchia & 
Sallusto 2005).  
 
A fourth subset is termed terminally differentiated memory T cells (TEMRA). 
These are antigen-experienced effector cells, which re-express CD45RA, and 
are thus CD45RA+CCR7-. Based on their limited functionality and short 
telomere lengths, indicating that these cells have undergone extensive 
division, this subset is the most differentiated of the antigen-experienced 
populations (Fritsch et al. 2005; Geginat et al. 2003). TEMRA are thought to be 
the last step before cell death, and are limited in function, producing only very 
low levels of cytokines, and are unable to proliferate. This subset of T cells is 
well described in CD8 T cells but not in CD4. TEMRA are associated with 
persistent or chronic infections such as CMV, Hepatitis B virus (HBV) and HIV 
infection (Walker et al. 2013; Harari et al. 2004). 
 
Other markers and cytokine/chemokine receptors that can be used to 
characterise T cells into memory phenotypes have been described. One such 
marker is CD27. CD27 is a member of the TNF receptor family and is used to 
delineate T cell differentiation stages in both CD4 and CD8 T cells. It is 
expressed at high levels on naïve T cells and upon stimulation T cells lose the 
expression of CD27. In CD4 T cells this marker has been well characterised in 





Many more markers are used as shown in Figure 5 below, adding to the 
complexity of defining memory T cell subsets. In this study, we aimed to 
characterise memory T cells induced by MVA85A vaccination and natural 
M.tb infection by measuring expression of a number of markers. 
 
 
Figure 5: Phenotypic and functional attributes of T cells in the differentiation pathway. 
(A) CD8 T cells as classified by the phenotypic markers CD45RA, CCR7, CD27 and 
CD28. Functional and other phenotypic properties are shown below. (B) CD4 T cells 
as classified by the phenotypic markers CD45RA, CCR7, CD27, CD28 as well as 
CD57 and CD11a. Functional properties such as cytokine production and cytotoxic 
capabilities are shown (Adapted from Appay et al., (Appay et al. 2008)).  
 
1.4.2. Memory T cells in mycobacterial infection 
The risk of progressing from infection to TB disease is highest immediately 
after primary infection and then wanes over time (Wiker et al. 2010). 
Mathematical models have been used to investigate this reduction in risk, 
which varies in different studies (Colijn et al. 2006). Some reports have 
suggested that the risk of active TB disease following TB exposure is 
significantly reduced in individuals with established latent M.tb infection, 
compared with uninfected persons (Andrews et al. 2012; Stead 1967; Chiang 




may be protective against TB upon re-exposure is supported by recent 
studies of isoniazid preventative therapy (IPT) in high endemic TB areas, 
where IPT was given to clear latent infection to reduce the incidence of TB. 
The results surprisingly showed that cumulative incidence of TB disease was 
not different between persons on IPT and untreated persons, most likely due 
to reinfection (Samandari et al. 2011; Churchyard et al. 2014). One 
explanation may be that clearing M.tb infection results in reduced effector 
memory T cell populations that may have protected against disease upon 
reinfection.  
 
These epidemiological findings suggest that M.tb-specific immune responses 
in persons with established infection, who did not develop TB within the first 1-
2 years after exposure, may protect against TB disease. In an attempt to 
understand which T cell memory subsets may be required to prevent 
progression from infection to disease, many human studies have 
characterised the function and phenotype of M.tb-specific T cell responses in 
asymptomatic latent M.tb infection and/or in active TB disease (Harari et al. 
2011; Day et al. 2011; Rozot et al. 2013; Rueda et al. 2010; Sutherland et al. 
2010). 
 
M.tb-specific CD8 T cells predominantly display effector memory phenotype in 
patients with active TB disease and a terminally differentiated phenotype in 
LTBI individuals (Rozot et al. 2013). In children with active TB, the direct ex 
vivo phenotype of CD8 T cells was greatly skewed to an effector memory 
phenotype, when compared with latently infected and uninfected children 
(Jacobsen et al. 2007). Reduced proliferative capacity of M.tb-specific CD8 T 
cells has been observed in individuals with smear-positive TB as compared to 
individuals with LTBI or smear negative TB (Day et al. 2011). Treatment of 
smear positive TB cases resulted in gradual restoration of proliferative 
capacity of M.tb-specific T cells, suggesting that mycobacterial load may drive 
functionality and differentiation of memory T cells.  
 
In healthy latently infected adults and children, mycobacteria-specific Th1 




IL-17 and IL-22 producing CD4 T cells predominantly displayed a central 
memory phenotype (Scriba et al. 2008; Tena-Coki et al. 2010; Mueller et al. 
2008). In another study, the authors showed that LTBI healthy individuals had 
higher frequencies of antigen-specific CD4 T cells that displayed a late-stage 
differentiated (CD45RA-CD27-) effector memory phenotype and the cells 
expressed PD-1, a marker associated with exhaustion or activation of T cells 
in virus models (Adekambi et al. 2012). A study of pleural fluid cells from 
patients with active TB disease also suggested that M.tb-specific CD4 T cells 
display an effector memory phenotype (Li et al. 2011).  
 
Spontaneous healing from TB disease has been documented in the pre-
antibiotic era. In one of these studies, ESAT6 and CFP10-specific CD4 T cells 
were detected up to 50 years after healing. Effector responses were detected 
in most participants and were attributed to incomplete clearance of M.tb. In a 
minority of participants, T cell responses were detectable only upon in vitro 
expansion of M.tb-specific T cells and were attributed to central memory 
lymphocytes (Millington et al. 2010). Understanding properties of memory 
cells that may have conferred the ability to heal TB disease may be critical for 
advancing our knowledge of TB pathogenesis in humans. 
 
However, phenotypes of M.tb-specific cells may also not always fit the model 
described for other infections. An unusual population of mycobacteria-specific 
memory T cells, with phenotypic characteristics of naïve lymphocytes, has 
been described in numerous human studies. These “naïve-like” (NL) memory 
T cells express effector cytokines such as IFN-" and TNF-#, but display a 
CD45RA+CCR7+CD27+ “naïve” phenotype (Kagina et al. 2009; Caccamo et 
al. 2006; Soares et al. 2008; Soares et al. 2013). These cells have been 
observed after vaccination and during natural infection (Kagina et al. 2009; 
Caccamo et al. 2006; Tena-Coki et al. 2010; Soares et al. 2008; Soares et al. 
2013). Phenotypic and functional properties of these naïve-like T cells in M.tb 





The above-mentioned studies of T cell phenotypes were limited by the 
necessity for T cell stimulation in order to identify antigen-specific T cells 
through cytokine production. A caveat to this is that activation of cells by 
antigen stimulation may have altered expression of key phenotypic markers 
and thus influenced the outcomes and the interpretation of the data (Mallone 
& Nepom 2004). On the other hand, CD4 T cells expressing different 
cytokines may belong to different memory subsets, as observed for Th1 and 
Th17 cells (Scriba et al. 2008). Identification of mycobacteria-specific CD4 T 
cells by expression of one or few cytokines may therefore bias expression 
patterns of phenotypic markers. Measurement of phenotypic markers on 
mycobacteria-specific T cells directly ex vivo would eliminate these limitations.  
 
1.4.3. Memory responses after vaccination 
It is thought that a long-lived T cell response characterised by central memory 
T cells may be important for protection against TB disease. With this in mind, 
it has been postulated that a TB vaccine should aim to induce antigen-specific 
central memory CD4 T cells (Orme 2010). Hence, many groups have studied 
the memory phenotype of T cells after vaccination with novel TB vaccines.  
 
Scriba et al. report a dominant effector memory phenotype of MVA85A-
induced CD4 T cells after vaccination and this phenotype remained 
unchanged up to 56 days after vaccination in adolescents and children. 
Ag85A-specific central memory CD4 T cells were virtually undetectable 2 
months after vaccination in these participants (Scriba et al. 2010). Another 
study of MVA85A-induced T cells in the United Kingdom also characterised 
Ag85A-specific T cells using different markers and found that these cells 
displayed a relatively immature (CD45RO+CD27intCD57–) memory phenotype!
(Beveridge et al. 2007).  
 
Soares et al. showed that, in 10-week old BCG vaccinated infants, 
mycobacteria-specific CD4 T cells predominantly displayed an effector 
memory phenotype (Soares et al. 2008). Kagina et al. observed 
predominantly an effector memory phenotype in infants who received BCG, 




low in these infants up to 1 year after vaccination (Kagina et al. 2009). 
However, in a more recent study, Soares et al. showed that BCG-specific 
cells mainly expressed a central memory phenotype 27 weeks after 
vaccination (Soares et al. 2013). This study highlighted two important 
differences. Firstly, the time at which T cell phenotype is assessed is very 
important, as the immune responses evolve from an early effector phase to 
establish the memory pool. Secondly, the antibody clones for CCR7 used in 
these studies were different and may have affected interpretation of the 
results. Orme et al., have hypothesised that one of the reasons for poor long-
term protection conferred by BCG may reside in the prevalent induction of 
effector memory cells. In this model, constant re-exposure in TB endemic 
settings drives effector memory cells to differentiate into short lived effector 
cells, which are not replenished by central memory T cells (Orme 2010). The 
reason for BCG not protecting against pulmonary TB disease remains unclear. 
 
To protect against TB disease, we propose that a TB vaccine should induce T 
cells that are long lived, have high proliferative potential, express Th1 
cytokines and be able to traffic to the lung upon antigen re-exposure. We 
aimed to characterise the memory phenotype of M.tb-specific CD4 T cells in 
natural infection and after vaccination using tools that do not require T cell 
activation. 
 
1.5 Tissue homing of T cells 
The capacity of memory T cells to rapidly traffic to the relevant tissue or site of 
infection is likely to be a critical factor in protective immunity. Many studies 
have shown that the site at which a T cell is primed influences the expression 
of markers required for homing (Kantele et al. 1997; Kantele et al. 1999; 
Campbell & Butcher 2002; Kaufman et al. 2008). For example, T cells that are 
primed in the mesenteric lymph node, in the gut, possess the ability to traffic 
back to the gut (Kantele et al. 1999). This gut homing potential was shown to 
be dependent on co-expression of the integrins #4 and !7. In a comparative 
study of oral and parenteral vaccination with Salmonella typhi Ty21a antigen, 




compartments and expressed #4!7 after oral vaccination. By contrast, 
antigen-specific T cells induced by parenteral vaccination were directed to the 
systemic compartment (Kantele et al. 1997). It has also been observed that 
skin homing receptors, such as cutaneous lymphocyte antigen (CLA), are 
preferentially induced when T cells are primed in dermal peripheral lymph 
nodes (Campbell & Butcher 2002). A study suggested that T cell expression 
of #4!1 may mark T cells that home to sites of inflammation, including the 
lung, but not the gut which requires #4!7 (Feng et al. 2000). A recent study 
by Silver et al., showed that a large proportion of the M.tb-specific CD4 T cells 
in the lung after PPD challenge expressed #4!1, further suggesting these 
integrins to be important in localising the CD4 T cells to the lung (Walrath & 
Silver 2010). 
 
The studies cited above based their interpretation on the premise that tissue 
homing is programmed. However, studies suggest that the 
compartmentalisation of T cell responses is less categorical. In mice and 
rhesus macaques vaccinated intramuscularly with a recombinant adenovirus-
based vaccine, antigen-specific T cell responses were found both systemically 
and at multiple mucosal surfaces (Kaufman et al. 2008). The ability to 
generate a potent mucosal immune response is an important goal of 
vaccination against pathogens acquired via mucosal transmission such as 
M.tb. Hence a better understanding of how the site of vaccination could 
influence the trafficking pattern of antigen-specific cells is critical. Optimal 
disease control would involve recruitment of specific T cells to the site of 
infection, such as the lung in M.tb infection, to carry out their protective 
functions immediately upon exposure.  
 
The studies referred to above suggest that T cells with lung homing capacity 
will be observed in natural M.tb infection, whereas intra-dermal administration 
with a vaccine may prime cells expressing skin homing markers. We aimed to 






1.6 Detection of antigen-specific cells 
In order to quantify immune responses induced by vaccinations or natural 
infection, multiple assays that measure T or B cell functions have been 
developed. These assays measure up regulation of effector functions such as 
cytokine production (Hanekom et al. 2004), or proliferation upon in vitro 
stimulation of cells with specific antigens. As T cells are likely key players in 
mediating M.tb-specific control, immunological assays to measure responses 
to M.tb vaccines or infection are mostly directed at T cells. The easiest 
compartment to assess these immune responses is the peripheral blood. 
Accessing other compartments, such as the lung or lymph nodes, is invasive 
and more challenging. Each assay can be highly informative in some ways. 
However assays are subject to limitations as will be outlined for each assay 
employed for this study, which are informed by the scientific question to be 
answered.  
 
1.6.1. Whole blood vs Peripheral Blood Mononuclear Cell (PBMC) based 
assays. 
In humans, whole blood or purified PBMCs are typically used to measure 
antigen-specific T cells and their functions. Whole blood must be stimulated 
fresh shortly after collection, followed by lysing of red blood cells and, 
optionally, fixation and cryopreservation of leukocytes. PBMCs can be 
isolated, cryopreserved without fixation and retain viability for subsequent 
stimulation and analysis. Cells are stimulated for different lengths of time 
(from a few hours up to 7 days) depending on the functional outcome 
assessed (Hanekom et al. 2008).  
 
Vaccinologists advocate simplification and harmonisation of assays used to 
measure immunogenicity, with the aim to compare results across sites and 
across vaccines.  
An advantage of whole blood assays (WBA) is that they allow assessment of 
T cell functions in the context of all components in the blood. The detected 
immune responses result from the interaction between all cell subsets 
normally present in the blood. PBMC preparations contain only mononuclear 




effector molecule production, however cryopreservation of the cells may 
introduce variability in their capacity to respond to in vitro stimulation 
(Hanekom et al. 2008).  
 
1.6.2. Intracellular cytokine stimulation assay 
The intracellular cytokine assay (ICS) is commonly used to detect antigen-
specific cells that are producing cytokines in response to antigenic stimulation. 
Cells are stimulated for a period of time (typically 12 hours in our assays) with 
the antigen of interest during which time the protein secretion inhibitor, 
Brefeldin A, is added to block secretion of cytokines. Cells are then fixed, 
permeabilised, and intracellular cytokines stained with fluorescently 
conjugated antibodies, and detected by flow cytometry (Hanekom et al. 2004). 
In ICS assays, both intracellular cytokines and surface markers can be 
stained, allowing simultaneous interrogation of T cell phenotype and function. 
Many investigators have used this method or an adaptation of it, to interrogate 
the memory phenotype of cells after vaccination or infection (Kagina et al. 
2009; Tena-Coki et al. 2010; Beveridge et al. 2007; Soares et al. 2010; Scriba 
et al. 2011; Scriba et al. 2012).  
 
A limitation of this assay is that it depends on stimulation in order to identify 
antigen-specific cells, and the cellular activation may result in changes in the 
cell phenotype. Stimulation has been shown to affect the expression of some 
memory markers, including CD28 and CCR7 (Chao et al. 1997; Sallusto et al. 
2004; Vallejo et al. 1999). Another limitation of this assay is that not all 
antigen-specific cells can be expected to produce the cytokines measured. A 
particular proportion of the antigen-specific cells may therefore remain 
undetected. 
 
In this study, a 12-hour whole blood assay was used to assess the 








1.6.3. ELISpot assay 
The Enzyme-linked Immunosorbent Spot (ELISpot) assay detects production 
and release of IFN-" by T cells after a short term in vitro stimulation of PBMC 
with specific antigens. It was first described 30 years (Czerkinsky et al. 1983) 
ago and has become one of the most commonly used assays to measure cell 
specific immune responses (Slota et al. 2011). This is a highly reproducible, 
robust and sensitive assay to enumerate cells with immediate effector 
functions. An individual spot on the membrane in the well represents an 
individual cytokine-producing cell. The spots can be counted manually or 
using an automated reader and quantified. 
 
ELISpot assays can be performed on freshly isolated or cryopreserved cells. 
ELISpots can be adapted in two ways: the short term assay to detect cytokine 
expression (direct ex vivo) or the cultured ELISpot assay which detects 
cytokines after the cells are cultured for an extended period of time (12-13 
days) in the presence of antigen. Cells may be cultured in the presence of 
antigen to promote expansion of antigen-specific cells before performing a 
direct ex vivo ELISpot.  The cultured ELISpot allows detection of antigen-
specific cells that are at very low frequencies by expanding this population to 
become readily detectable. 
 
As for IFN-" release assays in stimulated whole blood, this assay does not 
allow identification of the cellular source of IFN-", unless it is performed after 
depletion of cell subsets from the PBMCs.  
 
In this study, a cultured ELISpot assay was used to determine which M.tb-
specific epitopes were recognised by latently infected individuals, to facilitate 
the development of HLA class II tetramers. 
 
1.6.4. Proliferation Assay 
One of the key characteristics of long-lived memory cells is the ability of cells 
to proliferate more readily than naïve T cells as they require less stimulation. 
Therefore, by assessing the proliferative capacity of cells, one can infer some 




Initially the proliferation assay, a longer term assay, was used to identify 
antigen-specific cells, as cells were cultured with antigen for a period of 6 
days, then assessed for proliferation. The proliferation assay can also be used 
to assess effector functions of expanded T cells. Many different techniques 
are available to assess in vitro proliferation of antigen-specific T cells. In this 
study, we used an assay based on dilution of a fluorescent dye upon cell 
division. This assay involves staining of PBMCs with the fluorescent dye 5,6-
carboxyfluorescein diacetate succinimidyl ester (CFSE) or its derivative, 
Oregon green, which covalently bind intracellular proteins. As cells divide, the 
dye is diluted between the daughter cells, and as a consequence, its 
fluorescence intensity is halved with each division (Lyons 1999). The 
proportion of cells that proliferate and the number of divisions that have 
occurred in response to stimulation with a particular antigen can then be 
estimated by flow cytometry (Lyons 1999).  
 
In vitro expansion of antigen-specific cells also allows measurement of cells 
that may be present at frequencies too low to detect with a short-term assay.  
The proliferation assay is useful to address questions about induction of 
memory and long-lived responses. Although this assay can also be combined 
with staining of other cell markers to identify specific T cell populations, the 
long-term stimulation affects the expression of memory markers.  
In this study, a proliferation assay was used to assess the proliferative 
capacity of MVA85A induced CD4 T cells. 
 
1.6.5. HLA tetramers 
HLA tetramers are multimeric peptide-HLA molecule complexes that 
physically bind directly to the cognate T cell receptor (TCR) expressed on 
antigen-specific T cells (Figure 6). The use of tetramers takes advantage of 
co-operative binding to simultaneously bind more than one TCR on a specific 
cell, resulting in a slower dissociation rate between peptide-HLA and the TCR. 
This property makes tetramers labeled with a fluorochome suitable for direct 
staining and detection of antigen-specific T cells, without a requirement for 
cell activation. Another advantage of using tetramers is the ability to detect 





HLA class I tetramers were developed first (Altman et al. 1996). They have 
been used extensively to study virus-specific CD8 T cell function and 
phenotype. Much has been learnt about the development and different 
phases of chronic and acute viral infections from the use of class I tetramers 
(Klenerman, Lucas, et al. 2002b; Kantzanou et al. 2003). HLA class II 
tetramers have been more challenging to develop and only recently has the 
use of HLA class II tetramers increased due to technological advancements. 
The largest hindrance in developing HLA class II tetramers has been the 
technical difficulty of synthesising the alpha and beta polymorphic chains of 
the HLA molecule in E.coli (Ferlin et al. 2000). The use of mammalian cell 
lines brought about much progression in development of HLA class II 
tetramers (Crawford et al. 1998; Novak et al. 1999). The full potential of HLA 
class II tetramers has not yet been realized, and is likely to revolutionise the 
study of CD4 T cells.  
 
In this thesis, we used HLA class II tetramers to detect M.tb-specific T cells to 




Figure 6: MHC monomers with a single peptide from the antigen of interest are 
biotinylated, to allow for up to 4 monomers to be complexed together on streptavidin 
to form a tetramer, to make use of co-operative binding. The tetramer is then 
fluorescently labeled allowing for detection by flow cytometry. (Adapted from 




1.6.6. Gene expression by qPCR 
Current flow cytometry-based techniques are limited in the number of different 
molecules that can be simultaneously measured. Another way to characterise 
cell subsets is to measure gene expression. By sorting T cell into different 
memory subsets based on phenotypic marker expression, and perfoming 
transcriptional analysis on these memory subsets, genes have been identified 
that are present only in specific T cell subsets and completely absent in other 
subsets. These genes can be used to classify and differentiate T memory cell 
subsets from each other. Appay et al. used gene expression profiles to define 
the transcriptional differentiation stages of CD4 T cells as they differentiate 
from naïve (antigen-inexperienced) to antigen-experienced cells (Appay et al. 
2007). A recent study by Gattinoni et al. also utilised gene expression profiles 
to characterise a novel subset of T memory stem cells in humans, and to 
compare them to antigen-specific effector memory and central memory T cell 
subsets (Gattinoni et al. 2011). 
Advances in the field of real time polymerase chain reactions (RT-PCR) allow 
interrogation of gene expression even at a single cell level. Fluidigm has 
developed the BioMark HD high-throughput real time qPCR platform that 
allows simultaneous quantification of 96 transcripts in 96 samples on a single 
microfluidic chip.  
 
In this study, we characterise gene expression in sorted tetramer labeled T 
cell subsets to gain a better understanding of the transcriptional complexity in 






Objectives of this thesis: 
!
i.) Map and identify Ag85A, ESAT6 and CFP10-specific CD4 T cell 
epitopes and determine HLA restriction elements of these epitopes 
to design HLA class II tetramers (Chapter 2). 
 
ii.) Optimise HLA class II tetramer staining protocols for specific and 
sensitive detection and characterisation of M.tb-specific CD4 T cells 
(Chapter 2). 
 
iii.) Comprehensive delineation of the phenotype and function of 
MVA85A-specific CD4 T cells (Chapter 3). 
 
iv.) Develop and optimise protocols for mRNA expression profiling in 
sorted antigen-specific CD4 T cells (Chapter 4). 
 
v.) Determine phenotypic properties and transcriptional profiles of 




Chapter 2: Tetramer development 
 
2.1. Introduction 
CD4 T cells are crucial for protection against M.tb, however whether a 
particular memory phenotype of these cells is associated with protection 
remains a point of debate. To start addressing this question, we sought to 
characterise memory subsets of M.tb-specific CD4 T cells after MVA85A 
vaccination and in natural, asymptomatic M.tb infection. We chose to use 
MHC class II tetramers to avoid or minimize activation of lymphocytes and 
obtain a measure of the direct ex vivo phenotype of M.tb-specific CD4 T cells 
irrespective of their functionality (Chao et al. 1997; Sallusto et al. 2004; Vallejo 
et al. 1999).  
This chapter describes how we identified immunodominant M.tb specific CD4 
T cell epitopes and their HLA class II allele restriction in order to develop 
tetramers. Further, optimisation of staining conditions required to detect T 
cells with these tetramers is also described. 
We focused on Ag85A, the antigen contained in MVA85A vaccine, which is 
expressed by most mycobacteria, including BCG and M.tb. To characterise 
immune responses induced by natural infection with M.tb, we focused on two 
well known immunodominant antigens, ESAT6 and CFP10, which are not 





Because binding of different peptides is HLA allele restricted, in order to 
design HLA class II tetramers to be used in our study we aimed to: 
i.) Identify immunodominant CD4 T cell epitopes, within mycobacterial 
proteins Ag85A, ESAT6 and CFP10. 
ii.) Determine HLA restriction of selected epitopes. 






2.3. Materials and Methods 
The work in this chapter was performed by the candidate unless otherwise stated. 
 
2.3.1. Study participants for MVA85A vaccine trials performed in Dr Helen 
McShanes’ laboratory at Oxford University, United Kingdom 
Data generated from vaccine trials performed in the United Kingdom were 
used to determine HLA restrictions of epitopes, as described below. These 
trials aimed to determine the safety and immunogenicity profiles of the 
MVA85A vaccine in healthy adults.  
 
MVA85A vaccine trial (TB005): BCG-vaccinated adults were recruited under 
protocols approved by the Oxfordshire Research Council Ethics Committee. 
The age range for inclusion was 18–55 years. All participants tested sero-
negative for HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV) and had 
a Heaf test reaction not greater than grade II at screening. The Heaf test 
involved the injection of PPD into the forearm of an individual using a gun, 
which had needle points dipped in the PPD. The test was read between 2-7 
days after injection. If upon reading 6 minute punctures were found, this was 
considered a negative result, and participants were unlikely to be M.tb-
infected. If 4-6 papules were found at the injection site, this was also 
considered negative (Grade I). However, if a confluence of papules formed 
undurating the ring, this was considered positive (Grade II), and participants 
likely to be M.tb-infected. A central filling that formed a disc was also 
considered positive (Grade III). The largest grading was a Grade IV, which 
was characterised by a disc >10mm with or without blistering and this was 
considered strongly positive. Subjects received a single intradermal 
inoculation with MVA85A at a dose of 5x107 plaque forming units (pfu). The 
median time between BCG vaccination and immunisation with MVA85A was 
18 years (range: 0.5–38 years) (Beveridge et al. 2007). 
 
MVA85A vaccine Trial (TB009): BCG-vaccinated adults with no evidence of 
M.tb infection, as defined by a maximum Heaf test reaction grade II and a 
negative early secretory antigen target 6 (ESAT6) and culture filtrate protein-




Oxfordshire Research Ethics Committee. The age range for inclusion was 18-
50 years; all subjects were required to be seronegative for HIV, hepatitis B 
virus and hepatitis C virus. Subjects received a single intradermal inoculation 
with MVA85A at a dose of 1x108 pfu (Beveridge et al. 2008).  
 
2.3.2. Study participants for MVA85A vaccine trials performed at the South 
African Tuberculosis Vaccine Initiative (SATVI) 
PBMCs from the following participants were used for the proliferation assays, 
data mining as well as for the tetramer staining discussed in Chapter 3. 
Participants were enrolled into phase I/IIa clinical trials of the MVA85A 
vaccine in South Africa. These trials were aimed at determining the safety and 
immunogenicity profiles of the MVA85A vaccine in healthy adults (Hawkridge 
et al. 2008) and adolescents (Trial TB008) (Scriba et al. 2010) from the SATVI 
clinical site in Worcester, Western Cape. The trials were approved by the 
Research Ethics Committees of the University of Cape Town and Oxford 
University and conducted according to International Conference on 
Harmonisation/Good Clinical Practice guidelines. The trials were externally 
monitored by an independent contract research organisation and all protocols 
and subsequent amendments were approved by the Medicines Control 
Council of South Africa.   
 
Written, informed consent was obtained from all adults. Written, informed 
consent was also obtained from parents or legal guardians of all 
adolescents while written, informed assent was obtained from all 
adolescents who were judged to have a good understanding of the study.  
Enrolled participants were all HIV negative and had no evidence of M.tb 
infection, as defined by absence of PBMC reactivity to ESAT6 and CFP10 
in an ELISpot assay and a tuberculin skin test (TST) of less than 15mm. 
TST involves the intradermal injection of a standard dose of purified 
protein derivative (PPD), a tubercule extract, in the forearm. After 48-72 
hours the injection site is examined and the induration around it is 
measured. All participants had a normal chest X-ray and had received 





All individuals received an intra-dermal dose of 5x107 pfu of MVA85A. Adults 
and adolescents were followed up for 12 months. Blood products were 
obtained and stored at all post-vaccination time points indicated in Table 2. 
 
Table 2: Time points of study visits at which blood products were isolated  
and stored 
Participants No.  of 
participants 
Time points 
(days after vaccination) 
Adolescents 12 Baseline, 7, 14, 28, 56, 84, 168 and 364 
Adults 
 
24 Baseline, 7, 14, 28, 56, 84, 168 and 364 
  
2.3.3. Study participants for natural M.tb infection studies!
We aimed to enrol healthy latently infected donors under the healthy donor 
protocol (UCT HREC ref: 126/2006). Donors had to be HIV negative, not on 
any chronic medication and not pregnant. All donors had to have a 
QuantiFERON TB-GOLD In tube (QFT) result greater than 0.35IU/mL, which 
is considered positive for M.tb infection, as well as a TST induration greater 
than 15mm. Donors had to have given consent for HLA typing. Blood samples 
were collected and PBMCs isolated and cryopreserved as described in 
section 2.3.4, below. PBMCs were used for epitope mapping of ESAT6 and 
CFP10.  
 
2.3.4. PBMC isolation and cryopreservation 
Blood was collected from participants by venipuncture into heparinised tubes. 
Blood was diluted 1:1 with phosphate buffered saline (PBS, Lonza) and slowly 
layered onto 15mL of Ficoll (histopaque) to a maximum total volume of 45mL 
in a 50mL conical tube. This tube was then centrifuged at 800g for 30 minutes 
at room temperature with the brake off, to separate the PBMC from the other 
cells. PBMC were aspirated at the ficoll interface using a 5mL pipette and 
transfered to a 50mL tube and topped up with PBS and inverted 3 times. This 
tube was centrifuged for 10 min at 596g at 22°C with the brake on “max/high”. 
The supernatant was decanted and cells were resuspended in 1mL of PBS 
and gently pipetted up and down. The tube was topped up with PBS and 
centrifuged for 10 min at 596g at 22°C with brake on “max/high”. Supernatant 




and 10% Foetal calf serum (FCS, Lonza) in RPMI (Lonza) media. Ten million 
PBMCs were cryopreserved per vial. 
 
2.3.5. Peptides used for epitope mapping 
We designed 15mer peptides overlapping by 10 amino acids to cover the 
whole proteins Ag85A (66 peptides), CFP10 (18 peptides) and ESAT6 (17 
peptides) (Maecker et al. 2001). Peptides were used at a concentration of 
2µg/mL for stimulation of PBMCs in the direct ex vivo IFN-" ELISpot and at a 
concentration of 1µg/mL for the cultured IFN-" ELISpot. 
 
2.3.6. Direct ex vivo ELISpot 
PBMCs from MVA85A participants in all the vaccine trials were thawed into 
10mL of 10%AB+ human serum (Sigma) in RPMI containing DNase (50U/mL, 
Sigma). Cells were spun down at 596g for 10 minutes and then washed once 
by resuspending in 10mL of PBS. Cells were spun down at 596g for 10 
minutes and then resuspended into 10%FCS/RPMI media. Plates (Millipore) 
were coated with anti-IFN-" mAb antibody (15µg/mL, MAbTech), at 4°C 
overnight. Plates were then washed with PBS and blocked with 
10%FCS/RPMI for 3 hours at 37°C.  Three hundred thousand cells in 
10%FCS/RPMI were added into each plate well and were left unstimulated 
(uns) as a negative control or stimulated with a pool of MVA85A peptides 
(2µg/mL) or Phytohaemagglutinin  (PHA)(10µg/mL, Remel) as positive control. 
Stimulations were done in duplicate wells and plates were incubated at 37°C 
with 5% CO2 for 18 hours. Plates were developed according to the 
manufacturers instructions (Bio-Rad). Briefly, the plates were washed 5 times 
with 0.05% Tween 20 in PBS. We then added 50$L of a 1/1000 dilution of 
biotin-anti IFN-" antibody to each well. The plates were incubated for 2 hours 
at room temperature in the dark. The plates were then washed 5 times with 
0.05% Tween 20 in PBS and 50$L of a 1/1000 dilution of streptavidin-ALP 
(alkaline phosphatase) solution was added to each well and allowed to 
incubate for 1 hour at room temperature. The plate were washed again in 
0.05% Tween 20 in PBS. Fifty microlitres of developing buffer was added to 




developed. Washing the plates in tap water, four times, terminated the colour 
reaction. The plates were then allowed to dry overnight on the bench. Results 
were read on an ELISpot reader (AID). A positive response had to be greater 
than 17 spot forming cells (SFC)/million PBMCs after subtracting the 
unstimulated response. In wells where the response was too large to quantify 
the well was given a maximum value of 500/well or 1667 SFC/million PBMC, 
as previously described (McShane et al. 2004). 
 
2.3.7. Cultured IFN-" ELISpot for in-vitro expansion of antigen-specific cells  
Cryopreserved PBMCs from healthy M.tb latently infected participants were 
thawed into 10%AB+/RPMI medium containing DNase (50U/mL). Cells were 
washed once and then resuspended into 10%AB+/RPMI media. Two million 
PBMC were resuspended in 2mL of media and stimulated with ESAT6 or 
CFP10 15mer peptide pools (1µg/mL). Cells were incubated at 37°C with 5% 
CO2 for 12 days and 1mL of media was removed every 3 days and replaced. 
On day 3 and 6, IL-2 (50U/mL) was added with replenishment of media. On 
the 12th day, 1mL of media was removed and replaced with fresh media 
without IL-2 and left overnight at 37°C with 5% CO2. Plates (Millipore) were 
coated with anti-IFN-" mAb antibody at 4°C overnight. Plates were washed 
with PBS and then blocked with 10%FCS/RPMI for 3 hours at 37°C, 
according to the manufacturers protocol (MAbTech).  On the 13th day, 50000 
cells in 10%FCS/RPMI were added into each plate well, were left 
unstimulated as a negative control or stimulated with single ESAT6 or CFP10 
peptides (1µg/mL) or PHA (10µg/mL) as a positive control. Stimulations were 
performed in duplicate wells and plates were incubated at 37°C with 5% CO2 
for 18 hours. Plates were developed according to the manufacturers 
instructions (Bio-Rad). Results were read on an ELISpot reader, as described 
in section 2.3.6 (AID). A response was considered positive if it was 2.5x 
greater than the unstimulated, as had been previously determined for cultured 
ELISpots in our laboratory (M. Musvosvi et al., unpublished). Briefly, in a 
previous study, a cultured IFN-" ELISpot was performed in individuals before 
and after M.tb infection using ESAT6 peptides to stimulate PBMCs. The fold 




condition was determined and receiver operating characteristics (ROC) curve 
analysis was done. Discrimination between before and after infection and the 
area under the curve was significant at 0.98. The sensitivity and specificity for 
discriminating between pre and post infection, using various fold increase cut 
off was plotted. A fold increase value of 2.5 gave the maximum sensitivity and 
specificity, as shown in Figure below. 
 
         
Figure 7: Receiver operating characteristic curve analysis to determine a cut off for 
cultured IFN-" ELISpots. The sensitivity (red) and specificity (black) is shown for 
different cut offs. A cut off of 2.5x was considered optimal. (Courtesy of M. Musvosvi). 
!
2.3.8. Human leukocyte antigen class I and II typing 
Deoxyribonucleic acid (DNA) was extracted from PBMC using the Qiagen 
Mini-blood DNA isolation kit, following the manufacturers protocol. DNA was 
sent to the National Institute of Communicable Diseases (Johannesburg, 
South Africa) for high resolution Human Leukocyte Antigen (HLA) class II 
typing by DNA sequencing. Alternatively, DNA extracted from healthy M.tb-
infected participants was sent to our collaborators (Alex Sette et al.,) at the La 
Jolla Institute of Allergy and Immunology for high resolution HLA class II 
typing (La Jolla, California, USA).!
 
2.3.9. HLA class II epitope prediction 
Single peptides that were recognised by at least 30% of the responders to any 
antigen in the protein were considered immunodominant and were used as 




peptides were analysed using epitope prediction software to determine the 
putative binding epitopes to different HLAs. 
 
Epitope prediction databases used for this analysis included: 
• SYFPEITHI. Binding scores are arbitrary and are based on the binding 
affinity between amino acids in peptides and different HLA types. Amino 
acids that bind with high affinity are given a positive score and poor binding 
residues a negative score. The overall score is then calculated. The 
maximum achievable score is 40.  
• IEDB Analysis Resource, http://tools.immuneepitope.org/mhcii/. The 
median percentile rank calculates a consensus rank from three prediction 
methods (neural network-based alignment (NN_align), stabilization matrix 
alignment method (SMM_align) and Sturniolo), for each peptide. The 
median percentile rank is generated by comparing the peptide's score 
against the scores of five million random 15 mers selected from 
SWISSPROT database. A small numbered percentile rank indicates high 
affinity. The NN-align and SMM align scores are given as predicted binding 
affinity (half maximal inhibitory concentration 50, IC50) to each HLA allele, 
in nM. Peptides with IC50 values <50nM are considered high affinity, 
<500nM intermediate and <5000nM low affinity.  The prediction result of 
Sturniolo is an arbitrary raw score, the higher the score, the greater the 
affinity. 
• PROPED (http://www.imtech.res.in/raghava/propred/) uses quantitative 
matrices derived from published literature by Sturniolo et. al., (Sturniolo et 
al. 1999) to predict HLA Class-II binding regions in an antigen sequence. It 
also locates promiscuous binding regions within an antigen sequence. The 
higher the percentage score an epitope is given to a particular HLA allele, 
the greater the probability of it binding that allele (Singh & Raghava 2001). 
 
2.3.10. HLA-peptide binding assays 
Our collaborators (Alex Sette et al.,) at the La Jolla Institute for Allergy and 
Immunology in San Diego, USA, performed the HLA-peptide binding assays, 




Assays to quantitatively measure peptide binding to HLA class II molecules 
are based on the inhibition of binding of a high affinity radiolabeled peptide to 
purified HLA molecules (Sidney et al. 2001). Briefly, 0.1-1nM of radiolabeled 
peptide was co-incubated at room temperature or 37°C with 1µM to 1nM of 
purified HLA in presence of a cocktail of protease inhibitors. Following a 2-4 
day incubation, the percent of HLA bound radioactivity was determined by 
capturing HLA/peptide complexes on LB3.1 (DR), L243 (DR), HB180 
(DR/DP/DQ), SPV-L3 (DQ) or B7/21 (DP) antibody coated Optiplate, and 
bound counts per minute (cpm) measured using the TopCount 
microscintillation counter. Under the conditions utilised, where [label]<[HLA] 
and IC50%[HLA], the measured IC50 are reasonable approximations of the true 
Kd values. 
 
2.3.11. HLA class II tetramers 
DRB1*03:01 iTag HLA class II tetramers were obtained from Beckman 
Coulter. The tetramers were conjugated to PE and supplied at a concentration 
of 100µg/mL. ESAT6 and CFP10 tetramers were obtained from the NIH 
Tetramer Core Facility at Emory University, GA, USA. ESAT6 and CFP10 
tetramer concentrations varied and are shown in Table 3, below. All tetramer 
staining was done at a final concentration of 2µg/mL. 
 
Table 3: HLA class II tetramer concentrations 
HLA allele Peptide 
number 
 Protein Peptide Sequence Concentration 





DRB5*01:01   Clip PVSKMRMATPLLMQA 1.3mg/mL 
DRB1*0401 15  CFP10(71-85) EISTNIRQAGVQYSR 
 
0.8mg/mL 
DRB1*0401   Clip PVSKMRMATPLLMQA 1.3mg/mL 
DRB1*0301 12/13  Ag85A(55-75) VPSPSMGRDIKVQFQSGGAN  100µg/mL 
DRB1*0301   Apolipoprot
einB(2877-2894)  
(ApoB) 






2.3.12. HLA class II tetramer staining 
Cryopreserved PBMCs were thawed into 10%AB+ serum/RPMI medium 
containing DNase (50U/mL). Cells were spun down at for 7 minutes and then 
washed once by resuspending in 10mL of PBS. Cells were spun down at 
596g for 7 minutes. PBMCs were resuspended in 1mL of PBS and stained for 
30 minutes with LIVE/DEAD Fixable Violet Dead Cell Stain (ViViD, Molecular 
Probes, Invitrogen). Cells were then washed once in PBS and stained with 
2µg/mL of HLA class II tetramer at 37°C or room temperature (RT) for 1 hour 
in a total volume of 100µL of 2%FCS/PBS containing 0.05% sodium azide 
(Sigma) and 2mM ethylenediaminetetraacetic acid (EDTA, Sigma). Incubation 
length and temperature were optimised for each tetramer as shown in this 
chapter. Cells were washed and stained with all other antibodies, for which 
each panel is listed in the relevant chapter, at room temperature for 30 
minutes unless otherwise stated. Cells were washed, resuspended and fixed 
with 1% paraformaldehyde, unless otherwise stated. Cells were acquired on a 
BD Biosciences LSRII flow cytometer.  
 
2.3.13. Antibodies 
The antibody concentrations for each panel were titrated and the volume 
chose based on staining saturation and best signal-to-noise index, to ensure 
minimal background staining and best resolution of the positive and negative 
populations. Fluorescence minus one (FMO) staining was done for all 
fluorescent conjugated antibodies used in this panel. In such FMO 
experiments, a sample is stained with all fluorescent conjugated antibodies 
except one of the antibodies, which is left out. This is repeated for each 
individual antibody. This method allows identification of spillover fluorescence 
from all secondary antibodies (as well as auto fluorescence) into each primary 
detector in the absence of the primary antibody. This method also aids 
positioning of gates to distinguish a positive population from the negative, 
since spillover fluorescence and auto fluorescence can be accounted for 
(Roederer 2002). All antibody panels described in this thesis were optimised 





2.3.14. Flow cytometer instrument configuration 
The BD Biosciences LSRII flow cytometer was set up to ensure the following: 
i) we had the optimal optical filters, ii) the laser beam shape and location was 
optimal and iii) that resolution and sensitivity of photoelectron detection was 
maximal as described (Perfetto et al. 2012). Optimal voltages were 
determined for each fluorochrome and for each detector in the instrument to 
ensure optimal resolution of populations.  A quality assurance routine was set 
up to monitor and ensure consistent and optimal functioning of the machines 
was maintained over the period of use, and to ensure reproducibility. 
Cytometer setup and tracking Beads (BD Biosceinces) that fluoresce in each 
channel at a predetermined median fluorescence intensity (MFI) were run 
daily to ensure that these settings and MFI are maintained (Perfetto et al. 
2012). Photomultiplier tube (PMT) voltages were adjusted daily to ensure that 
consistent MFIs were maintained, using Rainbow fluorescent particle 
(Spherotech) beads. Compensation beads were acquired daily before 
acquisition of samples, to allow post-acquisition compensation. Shown below 
in Figure 8, are the configurations used on the BD LSRII flow cytometer. 
 
Figure 8: Filter and laser configuration of the BD LSRII flow cytometer. The dichroic 
mirrors are shown in green and the band pass filters in lilac. The detectors are shown 




2.3.15. Flow cytometry data analysis 
Flow cytometry data were analysed using Flowjo v9.1 to v9.7.1. 
Compensation on the flow cytometer was done using single stained beads 





2.4.1. Study participants for MVA85A vaccine trials 
A total of 24 adults and 12 adolescents were enrolled into the TB008 trial. 
Demographic characteristics of these adults and adolescents are shown in 
Table 4, below. 
 
Table 4: Demographic characteristics of enrolled adults and adolescents in 





(n = 12) 
Male, n (%)  8 (33) 6 (50) 
 



















Median body mass index in 
kg/m2 (range) 
 27.6 (21.8-39.2) 21.1 (17.5-31.4) 
 
We did not have access to the demographics from the MVA85A vaccine trials 
performed in Oxford. All participants were white adults. 
 
2.4.2. MVA85A tetramer design 
To design HLA class II tetramers bearing peptides of commonly recognised, 
immunodominant Ag85A epitopes, epitope identification and the HLA 
restriction of each epitope had to be determined. We analysed direct ex vivo 
IFN-" ELISpot data from routine immunogenicity outcomes measured in 
previous trials of the MVA85A vaccine, completed at Oxford (TB005 
(Beveridge et al. 2007) and TB009 (Beveridge et al. 2008)), and at SATVI 
(TB008) (Hawkridge et al. 2008; Scriba et al. 2010). Fifteen-mer peptides 
encoding Ag85A, overlapping by 10 amino acids, were either used individually 
or were divided into 7 different pools to stimulate PBMCs. As this was done as 
part of a vaccine trial, ELISpots were performed on freshly isolated PBMCs. In 
the Oxford vaccine trials (TB005 and TB009), which included 36 participants, 
25 of the 66 Ag85A peptides were recognised by at least one individual in 
either of the trials, whereas 23 peptides were recognised by at least one 




positive T cell response against the peptides are shown below (Figure 9). 
Peptides that were recognised by 30% or more of the cohort in both trials 
were considered immunodominant and investigated further. 
 
Figure 9: Peptide mapping in 36 adults who received the MVA85A vaccine (12 
participants in trial TB005, in red; 24 participants in trial TB009, in blue). Responses 
were measured by IFN-" ELISPOT assay in PBMCs collected 7 days after 
vaccination. Responses greater than 17 SFC/million PBMC were considered positive 
as defined previously (Beveridge et al. 2007). Only peptides recognised by at least 
one vaccinee are shown. The number of individuals from all 36 trial participants with 
a response to a peptide is shown as % responders. 
 
Three Ag85A regions, encompassing peptides 12/13, 27/28 and 37/38, 
appeared to be immunodominant (Table 5). It is likely that these regions 
represent epitope(s) that are common to the overlapping amino acid regions 
in these flanking peptides. For each region we therefore combined the two 
15mer amino acid sequences into single 20mer peptides for further HLA 










Sequence % responders 
(No.) in TB005 
(n=12) 
% responders  

































We then determined associations between HLA alleles and peptide 
responses. We observed a strong association between T cell responses to 
peptide 12/13 and individuals bearing the DRB1*03:01 allele (Figure 10). 
Such clear associations between specific HLA alleles and responses to 
peptides were not observed with P27/28 or P37/38. However, T cell 
responses to P27/28 were observed in donors bearing DRB1*15:01, and 






Figure 10: IFN-" ELISpot responses to Ag85A peptide 12/13 measured in 36 
MVA85A vaccines from the TB005 and the TB009 vaccine trials. Only the HLA allele 
for donors bearing HLA DRB1*03:01 are shown and their responses to peptide 12/13 
are highlighted in red. White bars represent donors who had responses to peptide 
12/13 but who did not have the HLA DRB1*03:01 allele. A response was considered 
positive if it was greater than 17 SFC/million PBMC (Beveridge et al. 2007).  
 
Binding of peptides to HLA class II molecules is known to be promiscuous; an 
individual peptide may bind multiple, unrelated HLA alleles. This is attributed 
to the degenerate binding motif found within class II HLA molecules (Godkin 
et al. 2001; Wang et al. 2008) and makes precise determination of allele 
restriction challenging. To biologically determine the HLA restriction of the 3 
immunodominant 20mer Ag85A peptides, we investigated whether 
responsiveness to each peptide was associated with expression of specific 
HLA DR alleles (Table 6). We found a significant association between the 
presence of DRB1*03:01 and responsiveness to peptide 12/13 in 48 MVA85A 
vaccinees (from TB005, TB008 and TB009 trials). By contrast, no such 




DRB1*15:01 or peptide 37/38 and DRB1*04:01. However, due to the 
promiscuity of HLA class II peptide binding, this result does not exclude these 
alleles as restricting HLAs for these peptides. These epitopes may be 
restricted by multiple HLA alleles. 
 
Table 6: HLA restrictions of MVA85A vaccinee peptide responses 
Peptide and 





bearing allele, n  
Vaccinees 





yes 12 12 p < 0.001 
no 24 0 
Ag85A P27/28 
DRB1*15:01 
yes 32 9 p = 0.176 
no 4 3 
Ag85A P37/38 
DRB1*04:01 
yes 36 4 p = 0.427 
no 7 1 
 
We therefore used multiple epitope prediction algorithms to estimate the 
putative HLA allele binding affinity of the three immunodominant Ag85A 
20mer peptides, P12/13, P27/28 and P37/38, to DRB1*03:01, DRB1*15:01 
and DRB1*04:01, as well as other alleles. The results for each prediction 
algorithm are shown in Table 7, below. The consensus percentile rank, which 
calculates a consensus binding score from 3 prediction algorithms was shown 
to allow more reliable HLA binding prediction than any single prediction 




Table 7: Predicted HLA allele binding scores or ranks for each 20mer Ag85A 
peptide from 5 different algorithms and the combined consensus percentile 
rank. 
 
*The MHCII binding predictions were made using the IEDB analysis resource Consensus tool. 
The Peptides with IC50 values <50nM are considered high affinity (red), <500nM intermediate 
(yellow) and <5000nM low affinity (green). SYFPEITHI, consensus percentile and Sturniolo 
scores are ranked from highest (green) to lowest (red). 
!
In order to narrow down possible candidates for tetramers, we focused on 
alleles that were prominent in our South African cohort.  
HLA allele DRB1*03:01 showed a high affinity for P12/13, as it had the 
highest percentile score, an intermediate SMM align and NN_a align score, a 
high Sturniolo score and a high Propred score, as well as a high SYFPEITHI 
score, suggesting it is very likely to be restricted by this HLA allele. As 
biological results also confirmed this association, the Ag85A 20mer, which 
spanned P12 and P13, was selected to continue further for tetramer synthesis. 
Furthermore, based on the peptide binding data published by Malcherek et al 
(Malcherek et al. 1993), Apolipoprotein B-100 (2877-2894), a self peptide, 
was selected as a negative control peptide for the DRB1*03:01 tetramer. 
Binding scores for this peptide to the DRB1*03:01 allele are also shown in 
Table 6, above. 
 
The SYFPEITHI predictions for P27/28 suggested that it was restricted by 
DRB1*04:01, however analysis with the IEDB database, suggested that it had 
low affinity binding to this HLA allele, based on the SMM_align, NN_a align 
and Sturniolo score. Its percentile rank score of 28.21 was indicative of low 
binders as well. Propred gave a relatively low percentage binding probability, 
and SYFPEITHI also yielded an intermediate score. This suggested that this 
peptide was not a strong binder to this HLA allele. Interestingly, this peptide 




SMM_align, NN_a align and Sturniolo score. It had higher Propred binding 
probability percentage to the DRB1*04:01 allele, and a lower SYFPEITHI 
score (Table 7). This further supported the finding that class II epitopes are 
promiscuous. We opted to continue with the synthesis of the DRB1*15:01 
tetramer. 
Alleles such as DRB1*07:01 showed a high affinity for P37/38, as they had a 
high percentile rank, as well as a low SMM align and NN_a align score, 
however this allele was not present in our cohort and thus this combination 
was not considered. 
While our biological data suggested that P37/38 was not restricted by the 
DRB1*04:01 HLA allele, we observed an intermediate binding affinity 
predicted by SMM_align, NN_a align and Sturniolo scores. Furthermore, the 
SYFPEITHI score given to this peptide binding to the DRB1*04:01 HLA allele 
was moderate. Its probability of binding this allele, as predicted by Propred, 
was low though (Table 7). These results were not conclusive, but suggested 
that it could be restricted by this allele. We went forward with the synthesis of 
this tetramer. 
Though the prediction binding software tools were informative about peptide 
restrictions and binding probabilities, they are known not to give a definitive 
answer. A combination of biological data and prediction tool results guided our 
tetramer selection.  
 
Selected tetramers (Table 8) were synthesised by Beckman Coulter. The 
class II invariant chain-associated peptide (CLIP), a self protein which is found 
naturally bound to peptide-free HLA molecules, and plays a role in stabilising 
the HLA molecule during HLA processing and loading during antigen 





Table 8: Selected tetramers. 
HLA allele Peptide 
number 
 Protein Peptide Sequence 
DRB1*03:01 12/13  Ag85A(56-75) VPSPSMGRDIKVQFQSGGAN  
DRB1*03:01   Apolipoprotein
B(2877-2894)   
(ApoB) 
ISNQLTLDSNTKYFHK LN 







DRB1*15:01 37/38  Ag85A(181-200) YHPQQFVYAGAMSGLLDPSQ 
   clip PVSKMRMATPLLMQA 
 
2.4.3. Study participants for natural M.tb infection studies 
Epitope mapping for ESAT6 and CFP10 was performed on cryopreserved 
PBMC samples that were available from a previous study. We used these 
samples, as we knew the M.tb infection status of the participants. Twenty-two 
healthy latently infected adolescents were enrolled. The demographics of the 
participants are shown in Table 9 below. 
 
Table 9: Demographic characteristics of enrolled donors in the natural M.tb 
infection epitope mapping. 
 
 Adolescents 
(n = 22) 
Male, n (%) 
 9 (41) 
Median age in years (range) 
 16.8 (14.4-19.3) 







2.4.4. ESAT6 and CFP10 epitope mapping 
To study M.tb-specific CD4 T cells elicited by natural infection, we focused on 
responses to ESAT6 and CFP10, which are expressed by M.tb and not BCG. 
To design HLA class II tetramers, we aimed to identify immunodominant 
ESAT6 and CFP10 epitopes and their HLA restriction in healthy, latently M.tb-
infected donors. We performed epitope mapping by using a 12day cultured 
IFN-" ELISpot, where cryopreserved PBMCs were stimulated with single 
15mer peptides from ESAT6 and CFP10. We have recently shown that when 




detected as compared to the cultured ELISpot (Figure 11) (M. Musvosvi et al., 
unpublished). The process of culturing cells for 12 days allowed the 
expansion of antigen-specific memory T cells, increasing the sensitivity of 
detection of rare T cell clones. An example of the cultured ELISpot responses 
is shown in Figure 12. The cultured ELISpot showed a greater magnitude of 
responses to single peptides when compared to the directly ex vivo ELISpot.  
 
 
Figure 11: Direct comparison of the number of ESAT6 peptides recognised, in a 
direct ex vivo IFN-" ELISpot as compared to a 12 day cultured IFN-" ELISpot, in 9 
latently infected donors (courtesy of M. Musvosvi et al., unpublished). All 17 ESAT6 
peptides were used to stimulate PBMCs. (A) A greater number of peptides were 
recognised by the direct culture compared with direct ex vivo ELISpot. (B) The 
summed magnitude of the responses to single ESAT6 peptides. 
 
When a positive response was regarded as at least 2.5 fold higher 
SFC/million PBMCs than the unstimulated, at least one individual recognised 
all CFP10 peptides. The median unstimulated response was 50 SFC/million 





Figure 12: Mapping CFP10 responses by cultured IFN-" ELISpot. (A) Representative 
results of a single individuals PBMCs, where single CFP10 15mer peptides were 
used for stimulation. Negative control (unstimulated), complete CFP10 peptide pool 
and positive control (PHA) are also shown. (B) ELISpot response (SFC/million 
PMBCs) before background subtraction.  (C) Proportion of the cohort that had 
responses to the single CFP10 15mer peptides is shown (n=22). At least 30% of the 
cohort had to have a response for that peptide to be considered further; the red line 





Eight CFP10 peptides were recognised by 30% or more responders (Figure 
12C). These peptides were selected as candidates for determination of HLA 
restriction and are listed in the Table 10. 
 
Table 10: CFP10 peptides recognised by at least 30% of the cohort. 
Peptide number Amino acid 
position 
Sequence No. of responders (out of 
22), and (%) 
1 1-15 MAEMKTDAATLAQEA 8 (36) 
4 16-25 GNFERISGDLKTQID 9 (41) 
9 41-55 GQWRGAAGTAAQAAV  9 (41) 
10 46-60 AAGTAAQAAVVRFQE  15 (68) 
11 51-65 AQAAVVRFQEAANKQ 12 (55) 










ESAT6 peptide mapping was also performed and, as for the CFP10, a 
positive response was defined as being 2.5x greater than the unstimulated. 
The median response in unstimulated samples was 40 SFC/million PBMCs. 





Figure 13: Mapping ESAT6 responses by cultured IFN-" ELISpot. (A) Representative 
results for a single individual’s PBMCs, where single ESAT6 15mer peptides were 
used for stimulation. Negative control (unstimulated), complete peptide pool and 
positive control (PHA) are also shown. (B) ELISpot response (SFC/million PMBCs) 
before background subtraction.  (C) Proportion of the cohort that had responses to 
the single ESAT6 15mer peptides is shown (n=22). At least 30% of the cohort had to 






Seven of the 17 peptides screened were recognised by greater than 30% of 
the cohort (Figure 13C). These peptides were selected further for HLA 
restriction determination (Table 11).  
 
Table 11: ESAT6 peptides recognised by at least 30% of the cohort. 
Peptide number Amino acid 
position 
Sequence No. of responders 
(out of 22), (%) 
1 1-15 MTEQQWNFAGIEAAA 12 (55) 
2 16-25 WNFAGIEAAASAIQG 7 (32) 
5 21-35 NVTSIHSLLDEGKQS 8 (36) 
7 31-45 EGKQSLTKLAAAWGG  8 (36) 
10 46-60 SGSEAYQGVQQKWDA 8 (36) 
12 56-70 QKWDATATELNNALQ 12 (55) 
15 71-85 NLARTISEAGQAMAS 7 (32) 
 
2.4.5. Determination of HLA restriction of selected epitopes 
Instead of using prediction software, our collaborators (Alex Sette et al.,) at La 
Jolla Institute of Allergy and Immunology performed epitope binding assays 
using 15mer overlapping peptides spanning the whole ESAT6 and CFP10 
proteins for every HLA allele in our cohort. Results for our peptides of interest 
are shown in Table 12. We considered IC50 scores below 100 (as highlighted 
in Table 12) as high affinity binders, showing a likely HLA restriction. As HLA 
class II peptides are known to be promiscuous, it was not surprising that the 




Table 12: Binding of peptides to DR HLA alleles. IC50 scores below 100nM are considered high affinity binders to that HLA allele, 
and are highlighted 
       
 
                                     





































CFP10        MAEMKTDAATLAQEA 1 3344 9439 364 476 57 76 58 586 60 920 583 6135 64 1261 9,0 82 512 8684 
P4 GNFERISGDLKTQID 16 61  - 7044 2213 354 123 701 2463 6236 841 899 21506 2215 7030 643 5367 2039 153 
P9 GQWRGAAGTAAQAAV 41 426 13 33 23 4,6  - 74 411 2707 35 74 36643  - 5127 3803 65 13508 48 
P10 AAGTAAQAAVVRFQE 46 2889 17 614 154 174  - 867 10451 1872 406 8560 9487 7882 3681 6869 1479 508 90 
P11 AQAAVVRFQEAANKQ 51 30170 3016 9780 692 583  - 4555 21895 981 3431 30914 19791 24297 7355  - 16166 747 81 
P12 VRFQEAANKQKQELD 56 4853 37930 13219 26908 12516  - 2102 8000 11822 6943 6535  - 42431  - 4969 24694 17959 11 
P15 EISTNIRQAGVQYSR 71 5382 91 444 74 245 893 44 204 27 1223 1067 2023 1228 1687 11241 4695 81 1601 
P16 IRQAGVQYSRADEEQ 76 105 6357 4676 2834 10365 19154 1912 8308 243 30682 38502 18401 31543 38969 13981  - 5198 28295 
               
ESAT6  
                    
P1 MTEQQWNFAGIEAAA 1 656 187 145 208 69  - 326 2981 23776 261 1189 13897 29397 7146 26477  - 11500 13851 
P5 NVTSIHSLLDEGKQS 21 6947 8905 2776 1344 2581 34059 3091 68 1202 14451 2304 90a3 5588 6475 571 23869 34 1774 
P7 EGKQSLTKLAAAWGG 31 26067 5899 52 42 11  - 4627 591 532 61 255 33  - 5678  -  - 7055 4118 
P10 SGSEAYQGVQQKWDA 46 1793 5565 3278 3296 6640  - 26425 2803  - 6716 33441 37854  - 21016 8303  - 31215 2512 
P12 QKWDATATELNNALQ 56 4864 14835 258 323 2335 35013 515 3875  - 10221 23011  -  -  -  - 16421 35976  - 
P15 NLARTISEAGQAMAS 71 19378 101 2405 4965 722 3886 1778  - 538 630 6739 19379 30426 14102 4451  - 9351 13551 
! "#!
When a single peptide bound multiple alleles, we reverted back to our 
ELISpot data, to determine which allele was dominant in individuals who 
responded to that particular peptide. For example, CFP10 peptide 1, bound 
the alleles in Table 13 below.  
 
Table 13: HLA alleles for which CFP10 peptide 1 bound in the binding assays 
Peptide HLA allele Binding IC50 (nM) 
CFP-10 P1 DRB1*01:01 57 
 DRB1*03:01 76 
 DRB1*04:01 58 
 DRB1*08:02 60 
 DRB1*13:02 64 
 DRB3*01:01 9 
 DRB3*02:02 82 
 
In our ELISpot results, DRB1*04:01 was the only HLA allele observed in more 
than one responder to CFP10 P1 (3/8 responders). This suggested that in our 
cohort it was most likely that CFP10 peptide 1 was restricted by DRB1*04:01. 
To biologically determine the HLA restriction of the CFP10 peptide, we 
investigated whether responsiveness to each peptide was associated with 
expression of specific HLA DR alleles (Table 14). We found a significant 
association between the presence of DRB1*04:01 and responsiveness to 
peptide 1 in 22 M.tb infected individuals. 
 
Table 14: CFP10 peptide 1 responses for HLA restrictions 
Peptide and 





bearing allele, n  
Individuals 






yes 5 3 p=0.036 
no 14 0 
 
The same analysis was repeated for all ESAT6 and CFP10 peptides that were 
selected based on the epitope mapping. Table 15, below, displays all peptide-




Table 15: HLA restrictions for ESAT6 and CFP10 peptides 
HLA allele Peptide 
number 









DRB1*04:01 2  ESAT6(6-20) WNFAGIEAAASAIQG 
 
39 
 1  CFP10(1-15) MAEMKTDAATLAQEA 
 
58 
 9  CFP10(41-55) GQWRGAAGTAAQAAV 
 
74 
 15  CFP10(71-85) EISTNIRQAGVQYSR 
 
44 
DRB3*02:02 1  CFP10(1-15) MAEMKTDAATLAQEA 
 
82 
 9  CFP10(41-55) GQWRGAAGTAAQAAV 
 
65 
DRB4*01:01 5  ESAT6(21-35) NVTSIHSLLDEGKQS 
 
34 
 15  CFP10(71-85) EISTNIRQAGVQYSR 
 
81 
DQB1*06:02 2  ESAT6(6-20) WNFAGIEAAASAIQG 
 
52 
 7  ESAT6(31-45) EGKQSLTKLAAAWGG 
 
42 
 9  CFP10(41-55) GQWRGAAGTAAQAAV 
 
23 
 15  CFP10(71-85) EISTNIRQAGVQYSR 
 
74 
 ! ! ! !
These tetramers were all synthesised by the NIH tetramer core facility. 
 
2.4.6. Optimisation of tetramer staining conditions 
A wide variety of conditions and concentrations for antigen-specific tetramer 
staining are reported in the literature. Some investigators have reported using 
tetramer concentrations as high as 20µg/mL (J. J. Yang et al. 2004; Day et al. 
2003; Novak et al. 1999), while others used concentrations as low as 1µg/mL 
(Scriba et al. 2005; Novak et al. 1999). Furthermore, the temperatures used 
for staining were variable, with 3 temperatures being commonly used for 
staining: 4°C, room temperature (20-23°C) or 37°C. The duration of staining 
varied from 10 minutes to as long as 20 hours. Due to this variation in 
conditions, the optimal tetramer concentration, staining temperature and 
duration of staining were determined for each tetramer.  
 
! "#!
Firstly, PBMCs were stained with a range of tetramer concentrations, in a two-
fold dilution series from 4μg/mL to 0.5μg/mL for 1 hour at room temperature 
or 37°C, in a total volume of 100μL of staining media (Figure 15). The gating 
strategy is shown in Figure 14. 
 
 
Figure 14: Flow cytometric analysis and gating strategy of tetramer stained CD4 T 
cells. Representative density plots showing the gating strategy employed to identify 
live, CD3+, small CD4 lymphocytes. Cell doublets were excluded using forward 
scatter-area (FSC-A) versus forward scatter-height (FSC-H) parameters, small 
lymphocytes were then selected before gating on CD19- and CD14- live (ViViDlow), 




Figure 15: Optimisation of HLA class II tetramer staining concentrations. 
Representative figure of PBMCs stained with 2-fold dilutions of class II tetramer 
concentrations, starting at 4μg/mL. The top panel shows staining with the 
DRB5*01:01 tetramer bearing the CFP10(51-65) peptide and the lower panel shows 
staining with the control tetramer (clip). Tetramer staining was performed at room 
temperature for a period of one hour (A) or at 37 degrees Celsius for a period of 1 
hour (B). The frequencies of tetramer+ CD4 T cells are shown in each box. 
!
Although variation was observed, 2µg/mL of tetramer was sufficient to label 
the antigen specific cells in PBMCs, with low background or unspecific 
staining. At higher tetramer concentrations, the amount of background or 
unspecific staining increased (Figure 16).  
! "#!
It has been shown that the tetramer can also be internalised at 37°C and in 
order to avoid this, we chose to stain at room temperature as the frequencies 
of tetramer+ CD4 T cells were comparable between the two conditions. 
Furthermore, staining at room temperature minimises T cell stimulation.  
The DRB1*03:01-Ag85A(56-75) tetramer acquired from Beckman Coulter 
showed more distinct labelling at 37°C for 1 hour as compared to room 
temperature (data not shown), whereas all the other HLA class II tetramers 
stained as efficiently at room temperature for 1 hour. 
!
!
Figure 16: Frequencies of tetramer+CD4+ T cells recorded for the DRB5*01:01-
CFP10(51-65) and the DRB5*01:01-clip (control) tetramers shown as dotted lines, at 
room temperature and at 37°C after a 1 hour incubation period. 
!
To determine if longer incubation periods with the tetramers resulted in 
increased frequencies and brighter staining of the tetramer specific T cells, we 
stained PBMCs for either 1 hour or 2 hours. Although longer incubation 
periods resulted in brighter staining (increased median fluorescent intensity 
(MFI)) the frequencies of antigen specific tetramer+ CD4 T cells were similar. 
There was also an increase in non-specific background staining, and MFI of 
the non-specific staining, with longer incubation periods (Figure 17). Based on 
these results, all staining was done for a period of 1 hour in all studies in this 
thesis unless otherwise stated. !
! "#!
Figure 17: Optimisation of HLA class II tetramer staining conditions. Representative 
dot plots of PBMCs stained with 2µg/mL of tetramer at room temperature for a period 
of 1 hour or 2 hours. The frequencies of tetramer+ CD4 T cells are shown in the plots, 
as well as the median fluorescence intensities (MFI) of the tetramer+ CD4 T cells. 
!
2.4.7. Final tetramer selection 
Using the above-mentioned methods we validated the use of only 3 out of the 
13 selected tetramers, as listed below in Table 16. We could not rule out that 
the other ESAT6 and CFP10 tetramers may be specifically binding antigen-
specific T cells, as we did not have a sufficient sample size of donors with the 
correct HLA alleles to definitively show this. The Ag85A P27/38 tetramer and 
the Ag85A P37/38 tetramer failed to work after multiple attempts of staining 
PBMCs from multiple donors in various conditions, no further work was done 
with these tetramers. 
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Table 16: Tetramers utilised in this thesis for Chapters 3,4 and 5. 
HLA allele Peptide 
number 
 Protein Peptide Sequence 




DRB5*01:01   Clip PVSKMRMATPLLMQA 
DRB1*0401 15  CFP10(71-85) EISTNIRQAGVQYSR 
 
DRB1*0401   Clip PVSKMRMATPLLMQA 
DRB1*0301 12/13  Ag85A(56-75) VPSPSMGRDIKVQFQSGGAN  
DRB1*0301   ApolipoproteinB(2877




Tetramers are extremely powerful tools to directly characterise antigen-
specific T cells with minimal in vitro manipulation. However, unlike class I 
tetramers, HLA class II tetramers have been challenging to develop and use.  
The work described in this chapter aimed to identify M.tb-specific CD4 T cell 
epitopes that are commonly recognised in our cohort, and to determine which 
HLA alleles restrict the identified epitopes, to develop tetramer reagents.  
While identifying epitopes in M.tb antigens has been a major focus in recent 
years (Arlehamn et al. 2012; Geluk & van Meijgaarden 2000; Commandeur et 
al. 2011), primarily to identify suitable antigens to develop new TB vaccines,  
determining the HLA restrictions of these epitopes has not been given an 
equal amount of attention. Of the studies that have sought to determine which 
HLA alleles restrict M.tb-specific epitopes (Pathan et al. 2001; Mustafa et al. 
2000), very few have published on synthesis of tetramer reagents with this 
data (Arlehamn et al. 2012; Hohn et al. 2007). Many of the studies have 
confirmed the epitopes identified in this chapter and some have even 
confirmed their HLA restrictions (Pathan et al. 2001; Hohn et al. 2007). .  
We identified 3 Ag85A epitopes that were recognised by more than 30% of 
participants of MVA85A vaccine trials. More than 30% of latently M.tb-infected 
donors recognised 7 different ESAT6 epitopes and 8 CFP10 epitopes. With 
the exception of 2 ESAT6 epitopes, similar results were reported by Arlehamn 
et al. (Arlehamn et al. 2012) and Pathan et al. (Pathan et al. 2001). 
 
Many of the peptides described in this chapter bound multiple HLA alleles 
confirming the promiscuity of class II peptides (Mustafa et al. 2000). This 
promiscuous binding of class II peptides has been observed across a wide 
range of antigens, and is not exclusive to bacterial antigens. However we 
were able to use biological data to confirm binding to HLA alleles that were 
common in our cohort, which is representative of the population. This aided in 
narrowing down the options of HLA allele peptide restrictions to those that 
may be applicable to our cohort.  
 
Due to the large discrepancy in literature on the use and conditions used for 
MHC class II tetramer staining, we next aimed to optimise the conditions to 
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utilise for staining. Studies have reported dramatic variations in incubation 
times for HLA class II tetramers, ranging from 1 to 20 hours (Arlehamn et al. 
2012; Novak et al. 1999; Day et al. 2003; Reijonen & Kwok 2003; Crawford et 
al. 1998; Cameron et al. 2002; Cameron et al. 2001). In this thesis, optimal 
staining was seen after 1 hour, and longer incubation periods were associated 
with increased non-specific staining. 
 
Different studies have reported specific staining at 4°C, at room temperature 
and at 37°C (Scriba et al. 2005; Day et al. 2003; Cameron et al. 2002). For 
the Ag85A tetramer, more efficient staining was observed when performed at 
37°C for 1 hour, whereas for the CFP10 tetramers, incubation at room 
temperature resulted in more efficient staining and lower background. In 
accordance with other studies (Cameron et al. 2001; Cunliffe et al. 2002; 
Lemaître et al. 2004), very little staining was observed at 4°C and higher 
tetramer concentrations were necessary (data not shown). This difference in 
staining temperatures is possibly influenced by differential binding affinities of 
the TCR/pMHC complex (Reichstetter et al. 2000). These studies suggest that 
only high affinity TCRs are bound by the tetramer at 4°C.  
 
We were unable to detect tetramer+ CD4 T cells with Ag85A p27/28 and 
p37/38 tetramers, as well as all the DRB1*04:01, DRB4*01:01 and 
DQB1*06:02 ESAT6 epitope bearing tetramers. There were no known issues 
with the synthesis of the tetramers; they were shown to have the peptide 
loaded on the correctly folded HLA molecule. Multiple staining conditions were 
attempted with no success. The reasons for this lack of staining are unclear 
and many groups have reported similar experiences. This lack of staining may 
be due to poor  binding of pHLA to the TCR, or due low T cell frequencies too 
low to detect. 
 
In conclusion, we generated and validated staining with 3 HLA class II 





Helen McShane allowed access to the data generated in the MVA85A vaccine 
trials at the University of Oxford 
 
Alex Sette’s lab at the La Jolla Institute of Allergy and Immunology in San 
Diego, USA performed part of the HLA typing of participants, as well as the 
epitope binding assays. 
 
Part of the HLA typing was performed at the National Institute for 
Communicable Disease in Johannesburg, South Africa. 
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Chapter 3: Heterologous vaccination against human 
tuberculosis modulates antigen-specific CD4+ T-cell function 
 
This data had been published and the paper is attached as an appendix. 
 
3.1. Introduction 
After clean water, vaccination is the most effective global public health 
intervention (Plotkin SA 1999). While protection by most currently licensed 
vaccines correlates with levels of induced antibodies, protection against 
pathogens such as HIV-1 and M.tb is thought to rely, at least in part, on 
specific T-cell responses (Kaufmann & McMichael 2005; Walzl et al. 2011). 
Heterologous prime-boost regimens, involving priming with either BCG or an 
improved live mycobacterial vaccine, followed by an adjuvanted subunit or 
viral vectored boost, may constitute the most promising vaccination strategy 
against TB (Kaufmann 2010; Lambert et al. 2009; Hatherill 2011).  
 
It is currently not known exactly which T-cell response vaccines should induce 
for protection against TB disease (Kaufmann & McMichael 2005; Walzl et al. 
2011). In phase I and II clinical trials of new TB vaccines, the frequencies of 
vaccine-induced antigen-specific T helper type 1 (Th1) cytokine-expressing 
CD4 and/or CD8 T cells are usually quantified with the premise that 
vaccination-induced responses should be higher than the pre-vaccination 
response (Hanekom et al. 2008). The pattern of effector cytokine expressed 
by specific T cells is also commonly measured (Hanekom et al. 2008; Abel et 
al. 2010; Soares et al. 2008). However, we recently showed that a Th1 
response-inducing vaccination strategy in infants, which involves a BCG 
prime at birth and a boost with the novel poxvirus-vectored TB vaccine 
candidate, MVA85A, showed no evidence of efficacy against TB disease or 
M.tb infection (Tameris et al. 2013). These results suggest that features other 
than frequencies and cytokine-expression patterns of induced T cells should 
be explored as correlates of vaccine-induced immunity. For example, it is 
thought that the capacity to expand after T cells re-encounter antigen is an 
important function that may be measured in vaccine trials (Esser et al. 2003). 
It is thought that memory T cells, which are long-lived and have the capacity 
to proliferate rapidly upon antigen encounter, should be a desirable vaccine-
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induced response. However, in recent years many in the field have been 
debating whether having a constant population of effector T cells may be a 
more efficient way to control new M.tb infections. Thus this is being actively 
investigated. 
 
In areas with a high incidence of TB, where most of the population is already 
infected with M.tb, the success of heterologous boost vaccines may depend 
on the modulation of the existing mycobacteria-specific T-cell repertoire to 
possess more “favourable” functional characteristics, rather than inducing de 
novo T-cell responses. In TB endemic countries, CD4 T cells specific for 
conserved immunodominant antigens such as Ag85A are detectable in most 
individuals beyond infancy (Scriba et al. 2011). These cells could have been 
induced by BCG vaccination and/or exposure to environmental mycobacteria 
and/or M.tb or even cross-reactive bacteria (Abel et al. 2010; Scriba et al. 
2012; Scriba et al. 2011). We propose two minimum criteria for a potentially 
successful heterologous vaccination strategy: (1) the boost vaccine should 
modify or reprogram the T-cell response to display different functional and/or 
phenotypic characteristics to the pre-vaccination response; (2) the induced T 
cell response should be long-lived. We also propose that the ability of the 
cells to home to the lungs is critical. Very little is known about whether cells 
primed in the dermis have the capacity to home to the lung mucosa or 
whether programming of the cells at the dermis is mutually exclusive to the 
capability to home to the lung. 
In this chapter, we comprehensively characterised mycobacteria-specific CD4 
T cells before and after vaccination with MVA85A using HLA class II tetramers. 
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3.2. Aims 
The need to develop a vaccine against TB that is better than BCG is evident 
and a priority in the vaccine field. However, the T cell characteristics that a 
vaccine should induce remain elusive and a point of debate. Understanding 
the immune responses induced by the current vaccines in clinical trials is very 
important and critical for informing rational vaccine design. The goal of this 
chapter was to enhance our understanding of the responses induced by a 
novel TB vaccine, MVA85A.  
 
Specific aims: 
i.) To delineate MVA85A-specific CD4 T cell memory phenotype  
ii.) To characterise the expression of tissue-homing markers on MVA85A-
specific CD4 T cells 
iii.) To describe the T cell effector function and proliferative capacity of 
MVA85A induced CD4 T cells.
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3.3. Materials and Methods 
The work in this chapter was performed by the candidate unless otherwise stated. 
 
3.3.1. Study participants, vaccination and follow-up, blood collection and HLA 
typing. 
We accessed cryopreserved samples from a subset of participants (24 adults, 
12 adolescents (TB008) and 24 children (TB014), Table 21) who were 
enrolled in to two completed phase I/IIa trials of MVA85A (Hawkridge et al. 
2008; Scriba et al. 2010). Participants were all vaccinated with BCG at birth, 
were all HIV negative and had no evidence of M.tb infection, as defined by a 
negative ESAT6/CFP10 ELISpot and a TST induration of <15 mm, and all had 
a normal chest X-ray. Participants received a single intra-dermal dose of 
5x107 pfu of MVA85A over the deltoid region of the left arm, and were 
followed up for a minimum of 6 months (Hawkridge et al. 2008; Scriba et al. 
2010). None converted to a positive ESAT6/CFP10 response during follow-up. 
DNA was extracted from PBMCs as described in chapter 2 section 2.3.8. and 
sent for HLA typing. 
 
3.3.2. Direct ex vivo IFN-! ELISpot assay 
The frequency of IFN-!-expressing cells was measured by ex vivo ELISpot 
assay. Briefly, antigens included pooled Ag85A peptides (2µg/mL each) and 
M.tb purified protein derivative (PPD, from Statens Serum Institute, used at 
20µg/mL). Medium alone served as negative control and phytohaemagglutinin 
A (PHA, Remel, 10µg/mL) as positive control. Results were expressed as the 
number of spot forming cells (SFCs) per million PBMCs above the negative 
control. The cut-off for a positive response was 17 SFC per million PBMCs, 
after the frequency of cells in the unstimulated sample had been subtracted.  
 
3.3.3. Lymphoproliferation assay 
PBMCs were thawed in 12.5%AB+/RPMI media containing DNAse (20 
µg/mL), washed and rested overnight at 37°C with 5% CO2 in medium in a 
15mL tube. The next day, the tube was topped up to 10 mL with 12.5% 
AB+/RPMI and centrifuged for 10 min at 596g at 22°C with brake on 
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“max/high”. The supernatant was decanted and cells were resuspended in 
1mL of PBS and gently pipetted up and down. The tube was topped up with 
PBS and centrifuged for 10 min at 596g at 22°C with brake on “max/high”. 
PBMCs were then stained with 0.5µg/mLCellTrace Oregon Green 488 
(Molecular Probes, Invitrogen) a cytoplasmic dye, per 1x107 cells for 30 
minutes in the dark, in a volume of 1mL.  Tube was topped up with PBS and 
centrifuged for 10 min at 596g at 22°C. Stained cells were resuspended in 
12.5%AB+/RPMI and incubated either with medium alone (negative control), 
66 pooled 15mer peptides overlapping by 10 amino acids spanning the 
mycobacterial Ag85A protein (1µg/mL each, Peptide Protein Research Ltd.) 
or PPD (used as positive control at 2µg/mL) for 6 days at 37°C with 5% CO2. 
After 6 days the cells were washed once in PBS and then stained with the 
live/dead, Violet Fixable Viability dye (Vivid, Molecular Probes, Invitrogen), 
fixed using FACSLysing Solution (BD Biosciences), permeabilised with BD 
Perm/Wash buffer (BD Biosciences) and stained with fluorescence-
conjugated antibodies (Table 17). Antibody panels had been optimised as 
described in Chapter 2 section 2.3.13. Stained samples were acquired on an 
LSRII flow cytometer, (see configuration in Chapter 2 section 2.3.14).  
 
Table 17: Panel of fluorochrome-conjugated antibodies and dyes used to stain 
cells for the lymphoproliferation assay.  
Marker Clone Manufacturer Fluorochrome/dye Volume/concentration 
used 
CD3 UCHT1 Invitrogen Quantum Dot 605 0.5µL 
CD8 SK1 BD Biosciences PerCP-Cy5.5 3µL 
Proliferation  Invitrogen Oregon Green 0.5µg/mL 
Live/dead  Invitrogen ViViD 0.5µg/mL 
  
3.3.4. Whole blood intracellular cytokine assay 
This assay was performed as previously described (Plotkin SA 1999; 
Hanekom et al. 2004), with minor modifications. Briefly, 1mL of heparinized 
whole blood was incubated immediately after collection in the presence of 
anti-CD28 and anti-CD49d (each at 0.5µg/mL, BD Biosciences). Pooled 
Ag85A peptides (2µg/mL per peptide) or viable BCG (Strain Danish 1331, 
Statens Serum Institute, 1.2 x 106 cfu/mL) were used as antigens. No antigen 
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was used as a negative control, and Staphylococcal enterotoxin B (SEB, 
5µg/mL, Sigma-Aldrich) as a positive control. After 7 hours, Brefeldin A 
(10µg/mL, Sigma-Aldrich) was added and samples were incubated for a 
further 5 hours.  EDTA (Sigma) was added at 2mM to break cell clumps, 
followed by high speed vortexing for 10 s, incubation at room temperature for 
15 minutes, and repeat of the vortexing.  Erythrocytes were lysed and white 
cells fixed using FACSLysing Solution (BD Biosciences), before 
cryopreservation in 10%FCS/RPMI and 10%DMSO. Cells were thawed in 
batch, washed in PBS, permeabilised with BD Perm/Wash buffer and stained 
with fluorescent antibody panel optimised as described in Chapter 2 section 
2.3.13, in a total volume of 100µL (Table 18 below), and acquired on the 
LSRII flow cytometer.  
 
Table 18: Panel of fluorochrome-conjugated antibodies used to stain cells for 
the whole blood intracellular cytokine assay. 
Marker Clone Manufacturer Fluorochrome/dye Volume 
used 
CD3 UCHT1 BD Biosciences Pacific Blue 1µL 
CD8 SK1 BD Biosciences PerCP-Cy5.5 3µL 
CD4 SK3 Invitrogen QuantumDot605 0.5µL 
IFN-! K3 BD Biosciences AlexaFluor700 1µL 
IL-2 5344.11 BD Biosciences FITC 5µL 
 
3.3.5. HLA class II tetramers and staining 
Custom ordered PE-conjugated iTag MHC class II tetramers (100 µg/mL) 
were obtained from Beckman Coulter. HLA-DRB1*03:01 tetramers were 
complexed either to the mycobacterial Ag85A 20mer peptide, 
VPSPSMGRDIKVQFQSGGAN (DRB1*03:01-Ag85A(56-75)), or the human 
apolipoprotein B-100 peptide, ISNQLTLDSNTKYFHKLN, (DRB1*03:01-
ApoB(2877-2894), negative control tetramer) (Malcherek et al. 1993; Rammensee 
et al. 1999). Cryopreserved PBMCs were thawed, washed and stained with 
Violet or Aqua LIVE/DEAD Fixable Dead Cell Stain. Cells were stained with 
2µg/mL iTAg class II tetramer at 37°C for 1 hour as previously optimised in 
Chapter 2. Tetramer-stained cells were washed and stained with surface 
marker antibodies for 40 minutes at 4°C in a total volume of 100µL, except for 
staining with anti-CCR7-APC, which was done separately at 37°C for 20 
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minutes, before the other monoclonal antibodies were added for 40 minutes at 
4°C (Table 19 or Table 20).  
 
Table 19. Panel of fluorochrome-conjugated antibodies and dyes used to stain 
cells for MVA85A T cell memory phenotype studies.  
Marker Clone Manufacturer Fluorochrome Volume/concentration 
Used 
CD3 UCHT1 BD Biosciences Alexa Fluor 700 1µL 
CD4 S3.5 Invitrogen Quantum Dot 605 
(Qdot 605) 
0.5µL 
CD45RA HI1700 eBiosciences PerCP Cy5.5 0.5µL 
CCR7 150503 R&D Systems Allophycocyanin 
(APC) 
5µL 
CD27 CLB-27/1 Invitrogen Quantum Dot 655 0.1µL 
CD38 HB7 BD Biosciences PeCy7 0.5µL 
CD14 M!P9 BD Biosciences V450 1.25µL 
CD19 HIB19 BD Biosciences V450 0.3µL 
Live/dead  Invitrogen ViViD 0.5µg/mL  
 
Table 20. Panel of fluorochrome-conjugated antibodies and dyes used to stain 
cells for MVA85A T cell homing and activation phenotype studies.  
Marker Clone Manufacturer Fluorochrome Volume 
Used 
CD3 UCHT1 BD Biosciences Alexa Fluor 700 1µL 






Integrin Beta 1 HB7R AbD Serotec Biotinilyated 0.5µL 
Streptavidin  BD Biosciences PECy7 0.15µL 
Integrin Beta 7 FIB504 eBiosciences eFluor 650 0.3µL 
Integrin Alpha4 44H6 AbD Serotec Alexa Fluor 647 0.3µL 
CD14 HCD14 Biolegend PerCP Cy5.5 1.25µL 
CD19 HIB19 BD Biosciences V450 0.3µL 
Live/dead  Invitrogen ViViD 0.5µg/mL 
 
Finally, cells were washed and fixed in 100µL of 1% paraformaldehyde in 
PBS and acquired on the BD LSRII.  
 
3.3.6. Flow cytometry analysis 
Stained cells were immediately acquired on a LSRII flow cytometer (BD 
Biosciences), configuration shown in Chapter 2 section 2.1.14. Flow 
cytometry data analysis was performed using FlowJo version 9.2 (TreeStar). 
Unstained cells and single stained mouse ! beads were used as controls and 
to calculate compensations for every run. Cell doublets were excluded using 
forward scatter (FSC)–area versus FSC–height parameters (Figure 21); 
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acquisition time gating was applied to exclude data with inconsistent 
fluorescence and antibody aggregates were gated out using “keeper” gating. 
Boolean gating was employed to discern memory populations (Figure 23). 
3.1.7. Statistical considerations 
For the intracellular cytokine staining assay, the cut-off for a positive CD4 T 
cell response was above 0.01%, after frequencies of cells in the unstimulated 
sample had been subtracted. Phenotypic data were included for analysis only 
for samples with specific tetramer+ CD4 T cell frequencies above 0.01%, the 
limit of detection of the flow cytometer and absolute numbers of tetramer+ 
CD4 T cells of !35 cells. Statistical tests were performed using Prism v.5.0a 
(GraphPad). Paired and unpaired comparisons were done using the non-




3.4.1 Study participants 
PMBCs from the following subset of participants, who were enrolled in 
previous MVA85A clinical trials (TB008 and TB014), were utilised in this 
chapter. Table 21 below, describes the demographics of the participants, as 
well which assays were performed on their PBMCs. 
 
Table 21. Details of trial participants 
Donor No. Age 
(years) 






DN01-1051 21  F Black African TB008  Tetramera), Elispotb) *03:01, *11:01 
DN01-1078 42  M Caucasian TB008 Tetramer, Elispot *03:01, *12:01 
DN01-1117 49  M Mixed Race TB008 Tetramer, Elispot *03:01, *12:01 
DN04-1002  2 M Mixed race TB014  Tetramer, Elispot *03:01, *04:03 
DN04-1011  6 M Mixed race TB014 Tetramer, Elispot *03:01, *15:03 
DN02-1002 13 M Black TB008 Tetramer, Elispot, 
Prolic), ICSd) 
*03:01, *13:02 
DN02-1006 15 F Mixed race TB008 Tetramer, Elispot, 
Proli, ICS 
*03:01, *13:02 
DN02-1001 13 F Black African TB008 Elispot, Proli, ICS *03:02, *15:03 
DN02-1003 13 M Black African TB008 Elispot, Proli, ICS *11:01, *14:01 
DN02-1005 14 M Black African TB008 Elispot, Proli, ICS *03:02, *12:01 
DN02-1007 15 M Black African TB008 Elispot, Proli, ICS *09:01, *13:01 
DN02-1009 14 F Black African TB008 Elispot, Proli, ICS *04:05, *13:01 
DN02-1011 15 F Black African TB008 Elispot, Proli, ICS *01:02, *12:01 
DN02-1017 15 F Black African TB008 Elispot, Proli, ICS *15:01, *15:03 
DN02-1020 15 M Mixed race TB008 Elispot, Proli, ICS *11:01, *13:01 
DN02-1023 14 F Mixed race TB008 Elispot, Proli, ICS *03:02, *03:02 
DN02-1025 15 M Black African TB008 Elispot, Proli, ICS *01:02, *03:02 
a) Ex vivo HLA class II tetramer staining and phenotyping.  
b) Ex vivo IFN-! ELISpot assay.  
c) In vitro proliferation assay.  
d)  Whole blood intracellular cytokine staining assay. 
 
3.4.2. Ex vivo detection of Ag85A-specific CD4 T cells by DRB1*03:01-
Ag85A(56-75) HLA class II tetramer staining  
Because the antigen-induced activation of T cells during in vitro stimulation 
may change the expression of certain phenotypic markers (Chao et al. 1997; 
Sallusto et al. 2004; Vallejo et al. 1999), we employed HLA class II tetramers 
to detect and characterise CD4 T cells directly ex vivo, in the absence of T-
cell activation. To establish whether CD4 T cell binding to the DRB1*03:01-
Ag85A(56-75)  HLA class II tetramer was specific, we thawed PBMCs collected 
7-14 days after MVA85A vaccination from 7 individuals bearing the HLA-
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DRB1*03:01 allele. Cells were stained either with the DRB1*03:01-Ag85A(56-
75) tetramer, or the DRB1*03:01-ApoB(2877-2894) control tetramer, which is 
complexed to a peptide spanning amino acids 2877–2894 from apolipoprotein 
B, a human protein involved in cholesterol transport (Malcherek et al. 1993). 
DRB1*03:01-Ag85A(56-75) tetramer+ CD4 T cells were detected in all 7 
vaccinees at frequencies between 0.015% and 0.53% as shown in Figure 1B. 
By contrast, DRB1*03:01-ApoB(2877-2894) tetramer+ CD4 T cells were detected 
at a median frequency of 0.017% (maximum frequency 0.024%) in these 
individuals (Figure 18 B). We also stained PBMCs from 6 HLA-DRB1*03:01 
non-bearing MVA85A vaccinees, who had robust Ag85A-specific CD4+ T-cell 
responses observed previously by IFN-! ELISpot assay (data not shown 
(Scriba et al. 2010)). No specific DRB1*03:01-Ag85A(56-75) tetramer staining 
was observed in these samples; frequencies of tetramer+ CD4 T cells were 
consistently observed below 0.02% (data not shown).  
Figure 18: Direct ex vivo detection of mycobacterial Ag85A-specific CD4 T cells by 
HLA class II tetramer staining. PBMCs from MVA85A-vaccinated individuals were 
stained with the DRB1*03:01-Ag85A(56-75) tetramer or the DRB1*03:01-ApoB(2877-2894) 
control tetramer. Flow cytometry plots show data gated on CD14–, CD19–, live 
(ViViD–), CD3+ lymphocytes. The gating strategy is shown in Figure 21. (A) HLA 
class II tetramer staining of PBMCs 7 days after MVA85A vaccination, from a single 
donor with or without the HLA-DRB1*03:01 allele is shown. (B) The frequencies of 
DRB1*03:01-Ag85A(56-75)  or DRB1*03:01-ApoB(2877-2894) tetramer+ CD4 T cells from 7 
HLA-DRB1*03:01-bearing donors 7 days after MVA85A vaccination are shown. Each 
symbol represents an individual donor and bar represents the mean.   
 
3.4.3. Frequencies of Ag85A-specific CD4 T cells peak 7 days after MVA85A 
vaccination 
Previous MVA85A studies in humans have measured cytokine expressing 
cells to determine the magnitude and kinetics of the Ag85A-specific T cell 
response after MVA85A vaccination (Hawkridge et al. 2008; Scriba et al. 
2010). We stained PBMCs collected before, and at multiple time points up to 
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1 year after MVA85A vaccination with the DRB1*03:01-Ag85A(56-75) tetramer. 
Pre-vaccination frequencies of DR3-Ag85A-specific CD4 T cells were mostly 
low (Figure 19A and B). Following MVA85A vaccination, frequencies of 
DRB1*03:01-Ag85A(56-75)-specific CD4 T cells increased markedly in all 
vaccinees (Figure 19A and B). The response peaked 7 days post-vaccination 
and had returned to pre-vaccination levels after 2 months (Figure 19B). This 
kinetic profile was remarkably similar to that of specific CD4 T-cell frequencies 
measured by IFN-! ELISpot assay, following incubation of PBMCs with 
peptides spanning the entire Ag85A protein (Figure 19C). However, Ag85A-
specific CD4 T cells detected by ELISpot assay remained at higher 
frequencies than those observed pre-vaccination for the entire follow-up 
period (Figure 19C), indicating greater magnitude when T cell responses to 
the entire Ag85A protein are measured, and/or possibly greater sensitivity of 




Figure 19: Direct ex vivo detection of mycobacterial Ag85A-specific CD4 T cells by 
HLA class II tetramer staining. PBMCs from MVA85A-vaccinated individuals were 
stained with the DRB1*03:01-Ag85A(56-75) tetramer or the DRB1*03:01-ApoB(2877-2894) 
control tetramer. (A) Representative flow cytometry plots of DRB1*03:01-Ag85A(56-75) 
tetramer staining of PBMCs collected before, and at the indicated time points, after 
MVA85A vaccination are shown from a single individual. (B) Longitudinal follow-up of 
DRB1*03:01-Ag85A(56-75) tetramer+ CD4 T-cell frequencies in 7 HLA-DRB1*03:01-
bearing donors before, and up to 1 year after, MVA85A vaccination is shown. (C) 
The frequencies of IFN-!-expressing T cells in the same 7 HLA-DRB1*03:01-bearing 
donors, measured by ELISpot assay after stimulation of PBMCs with 15-mer 
peptides spanning the entire Ag85A protein are shown. 
 
 
3.4.4. CD4 T cell activation after MVA85A vaccination is short-lived  
To investigate the kinetics and duration of T cell activation after vaccination, 
we measured expression of the activation marker CD38 on tetramer+ CD4 T 
cells (Figure 20). T-cell activation increased markedly by 7 days post-
vaccination and was short-lived, as CD38 expression levels returned to 
baseline levels in most vaccinees by 14 days (Figure 20A and B). These low 





Figure 20: Direct ex vivo detection of CD38 expression on Ag85A-specific CD4 T 
cells. PBMCs from MVA85A-vaccinated individuals were stained with the 
DRB1*03:01-Ag85A(56-75) tetramer. Flow cytometry plots show data gated on CD14–, 
CD19–, live (ViViD–), CD3+ DRB1*03:01-Ag85A(56-75) tetramer+ CD4 T lymphocytes. 
(A) Representative flow cytometry plots of CD38 expression on Ag85A-specific CD4+ 
T cells before (Day 0)and 7 or 14 days after MVA85A vaccination are shown for an 
individual. (B) Longitudinal post-vaccination follow-up of Ag85A-specific CD4 T-cell 
activation in the 7 HLA-DRB1*03:01-bearing donors are shown. Activation was 
measured as CD38 median fluorescence intensity on DRB1*03:01-Ag85A(56-75) 
tetramer+ CD4 T cells. P-values were calculated using the Wilcoxon matched pairs 
test.   
 
3.4.5. Activated MVA85A-induced CD4 T cells express a skin-homing 
phenotype 
The capacity of antigen-specific T cells to traffic to the site of infection-induced 
inflammation is critical for protective immunity. To determine the tissue 
homing potential of Ag85A-specific CD4 T cells induced by intradermal 
MVA85A vaccination, we measured expression of homing markers associated 
with trafficking to skin (cutaneous lymphocyte antigen, CLA (D. J. Campbell & 
Butcher 2002)), gut (!4"7 (Kantele et al. 1999)) and lung (!4"1 (Walrath & 
Silver 2010)) on DRB1*03:01-Ag85A(56-75) tetramer+ CD4 T cells (Figure 22A). 
The gating strategy used to discern T cell populations is shown in Figure 21.  
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Figure 21: Flow cytometric analysis and gating strategy of CD4 T cells. (A) 
Representative density plots showing the gating strategy employed to identify live, 
CD3+, small CD4 lymphocytes. Cell doublets were excluded using forward scatter-
area (FSC-A) versus forward scatter-height (FSC-H) parameters, small lymphocytes 
were then selected before gating on CD19- and CD14- live (ViViDlow), CD3+ T cells. 
Finally, CD4 T cells were selected.  (B) Representative flow cytometry plots showing 
CD4 T cell co-expression of the homing markers !7, !1, "4 and CLA.  
 
 
During the peak response, 7 days post-vaccination, Ag85A-specific CD4+ T 
cells predominantly expressed CLA, while a minority expressed "4!1 (Figure 
22B).  This expression pattern was short-lived and mirrored T-cell activation; 
by day 14 post-vaccination the proportion of CLA-expressing cells had 
returned from ~70% to pre-vaccination levels of ~20%, and remained at this 
level throughout the duration of follow-up (Figure 22C). The proportion of 
"4!1-expressing tetramer+ CD4 T cells remained relatively consistent at 
~20% during follow-up. Ag85A-specific T cells expressing the gut homing 
marker, "4!7, were infrequent or not detectable, at all time-points (Figure 
22B). Of note, more than 60% of the tetramer+ CD4 T cells detected 14 days 
after vaccination expressed none of the homing markers analysed. 
An important observation was that expression of CLA, "4!1 and "4!7 was 
not distinct; many cells co-expressed these markers. Seven days post-
vaccination, CLA-expressing Ag85A-specific CD4 T cells co-expressed the 
integrins "4!1, "4 alone or !1 alone (Figure 22). This co-expression pattern 




Figure 22: Homing marker expression by Ag85A-specific CD4+ T cells. (A) The 
expression of the T-cell homing markers CLA and integrin !7 on DRB1*03:01-
Ag85A(56-75) tetramer+ CD4 T cells (red dots) or the total CD4 T cell population (grey 
background) before or after MVA85A vaccination is shown for a single individual. 
Red numbers indicate proportions of DRB1*03:01-Ag85A(56-75) tetramer+ CD4 T cells 
in each quadrant. (B) The expression of "4!1, "4!7 and CLA on DRB1*03:01-
Ag85A(56-75) tetramer+ CD4 T cells, and the total CD4 T cell population, in 7 HLA-
DRB1*03:01-bearing individuals 7 days after MVA85A-vaccination is shown. 
Horizontal lines represent the medians; boxes the inter-quartile range (IQR) and 
whiskers represent the range. (C) Longitudinal homing marker expression by 
DRB1*03:01-Ag85A(56-75) tetramer+ CD4 T cells in the 7 MVA85A recipients, before 
and up to 1 year after MVA85A vaccination. Lines represent medians and error bars 
represent the IQR. (D) Co-expression of "4!1, "4 or !1 by CLA+ DRB1*03:01-
Ag85A(56-75) tetramer+ CD4 T cells, in the 7 MVA85A recipients 7 days after MVA85A-
vaccination.  
 
3.4.6. MVA85A-induced CD4 T cells display an effector phenotype 
Vaccines that protect for decades, such as smallpox, induce a long-lived 
memory T-cell response (Esser et al. 2003; Crotty et al. 2003; J. D. Miller et 
al. 2008; Akondy et al. 2009). Such long-lived central memory (TCM) CD4 cells, 
which home to lymph nodes by virtue of high CCR7 expression, produce 
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mostly IL-2 and possess greater proliferative potential compared with effector 
(TE) or effector memory (TEM) CD4 cells (Wrammert et al. 2009; Sallusto et al. 
1999). The latter subsets migrate to sites of infection and predominantly 
express effector molecules, such as IFN-! (Wrammert et al. 2009; Sallusto et 
al. 1999).  
To characterise the memory phenotype of MVA85A-induced T cells, we 
measured expression of CD45RA, CCR7 and CD27 on DRB1*0301-Ag85A(56-
75) tetramer+ CD4 T cells (Figure 24). The gating strategy utilised to discern T 
cell memory populations is shown below in Figure 23. 
 
Figure 23: Flow cytometric gating strategy of CD4 T cell memory populations.  (A) 
Representative flow cytometry plots showing CD4 T cell co-expression of the 
memory markers CD45RA, CCR7 and CD27. (B)Representative flow cytometry plots 
showing the boolean gating strategy used to identify memory populations. 
Expression of CD45RA, CCR7 and CD27 on DRB1*03:01-Ag85A(56-75)  tetramer+ 
CD4 T cell subsets (coloured dots) overlayed on the total CD4 T cell population (grey 
background) are shown. 
  
Ag85A-specific CD4 T cells detected before MVA85A vaccination 
predominantly displayed either a CD45RA+CCR7+CD27+ phenotype, typical 
of naïve T cells (Wrammert et al. 2009; Sallusto et al. 1999), and thus termed 
“naïve-like” T cells, or a CD45RA!CCR7+CD27+ TCM phenotype (Figure 24A 
and B). During the acute post-vaccination response, when Ag85A-specific 
CD4 T cells were highly activated (Figure 20B), these cells predominantly 
displayed a CD45RA!CCR7!CD27! effector phenotype (Figure 24B and C). 
As this effector response waned, DRB1*03:01-Ag85A(56-75) tetramer+ CD4 T 
cells reverted to displaying either the CD45RA+CCR7+CD27+ (Figure 24B 
and D) or CD45RA!CCR7+CD27+ TCM (Figure 24B and E) phenotype, which 
predominated before vaccination.  
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Figure 24: Memory phenotype of Ag85A-specific CD4 T cells. (A) Longitudinal 
changes in expression of CD45RA and CCR7 by DRB1*03:01-Ag85A(56-75) tetramer+ 
CD4 T cells (red dots) or the total CD4 T-cell population (grey background) before or 
after MVA85A vaccination (n=7). Red numbers indicate relative proportions of 
DRB1*03:01-Ag85A(56-75) tetramer+ CD4 T cells in each quadrant. (B) Kinetic 
changes in frequencies of DR3-Ag85A tetramer+ CD4 T cells expressing an effector 
phenotype (CD45RA–CCR7–CD27–), a “naive-like phenotype 
(CD45RA+CCR7+CD27+) or a central memory phenotype (CD45RA–CCR7+CD27+) 
at the indicated time points after MVA85A vaccination. Data are shown as median 
and IQR of the 7 donors.  (C-E) Kinetic changes in the proportions of DRB1*03:01-
Ag85A(56-75)  tetramer+ CD4 T cells expressing (C) an effector phenotype (CD45RA–
CCR7–CD27–), (D) a “naive-like” phenotype (CD45RA+CCR7+CD27+) or (E) a 
central memory phenotype (CD45RA–CCR7+CD27+) are shown. P-values were 







3.4.7. Increased proliferation and IL-2 expression of Ag85A-specific memory 
CD4+ T cells post-vaccination. 
To determine whether the phenotypes of pre- and post-vaccination Ag85-
specific CD4 T cells were associated with differential T-cell proliferative 
capacity, we measured in vitro proliferation in response to Ag85A peptides 
before and up to 1 year after MVA85A vaccination (Figure 25A and B). Pre-
vaccination proliferation of Ag85A-specific CD4 T cells was very low. Upon 
vaccination, Ag85A-specific in vitro proliferation of CD4 T cells increased 
gradually and peaked between 28 and 168 days post-vaccination. 
Frequencies of proliferating specific CD4 T cells remained above pre-
vaccination levels up to 12 months post-vaccination (Figure 25B and C).  
 
Figure 25: Lymphoproliferation of Ag85A-specific CD4+ T cells before and after 
MVA85A vaccination. PBMCs from MVA85A-vaccinated adolescents were stimulated 
with Ag85A peptide pool, PPD or left unstimulated for 6 days. Proliferation was 
measured by dye dilution of Oregon Green. (A) Flow cytometry plots of specific CD4+ 
T-cell proliferation from a representative donor, 28 days after MVA85A vaccination 
are shown. Numbers indicate proportions of Oregon Greenlow, proliferating CD4 T 
cells. (B) Ag85A-specific CD4 T cell proliferation before and after MVA85A 
vaccination, from a representative adolescent. (C) Longitudinal kinetics of Ag85A-
specific CD4 T cell proliferation before and after MVA85A vaccination in 10 
adolescents are shown.  
 
 
CD4 T cells that preferentially express IFN-! generally have lower proliferative 
capacity, while predominant IL-2 expression is associated with greater 
proliferation (Sallusto et al. 2000; Harari et al. 2004). To further characterise 
the function of MVA85A-induced memory cells, we measured the relative 
proportions of Ag85A-specific CD4 T cells expressing IFN-! and/or IL-2 at 7, 
28 and 168 days after MVA85A vaccination (Figure 26A). Ag85A-specific CD4 
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T cells at the pre-vaccination time point were too infrequent to analyse relative 
proportions of cytokine-expressing cells definitively (see methods). The acute 
response, 7 days post-vaccination, was characterised by similar proportions 
of CD4 T cells expressing IL-2 and/or IFN-!. The waning of TE cells after the 
peak response was associated with increasing proportions of Ag85A-specific 
IL-2-expressing cells and decreasing proportions of IFN-!-expressing cells 
(Figure 26A and B). However, most antigen-specific CD4 T cells co-
expressed IFN-! and IL-2 (Figure 26A). 
 
 
Figure 26: Vaccine induced CD4 T cell cytokine responses as measured by flow 
cytometry, in 12 adolescents. (A) Representative plots of IFN-! and IL-2 expression 
by unstimulated or Ag85A peptide pool stimulated CD4 T cells, at the indicated time 
points after MVA85A vaccination. The red gate indicates IFN-!-expressing CD4+ T 
cells; the blue gate indicates IL-2-expressing CD4 T cells while the green gate 
indicates co-expression of both cytokines. Numbers indicate the frequencies of CD4+ 
T cells falling into these gates. (B) The relative proportions of total Ag85A-specific 
cytokine+ CD4 T cells expressing total IFN-! (red) or total IL-2 (blue) or both 
cytokines (green), at the indicated time points after MVA85A vaccination in 12 
participants are shown as median, IQR (box) and range (whiskers). P-values were 
calculated using the Wilcoxon matched pairs test.   
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3.5.Discussion 
We characterised antigen-specific CD4 T cell response induced by MVA85A 
boost vaccination in adults, adolescents and children from a TB endemic 
setting, where BCG is routinely administered at birth. It is not known which 
characteristics of the T-cell response may mediate superior protection against 
TB than those primed by BCG or natural infection (Kaufmann & McMichael 
2005; Walzl et al. 2011). We proposed that a boost vaccine should induce 
long-lived modifications to the functional and/or phenotypic characteristics of 
pre-existing mycobacteria-specific T cell.  
We showed that Ag85A-specific CD4 T cells predominantly co-expressed 
IFN-! and IL-2, skin homing integrins and activation markers during the 
effector response, which was short-lived. Contraction of the immune response 
was marked by a transition to predominantly IL-2-expressing, CD45RA-
CCR7+CD27+ or CD45RA+CCR7+CD27+ specific CD4 T cells.  
The proportion of Ag85A-specific CD4 T cells bearing effector or central 
memory phenotypes was similar before and one year after vaccination, but 
functional differences could be shown: Ag85A-specific CD4 T cell proliferative 
capacity was markedly higher 6-12 months after MVA85A than before 
vaccination, highlighting discordance between proliferative function and 
memory phenotype.  
The short duration of Ag85A-specific CD4 T cell activation observed during 
the acute response to MVA85A was not surprising. Given the replication-
deficient nature of the MVA vector (Sutter & Moss 1992), the presence of 
antigen is likely to be very short-lived. The kinetics of this effector response 
are consistent with those reported for vaccination with live, rapidly cleared 
smallpox and yellow fever vaccines ( J. D. Miller et al. 2008). Predictably, the 
duration of CLA expression by these effector cells also reflected the short-
lived nature and location of the inflammatory response, which typically 
resolves within 7 days of vaccination and presents as redness and swelling at 
the intradermal injection site ( Scriba et al. 2010; Hawkridge et al. 2008). Only 
a small proportion of DRB1*03:01-Ag85A(56-75)-specific T cells expressed 
"4#1, while "4#7 expression was negligible. We found that the homing 
markers CLA, "4 and #1 were co-expressed on Ag85A-specific CD4+ T cells 
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during the acute response. The majority of previous studies have reported 
distinct expression patterns of these markers, implying that specific T cells 
possess homing potential to a single tissue site only  Kantele et al. 1999;  D. 
J. Campbell & Butcher 2002; Walrath & Silver 2010; J. A. Burns et al. 2001). 
One study reported a similar finding in mice and humans, showing transient 
co-expression of CLA, and !4"7 (Masopust et al. 2010). Whether cells co-
expressing homing markers may home to multiple sites is possible, but not 
definitive. These observations suggest that expression of homing markers 
may be more complex than previously acknowledged, and that studies of T-
cell homing should take co-expression of these makers into account, 
especially whilst inflammation is present at the site of infection or vaccination.  
Waning of the MVA85A-induced effector response coincided with a transition 
to CD45RA-CCR7+CD27+ TCM and CD45RA+CCR7+CD27+ naïve-like 
phenotypes, which also predominated the Ag85A CD4 T cell response before 
MVA85A vaccination. 
The observed TCM phenotype of Ag85A-specific CD4+ T cells following 
MVA85A vaccination contradicts our previous finding in adolescents, which 
showed that antigen-specific T cells predominantly displayed a TE-cell 
phenotype up to 2 months post-vaccination (Hanekom et al. 2008; Scriba et 
al. 2010; Abel et al. 2010; Soares et al. 2008). This discrepancy is likely due 
to the different assays employed to detect Ag85A-specific T cells. In our 
previous study, Ag85A-specific T cells were identified as cytokine-expressing 
CD4 T cells following 12 hours of in vitro re-stimulation with Ag85A peptides 
(Tameris et al. 2013; Scriba et al. 2010). Short-term in vitro T-cell stimulation 
has been shown to alter expression of certain phenotypic markers (Chao et al. 
1997; Vallejo et al. 1999; Fritsch et al. 2005), and may be a potential 
confounder in our peripheral blood measurements. By contrast, ex vivo 
detection of specific T cells by HLA tetramers offers more accurate 
measurement of T-cell phenotype, since it does not rely on T-cell activation. 
Regardless, our current data of Ag85A-specific T-cell phenotype, cytokine 
expression and proliferative potential following MVA85A vaccination support 
the well-described differences in function between TE and TCM cells Sallusto et 
al. 1999; Sallusto et al. 2000; Harari et al. 2004).  
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Whether long-lived memory cells with excellent proliferative potential, rather 
than effector functions, may confer better protection against TB is not known. 
A gradual loss of BCG-induced T cells through attrition has been mooted as 
an underlying reason for the waning of BCG-induced protection against TB 
observed during adolescence (Orme 2010). Long-lived TCM responses can 
provide protection for decades as illustrated by successful prophylactic 
vaccines, such as those against tetanus toxoid (Cellerai et al. 2007), yellow 
fever (J. D. Miller et al. 2008) and smallpox (J. D. Miller et al. 2008). The high 
proliferative potential observed up to 1 year after MVA85A vaccination may 
thus reflect an ability to rapidly generate large numbers of specific effector 
cells upon infection, which may improve longevity of anti-mycobacterial 
immunity. Such longevity is further supported by our finding that elevated 
frequencies of Ag85A-specific CD4 T cells persist up to 5 years after MVA85A 
vaccination, even in infants (Tameris et al. 2014). However, no evidence for 
efficacy against TB disease or M.tb infection was observed in infants after 
MVA85A vaccination in a recent phase IIb trial (Tameris et al. 2013). It is not 
known why MVA85A failed to confer protection over and above newborn BCG 
vaccination in this infant trial, or whether MVA85A would be more efficacious 
in the older populations studied here, who have greater frequencies of Ag85A-
specific responses before and after MVA85A vaccination than infants (Scriba 
et al. 2011). The possible reasons underlying the observed lack of efficacy in 
infants, which may include route and/or age of administration, dose of the 
vaccine, the high rate of M.tb transmission in the trial population, or the 
magnitude, function and/or phenotype of the induced immune response, have 
been discussed in detail (Tameris et al. 2013; Dye & Fine 2013).  
Induction and maintenance of a persistent, specific TEM response, by chronic 
antigen stimulation, has also been suggested as an effective strategy against 
chronic infections (Hansen et al. 2011), including M.tb. The partially protective 
effect of BCG vaccination against M.tb challenge in mouse models may 
support this: BCG persists and replicates in mice (Mittrucker et al. 2007) and 
thus maintains a consistent population of TEM cells (Kaveh et al. 2011). The 
reason for a more protective response may be the preferential homing of TEM 
cells to peripheral sites of inflammation, such as the lung. This is supported by 
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results from murine vaccination with a recombinant BCG vaccine that 
expresses the membrane-perforating listeriolysin and is devoid of the urease 
C gene (Desel et al. 2011). This vaccine was shown to recruit more antigen-
specific cells to the lung and enhance protection against M.tb than parental 
BCG. Regardless, studies are needed to determine which phenotypic and/or 
functional attributes of T-cell responses induced by BCG and novel vaccine 
candidates may be associated with long-lived protection in humans. 
We decided to focus on vaccine-induced antigen-specific CD4 T cell 
responses because previous studies showed that MVA85A induced low or 
undetectable Ag85A-specific CD8 T cell responses (Scriba et al. 2010; Scriba 
et al. 2011). Other prime-boost strategies, such as those employing 
recombinant BCG or adenoviral Aeras402 (Hoft et al. 2012; Abel et al. 2010), 
did induce antigen-specific CD8 T-cell responses. 
 
Substantial proportions of mycobacteria-specific CD45RA+CCR7+CD27+ or 
CD45RA+CCR7+ naïve-like CD4 T cells have been reported in multiple 
studies (Soares et al. 2008; Tena-Coki et al. 2010; Kagina et al. 2009; 
Caccamo et al. 2006), but have not been characterised. BCG-specific naïve-
like CD4 T cells expressed cytokines in response to antigen stimulation 
(Soares et al. 2008; Tena-Coki et al. 2010; Kagina et al. 2009) and were 
present at frequencies considerably greater than those described for 
pathogen-specific naïve T cells (Geiger et al. 2009; Kwok et al. 2012). 
Additional studies are required to delineate the functional attributes of naïve-
like CD4 T cells and how they fit into the ontology of T-cell differentiation. We 
further characterise these naïve-like CD4 T cells in Chapter 5. 
A limitation of our study was that our analyses were confined to T cells 
circulating in the peripheral blood. It is likely that, early after vaccination, most 
antigen-specific T cells traffic to the vaccination site and are thus not 
circulating in the periphery.  
Another limitation of our approach was the use of a single tetramer complexed 
to a single Ag85A epitope. We cannot rule out that CD4 T cells recognising 
different Ag85A epitopes may yield different results to the ones reported here. 
In conclusion, we report that a prime-boost vaccination strategy against TB in 
children, adolescents and adults modulates the function of long-lived memory 
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CD4 cells and endow them with the capacity to proliferate readily upon 
secondary antigen encounter. Our recent phase IIb trial results suggest that 
these memory CD4 cells may not be sufficient for protection against TB in 
infants (Tameris et al. 2013). More studies are needed to explore whether a 
greater magnitude, a qualitatively different, or a completely new 





HLA typing of MVA85A vaccines was performed at the National Institute for 
Communicable Disease in Johannesburg, South Africa. 
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Chapter 4: Optimisation of high throughput microfluidic qRT-
PCR platform (Fluidigm) and T cell sorting 
 
4.1. Introduction 
Next, we aimed to characterise the interesting and novel mycobacteria 
specific naïve-like CD4 T cells observed in Chapter 3, by comparing mRNA 
expression with those of naïve, central memory, effector T cells as well as 
other M.tb-specific CD4 T memory cell populations. 
 
Gene expression profiling of cells has given us the ability to simultaneously 
investigate many cell characteristics, which uniquely define and identify cell 
subsets (Bedognetti et al. 2010). Measurement of only a few markers, though 
informative, may underestimate complexity and limit understanding of the 
roles of specific T cells. This is exemplified by the initial reports that T helper 
(Th) cell subsets fell into 2 subsets only, Th1 and Th2 (Mosmann & Coffman 
1989). Due to technological advancements, it is now known that 
measurement of a handful of phenotypic and functional markers may not be 
sufficient to define the great complexity in Th cells subsets especially in the 
context of immune interactions with M.tb. The scientific community is showing 
a strong drive to delve deeper into intricate signalling pathways, gene 
expression profiles and regulation thereof in disease or after vaccination. Until 
very recently, DNA microarrays were the best tools to interrogate expression 
of a large number of genes. However, this method has been historically 
hindered by a requirement for large numbers of cells or input material.  
 
The development of high throughput qRT-PCR has revolutionised the 
capability to study cells at a transcriptional level. The BioMark microfluidic 
qRT-PCR platform (Fluidigm) allows simultaneous quantification of 96 mRNA 
transcripts in 96 samples in a single chip. By combining the sensitivity and 
dynamic range of single cell qRT-PCR with the multiplexing of microarrays, 
BioMark technology overcomes the need for large amounts of starting 
material. With a PCR reaction volume of 3nL, this platform facilitates analyses 
of transcriptional profiles using very little starting material, even down to single 
cells. When combined with the ability to sort rare populations of antigen-
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specific cells, this technology provides an invaluable tool for scrutiny of 
transcriptional complexity amongst T cell subsets. This novel platform has 
been used disparately and, until recently, no optimal and quantitative 
application of this technology had been detailed (Flatz et al. 2011). A recent 
study was the first to publish rigorous methodology to assess quantitative 
application of this technique to measure gene expression in small cell 
populations (Dominguez et al. 2013). 
 
In this chapter, we set out to develop and optimise methodology for 
quantification and comparison of mRNA expression patterns amongst 
different subsets of antigen-specific T cell memory populations, sorted by 
FACS. Quantification of mRNA depends on accurate, reliable and linear 
measurement of each transcript, necessitating qualification of each set of 




To analyse the transcriptional profile of T cell memory subsets, including the 
newly described naïve-like CD4 T cells, antigen-specific T cells had to be 
sorted according to expression patterns of established memory surface 
markers. We also sought to optimise conditions required for qRT-PCR assays, 
and to qualify the Taqman primer/probe sets used in BioMark Fluidigm 
technology. Finally, determining the minimum number of cells required to yield 
reliable detection of gene transcripts, given our limited input material, was 
essential.  
 
To establish methods for mRNA expression profiling in sorted antigen-specific 
cells, we had to: 
i) Select genes for transcriptional profiling of T cells 
ii) Qualify and validate the primer/probes for detection of selected 
genes 
iii) Optimise simultaneous and efficient sorting of four distinct CD4 T 
cell populations  
iv) Sort different T cell numbers and determine the reliability of gene 
transcript detection 
v) Determine if HLA class II tetramer binding of antigen-specific T cells 
results in mRNA transcript expression changes   
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4.3. Materials and methods 
The work in this chapter was performed by the candidate unless otherwise stated. 
 
4.3.1. Gene selection 
We aimed to determine if M.tb-specific naïve-like CD4 T cells, which shared a 
memory phenotype profile with naïve CD4 T cells, had a transcriptional profile 
distinct from truly naïve CD4 T cells, effector and central memory CD4 T cells. 
We therefore selected genes to quantify mRNA expression by genes that 
differentiate naïve, effector and central memory CD4 T cells from each other, 
based on published literature. In-depth criteria for gene selection are 
described in section 4.4.1 of this chapter. 
 
4.3.2. PBMC stimulation and RNA extraction for primer/probe qualification 
PBMCs from healthy donors were thawed into 10mL of 10%AB+/RPMI media 
containing DNase (50U/mL). Cells were spun down at 596g for 10 minutes 
and then washed once by re-suspending in 10mL of PBS. Cells were spun at 
596g for 10 minutes and then re-suspended into 10%AB+/RPMI media. A vial 
of 10 million PBMCs was split into 2 aliquots, one aliquot was left 
unstimulated and the second aliquot was stimulated with PHA (10μg/mL) for 5 
hours at 37°C in a 5% CO2 incubator. Cell aliquots were then combined at the 
end of the stimulation and RNA was extracted using the Qiagen RNeasy Plus 
kit following the manufacturers’ protocol (Qiagen). 
 
4.3.3. Primer/probe qualification 
RNA extracted from the combined, unstimulated and stimulated cells was 
diluted in a 12-point two-fold serial dilution ranging from a concentration of 
80ng/mL to 0.02ng/mL. Each dilution series was loaded in 8 replicate wells 
across a 96 well plate. RNA was reverse transcribed to cDNA using the First 
strand cDNA synthesis kit following the manufacturers’ protocol (Invitrogen). 
cDNA synthesis was then confirmed as described below in section 4.3.4., at 
random from a few dilutions on the plates. The cDNA was then loaded onto a 
Fluidigm 96.96 gene expression chip and run as described below. Threshold 
expression (Et) values are used as they are the reciprocal of the Ct values, 
and this eases interpretation of data, as a high value is high mRNA transcript 
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levels. The raw Et (40-Ct) values were then plotted against RNA input and the 
slope of the line as well as the correlation coefficient determination (R2), were 
calculated across any 5 or more points, using R version 3.0.1 according to the 
method published by Dominguez et al (Dominguez et al. 2013). 
 
4.3.4. cDNA synthesis and amplification for qRT-PCR from low cell numbers 
The CellsDirect One-Step qRT-PCR kit (Invitrogen) was used. This kit is ideal 
for gene expression analysis in a single cell and up to 10000 cells per reaction 
(Fox et al. 2012; Dominguez et al. 2013).  T cell populations were sorted 
directly into 9μL of the Reverse Transcribe Specific Target Amplification (RT-
STA) mix that contained the reagents in Table 22. 
 
Table 22: RT-STA mix (CellsDirect One-step qRT-PCR kit). 
Reagent Per reaction 
volume 
CellsDirect 2x reaction mix 5μL 
Superscript III RT/Platinum Taq mix 0.5μL 
0.2x primer/probe mix 2.5μL 
DNA suspension buffer 1μL 
Total 9μL 
  
Polymerase chain reaction (PCR) tubes containing the RT-STA mix and cells 
were placed in a thermal cycler and following thermal profile in Table 23 was 
used for the reverse transcriptase (RT) reaction, followed by an 18 cycle pre-
amplification step. The pre-amplification step is required to increase the level 
of mRNA transcripts of genes of interest without bias, as all 96 primer probes 
are included. Because the sample is split 96 ways in the microfluidic chip, pre-
amplification is performed to ensure even distribution of rare template across 
the 96 reactions. 
 
Table 23: Reverse transcription and pre-amplification thermal cycling protocol. 
 RT Taq activation Specific target Amplification (18 
cycles) 
Temperature 50°C 95°C 95°C 60°C 
Time 20 minutes 2 minutes 15 seconds 4 minutes 
 
Upon completion of the thermal cycling, the cDNA was diluted with 40µl of 
molecular biology grade water to dilute out the primer/probes used for pre-
amplification to very low levels (1:5 dilution). Dilution of cDNA was performed 
! "#$!
to drastically reduce the probability of non-specific amplification of particular 
transcripts due to remaining primer/probes from the pre-amplification step. To 
confirm successful reverse transcription to cDNA and pre-amplification, a 
PCR with a single primer was performed to detect PCR product. The following 
reagents, Table 24 below, and thermal cycling protocol was used according to 
the TaqMan protocol (Table 25). 
 
Table 24: Reagents for confirmation of successful cDNA synthesis and pre-
amplification.  
Reagent Per reaction 
volume 
TaqMan Universal PCR master mix (Applied Biosciences) 10μL 
20x TaqMan gene expression assay 1μL 




Table 25: Thermal cycling profiling for conventional PCR on Rotorgene light 
cycler following the TaqMan gene expression assay protocol. 
 Initial Setup Denature Anneal/Extend 
HOLD HOLD 40 Cycles  
Temperature 50°C 95°C 95°C 60°C 
Time 2 minutes 10 minutes 15 seconds 1 minutes 
 
Once cDNA pre-amplification was confirmed, cDNA samples were mixed with 
the reagents listed below (Table 26) and 5μL of the sample mix was loaded 
into each sample well of the Fluidigm 96.96 gene expression chip. The single 
primer/probes were also mixed with the assay reagents (Table 27) and 5μL 
was loaded into each assay well on the Fluidigm 96.96 gene expression chip, 
shown in Figure 27. 
 
Table 26: Sample preparation for Fluidigm 96.96 gene expression chip run 
Reagent Per sample volume 
TaqMan universal PCR master mix 5.55μL 
DA sample loading reagent (Fluidigm) 0.55μL 
cDNA sample 5μL 
 Total 11.1μL  
 
Table 27: Assay preparation for Fluidigm 96.96 gene expression chip run 
Reagent Per sample volume 
20x TaqMan gene expression  5.55μL 
DA sample loading reagent (Fluidigm) 0.55μL 
cDNA sample 5μL 




Figure 27: The Fluidigm 96.96 gene expression chip layout demonstrating where the 
samples and assays are loaded. The single primer probes in assay reagent are 
loaded on the left of the chip and the pre-amplified cDNA samples in sample reagent 
are loaded into the wells on the right. 
 
 
4.3.5 Selection of candidate primer/probes for qualification 
The following primer/probes were selected as candidates for qualification 
based on their ability to discriminate between T cell memory subsets. Those 
that qualified, as described in section 4.4.2 of this chapter, were then selected 
to address our aims.  
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4.3.6. Flow cytometer configuration 
A BD FACS Aria II flow cytometer was utilised for sorting T cell memory 
populations for microfluidic qRT-PCR. Optimal voltages were determined for 
each fluorochrome and for each detector to ensure optimal resolution of 
stained cell populations.  A quality assurance routine was set up to monitor 
and ensure consistent and optimal functioning of the instrument and was 
maintained over the period of use, and to ensure consistent and reproducible 
measurements. Cytometer setup and tracking (BD Biosciences) beads that 
fluoresce in each channel at a predetermined median fluorescence intensity 
(MFI) were run daily to ensure target MFI and signal CVs are maintained 
(Perfetto et al. 2012). Photomultiplier tube (PMT) voltages were adjusted daily 
to ensure that consistent MFIs were maintained, using Rainbow fluorescent 
particle (Spherotech) beads. Compensation beads were also acquired daily 
before acquisition of samples, to allow pre-acquisition compensation. Shown 
below in Figure 28, are the mirror and filter configurations used on the BD 
FACS Aria II flow cytometer. 
 
Figure 28: Filter and mirror configuration for each laser of the BD FACS Aria II flow 
cytometer. The dichroic mirrors are shown in green and the band pass filters in lilac. 
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4.3.7. Antibodies  
Fluorescence-conjugated antibody panels utilised for cell sorting experiments 
are shown in Table 29. Panels were optimised as described in Chapter 2 
section 2.3.13. 
 
Table 29: Panel of fluorochrome-conjugated antibodies and HLA class II 
tetramer used for cell sorting studies.  
Marker Clone Manufacturer Fluorochrome Volume/concentratio
n used (in 100μL 
final staining volume) 
CD14 (dump) M5E2 Biolegend Brilliant Violet 421 0.5μL 
CD19 (dump) HIB19 BD Biosciences Brilliant Violet 421 0.25μL 
CD8 (dump) RPA-T8 BD Biosciences Brilliant Violet 421 0.5μL 
CD335 
(dump) 
9E2 Biolegend Brilliant Violet 421 0.5μL 
Live/dead 
(dump) 
 Invitrogen ViViD 0.5μg/mL 
CD4 S3.5 Invitrogen Quantum Dot 605 0.5μL 
CD95 DX2 Biolegend APC 1.25μL 
CD3 UCHT1 BD Biosciences Alexa Fluor 700 1μL 
CD27 M-T271 BD Biosciences FITC 1.25μL 
Tetramer  NIH tetramer 
core facility 
PE 2μg/mL 
CCR7 150503 BD Biosciences PerCP Cy5.5 1.25μL 
CD45RA HI100 eBiosciences PECy7 0.05μL 
  
The markers CD14, CD19, CD335 and CD8 were all conjugated to the same 
fluorescent molecule to exclude them from analysis, this is known as a dump 
channel. This channel is also used for the live/dead, to exclude dead cells. 
 
4.3.8. Four-way sorting of CD4 T cell populations 
PBMC were stained with the memory phenotype antibody panel in Table 8 
(except tetramer). Tube adaptors were evaluated for their capacity to capture 
single cells being sorted into collection tubes of varied sizes. We sorted bulk 
naïve CD4 T cells (CD45RA+CCR7+CD27+), effector CD4 T cells (CD45RA-
CCR7-CD27-/+), central memory CD4 T cells (CD45RA-CCR7+CD27+) and 
CD3+CD8-CD4- T cells. 
 
4.3.9. Sorting of different cell numbers 
PBMC were stained with the memory phenotype antibody panel in Table 8 
(except tetramer). Twenty-five and 50 cells from each cell population were 
sorted directly into RT-STA mix, containing all 96 selected primer probes. We 
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sorted bulk naïve CD4 T cells (CD45RA+CCR7+CD27+), effector CD4 T cells 
(CD45RA-CCR7-CD27-), central memory CD4 T cells (CD45RA-
CCR7+CD27+) and CD3+CD8-CD4- T cells. This was replicated numerous 
times, depending on the experiment. 
 
4.3.10. Tetramer staining for determination of effects on gene expression 
PBMCs from healthy donors were thawed into 10mL of 10%AB+/RPMI 
containing DNase (50U/mL). Cells were spun down at 596g for 10 minutes 
and then washed once by re-suspending in 10mL of PBS. Cells were spun at 
596g for 10 minutes and then re-suspended into 10%AB+/RPMI media. 
Washed PBMCs were split into 6 aliquots of 2 million PBMC each. Tetramer 
staining was performed following the protocol described in Chapter 2 section 
2.3.12, except that tetramer staining periods were varied as follows: one 
aliquot was stained with the DRB1*04:01-CFP10(71-85) tetramer for 10 minutes, 
another for 30 minutes, another for 60 minutes, another for 2 hours and 
another for 4 hours at RT. The last aliquot was stimulated with PMA 
(15ng/mL) and Ionomycin (740ng/mL) for 4 hours at 37°C in a 5% CO2 
incubator. Cells were washed once in 2%FCS/PBS after specified periods to 
stop staining and the rest of the protocol followed. Thirty DRB1*04:01-
CFP10(71-85) tetramer+ cells were sorted in triplicate directly into Cellsdirect 
RT-STA mix for each condition, and then run on the microfluidic qRT-PCR 
platform as described in section 4.3.4 above. 
 
4.3.11. Data analysis (performed in collaboration with M. Musvosvi, SATVI).  
The R2 of Et (40-Ct) values for the dilution series of cells and efficiency values 
for qualification of the primer/probe sets were calculated using R v3.0.1, 
across any 5 or more points, as explained in the results section.  Data were 
expressed as Et values to facilitate intuitive interpretation of results, because 
high Et values depict high mRNA transcript levels. Et values are therefore the 
converse of Ct values. The Mann-Whitney test was used to compare different 
conditions in cell sort efficiency and cell number requirements, using R v3.0.1. 
In the tetramer stimulation experiment where we wanted to determine the 
effects of tetramer staining of gene expression, data for all genes was 
normalised to B2M and delta Ct values were used to calculate fold indices 
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and p-values. The t-test was used to compare tetramer results in the tetramer 
stimulation experiment due to the small sample size of sorts (n=3). A Mann 
Whitney test could not be used as a sample size of greater than 4 is required 
per condition/sort to utilise this statistical test (De Winter 2013).  
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4.4. Results 
4.4.1. Gene selection 
To characterise naïve-like M.tb-specific T cells at a transcriptional level, we 
sought to measure mRNA expression of genes that are differentially 
expressed between naïve, effector, central memory and T memory stem cells. 
Genes encoding proteins that are traditionally different between memory 
subsets, such as functional and effector molecules were selected, as well as 
genes involved in T cell migration, activation markers, apoptosis, cell 
signalling, effector molecules and transcription factors. Housekeeper genes, 
which are genes expressed at highly consistent levels in all cell subsets, were 
used as reference genes for normalising gene expression data. We selected 
reference genes (GAPDH, B2M, HPRT, G6PD) based on published literature 
(de Jonge et al. 2007). 
 
Many publications were considered for gene selection. Furthermore, a recent 
publication by Gattinoni et al., described the transcriptional profile of CD8 T 
memory stem cells (TSCM) in humans. The authors published a list of genes 
that distinguished TSCM from all other memory populations, as well as from 
truly naïve T cells (Gattinoni et al. 2011). This T memory stem cell population 
shares a phenotypic profile similar to that of the naïve-like cells we sought to 
characterise, namely CD45RA+CCR7+CD27+. The fact that the Gattinoni 
published gene list was derived from CD8 T cell subsets was not ideal as we 
aimed to study naïve-like CD4 T cells. However, since this was the only 
published comprehensive set of genes, we reasoned that many of the genes 
may also apply to differentiation of CD4 T cell memory subsets. We selected 
genes that highly differentiated truly naïve T cells from T memory stem cells 
based on fold difference in expression and a significant p-value, as well as 
from the other memory populations to include in our panels. Genes selected 
from this publication are shown in Table 30. 
 
Another study, by Appay et al., described cell surface markers that were 
differentially expressed on CD4 cells as they transitioned from antigen 
inexperienced, naïve cells to memory cells, and then described genes that 
were differentially expressed in these subsets (Appay et al. 2007). We also 
! """!
incorporated genes from their results, which were differentially expressed 
between naïve cells and cells in an early memory differentiation stage, as well 
as cells in a late differentiation stage. Genes selected from this publication are 
shown in Table 30.  
 
There was considerable overlap between genes selected form the Gattinoni et 
al., and the Appay et al., lists and those selected from other published 
literature (Lanzavecchia & Sallusto 2005; Sallusto et al. 2004; H. H. Zhang et 
al. 2010; Seiler et al. 2003; Song et al. 2005; Latta et al. 2007; Guarda et al. 
2007; Acosta-Rodriguez et al. 2007; Ahmed & Akondy 2011; Akondy et al. 
2009; Baekkevold et al. 2005; Caccamo et al. 2006; Campbell & Butcher 
2002; J. J. Campbell et al. 1999; Cui & Kaech 2010; Esser et al. 2003; 
Gattinoni et al. 2009; Geginat et al. 2001; Hand & Kaech 2009; Harari et al. 
2005; Mohan et al. 2005; Rivino et al. 2004; Sallusto et al. 2000; Sallusto et 
al. 1999). Transcripts that were unique to the Gattinoni et al., and Appay et al., 
gene lists are shown in Table 30. Many of the genes shown in Table 30 have 




Table 30:Genes selected according to published gene literature and T cell 
function 
 
4.4.2. Primer/probe qualification 
The primer and probe combinations used to detect and quantify mRNA 
transcripts by qRT-PCR must be qualified to ensure they meet the minimum 
requirements for quantitative analysis. The efficiency of a primer/probe set 
relies on its ability to consistently amplify a gene product, doubling the product 
after each cycle during the logarithmic phase of the amplification reaction. A 
primer/probe set with a perfect PCR efficiency (100%) would demonstrate a 
reduction or increase in 3.3 Et values when comparing templates that differ by 
1 log (10 fold) in concentration. This efficiency across a 10-fold dilution series 
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is calculated as the slope (Dominguez et al. 2013). An efficiency between 
90% and 110% is considered to be acceptable, corresponding to a slope of 
3.1-3.6. Secondly, the signal should be proportionate to the RNA input, a 
property known as “linearity”, expressed as the R2 across a dilution series. 
The R2 was calculated from the slope, where the logarithm of the RNA input 
was plotted against the amplification cycles (Et = 40-Ct). To meet linearity 
requirements, the coefficient of determination (R2) had to be greater or equal 
to 0.97 across any 5 consecutive points in the dilution series. Both efficiency 
and linearity criteria had to be met for a primer/probe to be qualified in any of 
the 8 replicate dilution series. An example of the dilution series and evaluation 
of the slope and R2 value across >5 points is shown in Figure 29. The 
primer/probe R2 and slopes for all tested primer/probe sets are represented in 
Figure 30.  
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Figure 29: Primer/probe qualification method. A broad range (0.02ng-80ng) of RNA 
template concentrations was plotted against their corresponding observed Et (40-Ct) 
values. We evaluated segments of >5 points where amplification is efficient. 
Efficiency is defined as points in a segment where the signal doubles with every PCR 
cycle. To pass, the R2 representing linearity, had to be greater than 0.97 and the 
slope had to fall between 3.1–3.6. When one segment within a replicate dilution 




Figure 30: Qualification of primer/probe sets. R2 values for each primer probe set are 
plotted on the left Y-axis and slopes are plotted on the right Y-axis. Primer probe sets 
(n = 4) with the R2 values below the threshold (shown in red dashed line at 0.97) 
where excluded. Similarly, primer/probe sets (n = 8) with slopes above or below the 
threshold (shown in blue dashed lines at 3.1-3.6) where excluded.  
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We tested a total of 109 primer-probe sets. After excluding the sets that did 
not qualify, 96 genes were selected for our panel. The final genes selected 




Table 31: Final list of genes selected for transcriptional profile studies. 
 
 
4.4.3. Cell sorting (4-way vs 1-way) 
Frequencies of antigen-specific CD4 T cells in peripheral blood are extremely 
heterogeneous and depend on a number of variables including the antigen, 
nature of infection, and length of persistence of infection. Regardless, most 
CD4 T cells that bear the TCR for a single epitope restricted by a single HLA 
allele are very infrequent. Our previous work showed that when using a 
sample of 10 million PBMC, a range of 0-1000 tetramer-positive CD4 T cells 
were detected using an Ag85A DRB1*03:01 HLA class II tetramer. Given 
these very low frequencies and the limited numbers of cryopreserved PBMC 
from study participants, it was clear that simultaneous sorting of tetramer 
positive T cells within the different memory T cell populations was necessary. 
Furthermore, the low frequencies dictated that the Cells-direct method of RNA 
analysis should be followed, which required sorting of cells directly into a 
volume of 9μL of Cells-direct solution. Such a small volume limited the type of 
ARGHEF18 FAS NFKB1 CD44
AXIN2 FOXO3A PDCD1 B2M
BCL2 FOXP3 PRF1 HPRT
BCL2L11 GATA3 PRKCA G6PD
BTLA GNLY PTPRC GAPDH
CAMK4 GZMA RHOH Glob
CCR2 GZMB RORA GPR15
CCR5 GZMK RORC CCL5
CCR6 ICOS SELL ENTPD1
CCR7 IFNGR1 SOCS1 TIMD4
CCR9 IL-10 STAT1 FCER1G
CD137 IL12RB2 STAT3 IGF1R
CD154 IL2RA STAT4 FAM129A
CD27 IL2RB STAT5A PRR5L
CD28 IL2RG STAT5B CCR4
CD38 IL6 STAT6 GFPT2
CD4 IL7R TBX21 BAG-1
CD69 ITGAX TCF3 JUNB
CD8A ITK TCF7 IPLA2
CTLA4 JNK TCF7L2 IFNG
CXCL10 KI67 TFRC IL-2
CXCR3 LEF1 TGFB1 TNF-a
CXCR6 LTB CD31 CD200
EPHA4 MAN1C1 B-CATENIN IL4
Gene
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tube the BD FACS Aria II flow cytometer could sort cells into, as compatible 
tube adaptors are limited. A 0.6mL tube adaptor from the BD FACS Aria I was 
modified to fit the Aria II. Many collection tubes were tested previously on the 
BD FACS Aria II adaptors and none yielded optimal cell sorts, as determined 
by sorting a defined number of cells and determining whether gene transcripts 
were detectable (described in more detail below). The modified 0.6mL 
Eppendorf tube adaptor performed with the highest sorting efficiency (data not 
shown). These tubes were selected for further sorting experiments.  
 
While sorting of cells into a single tube was relatively straightforward, sorting 
of 4 cell populations simultaneously presented more challenges. The BD 
FACS Aria can sort cells into four streams of micro-droplets containing a 
single cell (Figure 31). The distance between the streams is manually 
adjustable.  
 
Figure 31: Photo of the BD FACS Aria II sorting layout used in our experiments.  The 
adaptor holds four 0.6mL Eppendorf tubes. The distance between the streams is 
manually adjusted to ensure that cells are deposited into each tube. 
!
An important aspect of our optimisation experiments was to ensure that equal 
cell sorting efficiencies (i.e. accurate cell deposition) could be achieved for all 
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four tube adaptors. We tested whether simultaneous sorting of four 
populations at a range of pre-determined cell numbers yielded similar mRNA 
transcript detection compared to one-way sorting (Figure 32). 
 
Figure 32: Comparison of 4-way T cell sorting method with 1-way T cell sorting. (A) 
Twelve replicates of 2, 10, 20 or 50 T cells were sorted using 1-way or 4-way sorting 
and GAPDH transcripts were detected by qRT-PCR. No statistical differences were 
observed. (B) Bland Altman plot of the percentage difference of the average raw 
GAPDH Ct values between the two sort methods for all the samples. 
!
Different numbers (2, 10, 20 and 50 cells) of bulk CD4+ T cells were sorted 
using 1-way or 4-way sorting and GAPDH transcripts were detected by qRT-
PCR. We chose the reference gene, GAPDH, because it is known to be 
expressed at highly consistent levels in most cells (de Jonge et al. 2007). We 
sorted each cell number 12 times to have a large enough sample size to 
detect differences. Using the 1-way sorting method, all twelve cell sorts of 2 
cells yielded detectable GAPDH transcript, compared with 9 out of 12 
samples when using the 4-way sorting method. However, with increasing cell 
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numbers, the number of samples with detectable GAPDH transcripts was 
more consistent between the 1-way and 4-way sorting methods (Figure 32). 
We therefore concluded that the 4-way sorting method could be applied to 
analyse antigen-specific CD4 T cells from each memory population, provided 
at least 10 cells were sorted for each experiment. 
 
To further confirm this finding, we performed a Bland Altman test to determine 
how similar the results of 4 way sorting were to 1 way sorting. The percentage 
difference of the average raw GAPDH Ct values between the two sort 
methods for all the samples were plotted Figure 32B. We observed a 7.8% 
bias towards one way sorting as compared to 4 way sorting. We did not view 
this result as a concern as all samples were to be sorted using the 4 way 
method, given its advantages, and thus the bias would be eliminated as a 
factor.  
 
Next, we sought to determine whether sorting of different T cell memory cells, 
based on their distinct expression of surface molecules, also yielded 
consistent sort accuracies. We again compared the 4-way and 1-way sorting 
methods with bulk T cell memory populations, naïve CD4 T cells 
(CD45RA+CCR7+CD27+), effector CD4 T cells (CD45RA-CCR7-CD27-/+), 
central memory CD4 T cells (CD45RA-CCR7+CD27+) and CD3+CD8-CD4- T 
cells (Figure 33).  This was assessed by quantifying all 96 genes on the 
Fluidigm 96.96 gene expression platform. 
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Figure 33: Determination of sorting efficiency of distinct CD4 T cell memory subsets. 
(A) The number of transcripts detected in 50 cells sorted either by the 1-way cell 
sorting method or the 4-way cell sorting method are shown. T cell memory 
populations were sorted and gene transcript levels for 96 genes were detected by 
microfluidic qRT-PCR.  (B) Representative plots of the raw Ct values, for 4 of the 96 
genes, for the 4 way sort and 1 way sort. Each T cell memory population was sorted 
12 times per sorting method. The Mann-Whitney test was used to calculate p-values. 
!
No significant differences in the number of gene transcripts were detected in 
any of the sorted T cell memory populations when the two different cell-sorting 
methods were compared. Furthermore, we assessed whether mRNA 
transcripts were detected at similar levels in both methods within each aorted 
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T cell population. Gene transcript levels were similar for all 96 genes (Figure 
33B and data not shown).  
!
4.4.4. Cell numbers required for efficient transcript quantification 
As mentioned above, the frequencies of mycobacteria-specific CD4 T cells in 
persons with latent M.tb infection are typically very low and highly variable. 
Another important consideration was the minimum number of cells required to 
allow reliable detection of mRNA transcripts amongst the different 
mycobacteria-specific CD4 T cell memory subsets. Using different cell 
numbers to analyse gene expression may introduce bias among different 
subsets, as differential transcript expression may not reflect real inter-subset 
differences but rather differences due to different cell numbers. By keeping 
cell numbers consistent in each cell population eliminates this. From previous 
experience, we expected to detect a maximum of 20-50 cells for the most 
infrequent tetramer+ CD4 T cell memory subset, namely naïve-like cells, from 
10 million PBMC. We sorted 25 and 50 cells from each memory CD4 T cell 
population using the 4-way cell sorting method and measured mRNA 
expression by microfluidic qRT-PCR.  
No differences in the number of transcripts detected between the 25 cells and 
50 cells were detected (Figure 34). 
 
Figure 34: Comparison of mRNA transcript detection in 25 and 50 sorted T cells. 
Bulk CD3+CD8-CD4- T cells and naïve, central memory or effector memory CD4+ T 
cell populations were sorted using 4-way sorting on the BD FACs Aria II. The number 
of transcripts detected in each cell number was determined for 12 replicates of each 




Because the number of transcripts detected between 25 cells and 50 cell 
sorts were not different, we concluded that transcriptomic analyses could be 
performed on sorted CD4 T cell memory populations consisting of 25 cells. 
Since previous experiments performed on 5-10 million PBMC, consistently 
yielded more than 30 tetramer+ CD4 T cells of each memory subset, we 
decided to sort exactly 30 cells per memory population for all experiments 
going forth in this thesis. 
 
4.4.5. Changes in transcript expression after staining with tetramers 
MHC class II tetramers engage the TCR, suggesting that it could potentially 
activate cells. Previous work has shown that tetramer staining does not alter 
the expression of phenotypic markers of T cells (Chao et al. 1997; Sallusto et 
al. 2004; Vallejo et al. 1999). Whether tetramer staining affects the 
transcriptional profile of cells is not known. Because we were interested in 
mRNA expression by antigen-specific T cells detected with HLA class II 
tetramers, we sought to determine if tetramer staining would affect mRNA 
transcript levels. 
PBMCs were stained with the DRB1*04:01-CFP10(71-85) HLA class II tetramer 
for varied time periods and mRNA transcript levels measured for all 96 genes. 
Samples stained with tetramer for 10 minutes were treated as the baseline, 
since this was the minimum required to allow detection of tetramer+ T cells for 
analysis. mRNA transcript levels for all genes, at all other time points were 
measured in relation to those of the 10 minute time point sample, to calculate 
the fold change in expression. P-values were calculated using the Student t-
test. Gene expression was considered different when the fold change was 
greater than or equal to 2, and the p-value was less than 0.05.  
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Figure 35: Influence of tetramer staining on mRNA gene transcript levels. T cells 
were stained with the DRB1*04:01-CFP10(71-85) tetramer for the indicated time 
periods and temperatures. The fold change was calculated as transcript levels of 
cells at each condition relative to the 10-minute tetramer stain. Data represents 3 
sorts of 30 cells for each condition, all from 1 individual.   
 
For the T cells stained with the DRB1*04:01-CFP10(71-85) HLA class II tetramer 
at room temperature (RT) for 30 minutes, mRNA transcript levels from 2 
genes (NFKB1 and STAT3) were significantly different. Following 1 hour of 
staining at RT, expression of two genes (PRKCA and FAM129A) was different. 
Following 2 and 4 hours staining at RT, 3 (BCL2L11, CD28 and IFNG) and 5 
(AXIN2, EPHA4, SELL, TCF7L2 and GPR15) genes were expressed at 
different levels, respectively (Figure 35). 
 
Cells stimulated with PMA/Ionomycin for 4 hours at 37°C before tetramer 
staining were used as a positive control. mRNA expression of 8 genes (CCR7, 
CXCL10, G6PD, GZMK, IFNGR1, RHOH, TBX21,  and CCR4) was  different 
in the PMA/Ionomycin stimulated T cells (Figure 35). 
 
This data suggested that staining with tetramer for 1 hour would have 





The development of high throughput qRT-PCR has revolutionised our ability 
to study cells on a transcriptional level. The Fluidigm microfluidic platform 
allows simultaneous quantification of 96 gene transcripts on 96 samples in a 
single chip. This platform has been successfully utilised for transcriptional 
analyses of single cells (Dominguez et al. 2013). We combined this 
microfluidic qRT-PCR platform with sorting of rare tetramer-stained CD4 T 
cells to allow characterisation of mycobacteria-specific CD4 T cell memory 
subsets, including the novel naïve-like cells described in Chapter 3. Our 
methodology combines the sensitivity of single cell qRT-PCR with the 
multiplexing capability of microarrays and thus circumvents the need for large 
amounts of starting material. The work in this chapter describes the 
optimisation of conditions required to combine these two methods to optimally 
perform transcriptional profiling of mycobacteria-specific T cells (manuscript in 
preparation). 
 
While the Fluidigm platform has been used in a few studies, until recently no 
optimal and quantitative application of this technology had been detailed 
(Flatz et al. 2011). A recent study described protocols to assess the 
quantitative application of this technique with rigorous methodology 
(Dominguez et al. 2013).  We followed the procedure described by 
Dominguez et al., to qualify our selected primer/probe sets. The cut-off for 
efficiency was set at 0.97 for our study, and for linearity, the slope had to lie 
between 3.1 and 3.6. Of the 109 primer/probe sets selected, 96 passed the 
qualification criteria and were selected for further experiments. All inventoried 
Taqman primer/probe sets supplied by Applied Biosystems are reported to 
have an amplification efficiency of 100%.  However, some of these inventoried 
primer/probe sets did not meet our qualification criteria. The reasons for this 
discrepancy remain unclear. We postulate that one of the reasons for this 
discrepancy could be the difference in the qRT-PCR platform used for 
qualifying the primer/probes. While the manufacturer of the primer/probes 
have used multiple different systems to determine their efficiency, at the time 
of submission of this thesis, no efficiency analysis had been done by Applied 
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Biosystems using the Fluidigm platform. As we will study low cell numbers, we 
only used the primer/probe sets that passed our qualification criteria to ensure 
that our experiments yield reliable and accurate transcriptomic measurements. 
 
From previous experience in our lab, we know that the frequencies of 
mycobacteria-specific CD4 T cells detected using MHC class II tetramers are 
low, ranging from 0 to 0.53%. We determined the minimum number of cells 
required for consistent and reliable detection of gene transcripts in sorted CD4 
T cell memory subsets. Further, given the limited availability of PBMC, our 
planned transcriptional analyses of different mycobacteria-specific memory 
CD4 T cell subsets would have to be done on a single vial of PBMC, 
necessitating 4-way FACS. We therefore demonstrated that sorting four 
subsets simultaneously would be as efficient and accurate as sorting each 
subset individually in a 1-way sort. At cell numbers below 10, the 1-way sort 
was more efficient and more transcripts were detectable than using the 4-way 
sorting method. However, for analyses of cell numbers above 10, 4-way 
sorting was as efficient as the 1-way sorting method and we continued with 
the 4-way sorting method.  
It was also important to establish the minimum number of cells required for 
accurate detection of gene transcripts amongst the different memory T cell 
populations. No significant differences in the number of transcripts detected in 
25 and 50 cell sorts were observed for all the sorted memory T cell subsets.  
Previous experiments in our group showed that at least 30 antigen-specific 
tetramer+ naïve-like T cells could consistently be detected when staining 10 
million PBMCs. Transcriptional patterns in different memory subsets can only 
be compared when cell numbers within each subset are kept constant, as the 
likelihood of detecting rare gene transcripts is greater with higher cell numbers. 
By contrast, in very low cell numbers detection may become stochastic. 
Sorting constant cell numbers eliminates this issue. Our results suggested 
that 4-way sorting of 30 cells per subset would yield reliable and consistent 
transcriptomic profiling. 
 
Finally, it was important to determine whether staining with the tetramer would 
influence mRNA transcript levels since the HLA class II tetramer engages the 
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TCR of the T cell. It had been suggested that the tetramer might be able to 
activate stained cells. We assessed if tetramer staining time and temperature 
could affect the transcriptional profile of tetramer stained CD4 T cells. mRNA 
transcript levels did not change when staining at RT for 1 hour; only FAM129A 
and IGF1R were different. The result that only 2 genes were differentially 
expressed after 60 minutes provided confidence that tetramer staining had 
minimal effects on mRNA expression. We acknowledged this difference and 
took it into account in our experiments going forth.  
 
The methods optimised in this chapter were taken further to address the 




Munyaradzi Musvosvi contributed to the qualification of primer/probes sets, as 
well as to the analysis of the qRT-PCR data generated in this chapter.  
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Chapter 5: Phenotypic and transcriptional profile analysis of 
antigen-specific naïve-like CD4 T cells  
 
5.1. Introduction 
Antigen-experienced or memory T cells have been classified into central 
memory and effector/effector memory T cells, based on their functions, such 
as proliferative capacity, cytokine secretion and tissue homing. Several 
groups, including our own, who have studied human immune responses 
against Mycobacterium tuberculosis, have reported an unusual population of 
mycobacteria specific T cells, with phenotypic characteristics of naïve T cells. 
These “naïve-like” (NL) T cells, which express effector cytokines but display a 
naïve CD45RA+CCR7+CD27+ phenotype, have been identified across 
different age groups (Kagina et al. 2009; Caccamo et al. 2006; Tena-Coki et 
al. 2010; Soares et al. 2008). A novel, long-lived T cell population, memory 
stem T (TSCM) cells, has recently been described in animals (Gattinoni et al. 
2009; Y. Zhang et al. 2005) and humans (Gattinoni et al. 2011). These cells, 
which share phenotypic characteristics with CD45RA+CCR7+ naive T cells, 
possess an enhanced capacity for self-renewal and multipotent ability to 
derive TCM, TEM and TE cells (Gattinoni et al. 2011).  
 
In Chapter 3 we described detection of naive-like cells after MVA85A 
vaccination. We now seek to characterise this unusual subset of 
mycobacteria-specific naïve-like CD4 T cells using methodology optimised in 
Chapter 4, which we propose may be an important target for new TB vaccines 






The aim of this chapter was to characterise the naïve-like CD4 T cells 
observed in natural M.tb infection or after vaccination against TB disease. 
 
Specific aims:  
i.) To determine if naïve-like M.tb-specific CD4 T cells share 
phenotypic properties with memory stem T cells. 
ii.) To elucidate and compare the transcriptional profile of these naïve-
like M.tb-specific CD4 T cells with those of naïve, central memory 
and effector memory CD4 T cells. 
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5.3. Materials and Methods 
The work in this chapter was performed by the candidate unless otherwise stated. 
 
5.3.1. Study participants for phenotypic profiling of MVA85A induced NL T cell 
studies 
We retrieved cryopreserved samples from a subset of 12 adolescents 
(TB008) who were enrolled into a completed phase I/IIa trial of MVA85A 
(Scriba et al. 2010). Participants were all vaccinated with BCG at birth, were 
all HIV negative and had no evidence of M.tb infection, as defined by a 
negative ESAT6/CFP10 ELISpot and a TST induration of <15 mm, and all had 
a normal chest X-ray. Participants received a single intra-dermal dose of 
5x107 pfu of MVA85A over the deltoid region of the left arm, and were 
followed up for 1 year (Scriba et al. 2010). None converted to a positive 
ESAT6/CFP10 response during follow-up. 
 
5.3.2. Study participants for natural M.tb infection studies!
We enrolled healthy donors with asymptomatic M.tb infection, under the 
healthy donor protocol approved by the Human research ethics committee of 
UCT (HREC 160/2006). All donors had to be HIV negative, not on any chronic 
medication and not pregnant. The donors had to have a QuantiFERON TB-
GOLD In-tube (QFT) result greater than 0.35IU/mL, to be considered positive 
for M.tb infection. Donors had to give consent for HLA typing. For those who 
met these criteria, blood samples were collected and PBMCs isolated and 
cryopreserved as described in chapter 2, section 2.3.4.  
 
5.3.3. HLA typing 
DNA was extracted from PBMCs and sent to our collaborators, Alex Sette et 
al., at La Jolla Institute of Allergy and Immunology (LIAI) for HLA typing , as 
described in chapter 2, section 2.3.8. 
 
5.3.4. HLA class II tetramer staining 
Ten to 20 million PBMCs from each donor were thawed and stained with 
tetramers as described in chapter 2, section 2.3.12. Briefly, PBMCs were 
thawed and washed. PBMCs were stained with anti-CCR7 antibody for 30 
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minutes at 37°C, and then washed once in 2%FCS/PBS. PBMCs were then 
stained with 2μg/mL of tetramer (Table 32) for 1 hour at room temperature, in 
a total volume of 100μL. PBMCs were then washed and stained with the rest 
of the antibodies listed in section 5.3.5. of this chapter, as previously 
described. 
 
Table 32: HLA class II tetramers used to stain PBMCs for cell sorting of 
CFP10-specific CD4 T cells. 
HLA allele Peptide 
number 
 Protein Peptide Sequence 




DRB1*04:01 15  CFP10(71-85) EISTNIRQAGVQYSR 
 
 
5.3.5. Antibodies  
Fluorescence-conjugated antibody panels utilised for cell sorting experiments 
are shown in Table 33. Antibody panels were optimised as described in 
Chapter 2, section 2.3.13. 
 
Table 33: Panel of fluorescence-conjugated antibodies and dyes used to stain 
cells for the natural M.tb infection T cell phenotype tetramer staining and cell 
sorting studies.  
Marker Clone Manufacturer Fluorochrome Volume Used ( in 
final staining 
volume of 100μl)  
CD3 UCHT1 BD Biosciences Alexa Fluor 700 1μL 
CD4 S3.5 Invitrogen Quantum Dot 605 0.5μL 
CD45RA HI100 eBiosciences PECy7 0.05μL 
CCR7 150503 BD Biosciences PerCP Cy5.5 1.25μL 
CD95 DX2 Biolegend APC 1.25μL 
CD27 M-T271 BD Biosciences FITC 1.25μL 
CD14 (dump) M5E2 Biolegend Brilliant Violet 421 0.5μL 
CD19 (dump) HIB19 BD Biosciences Brilliant Violet 421 0.25μL 
CD8 (dump) RPA-T8 BD Biosciences Brilliant Violet 421 0.5μL 
CD335 (dump) 9E2 Biolegend Brilliant Violet 421 0.5μL 
Live/dead 
(dump) 
 Invitrogen ViViD 0.5μg/mL 
 
The markers CD14, CD19, CD335 and CD8 were all conjugated to the same 
fluorescent molecule to exclude them from analysis, this is known as a dump 
channel. This channel is also used for the live/dead, to exclude dead cells. 
Cells were acquired and sorted on the BD FACS Aria II flow cytometer, as 
described in Chapter 4, section 4.4.3. 
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5.3.6. CD4 T cell sorting 
Thirty cells from each bulk CD4 T cell memory populations, as well as from 
each antigen-specific tetramer+ CD4 T cell subset were sorted directly into 
9µL of Cells-direct solution as described in chapter 4 section 4.3.4. Four 
replicates of each population were sorted, with the exception of naïve-like 
antigen-specific CD4 T cells which were too infrequent; for these we sorted 1 
or 2 replicates of 30 cells. cDNA was synthesised and reverse transcribed as 
described in Chapter 4 section 4.3.4. was followed.  
 
5.3.7. Data analysis (performed in collaboration with M. Musvosvi, SATVI). 
Flow cytometry data was analysed using Flowjo version and Graphpad Prism 
version 6. Analysis of all the qRT-PCR data was performed in R version 3.0.1.  
 
As a first step in performing quality control on our data, samples that did not 
express CD4 or B2M mRNA transcript were excluded from any further 
analysis. Identification of outlier samples, which were excluded from analysis, 
is described in detail in section 5.3.4 in this chapter. The delta Ct was 
calculated by subtracting the B2M Ct value from the Ct of your gene in that 
sample, to normalise the data. We then calculated a delta Et (25-delta Ct) for 
each gene for all the samples. By plotting the data in a reciprocal manner, the 
data is read intuitively, since a high delta Et value represents higher transcript 
numbers and lower delta Et values, lower transcript numbers. All analyses 
going forward in this Chapter were performed and reported using delta Et. We 
then performed a Kruskal-Wallis test to identify significant differences in 
transcript abundance between cell populations. The Benjamini Hochberg 
(Benjamini & Hochberg 1995) test was used to correct for multiple 
comparisons, with a stringent false discovery rate (q<0.05).  
Principal component analysis (PCA) is a statistical procedure of identifying 
patterns in data and expressing the data in a way that highlights similarities 




5.4.1 Study participants for natural M.tb infection studies 
Demographics of the 7 healthy M.tb latently infected donors are shown in 
Table 34.  
 
Table 34: Demographic characteristics of enrolled healthy donors  
  Adults  (n=7) 
 
















5.4.2. Naïve-like Ag85A-specific CD4+ T cells are not memory stem T cells  
Because CD95 was shown to discern TSCM from naïve CD4 T cells, we 
measured CD95 expression by DRB1*03:01-Ag85A(56-75) tetramer+ 
CD45RA+CCR7+CD27+ CD4 T cells in PBMCs from adolescents who 
received MVA85A (Figure 36A), as described in section 5.3.1. We combined 
all data we had from different time points after vaccination because limited 
samples were remaining from the TB008 vaccine trial, and because similar 
frequencies of NL-Ag85A-specific CD4 T cells were observed at different time 
points (Figure 36B). Naïve-like Ag85A-specific CD4 T cells were detected at 
frequencies 10-20 fold lower than Ag85A-specific CD45RA! memory CD4 T 
cells. In turn, CD95+ TSCM comprised at most 5-10% of this naïve-like CD4 T 
cell subset, while being undetectable in some vaccinees (Figure 36B). These 
data suggest that most of the CD45RA+CCR7+CD27+ naive-like memory 
CD4 T cells are not TSCM cells. 
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Figure 36: Phenotypic characterisation of naïve-like Ag85A-specific CD4 T cells. 
(A) Representative flow cytometry plots of CD95 and DRB1*03:01-Ag85A(56-75) 
tetramer staining of CD4 T cells in PBMCs collected 14 days after MVA85A 
vaccination from an individual adolescent. Shown are cells gated on total 
CD45RA+CCR7+CD27+ naïve CD4 T cells (left) and cells gated on total CD45RA–
CCR7–CD27– TE CD4 cells (right). (B) Frequencies of DRB1*03:01-Ag85A(56-75) 
tetramer+ CD4 T cells classified as TSCM cells, naïve-like memory (TNL) CD4 T cells. 
and CD45RA- memory (TM) CD4 T cells in 4 HLA-DRB1*03:01-bearing participants, 
All post-vaccination time points are shown. The values for 3 samples in the TSCM 
were 0, and are therefore not plotted on the logarithmic scale. Horizontal lines 
represent the medians, and error bars the IQR.  
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5.4.3.  Sorting of CD4 T cell populations  
To assess transcriptional profiles of antigen-specific naïve-like CD4 T cells, 
thirty cells from bulk CD4 T cell memory populations, as well as from antigen-
specific tetramer+ CD4 T cell memory populations were sorted. TSCM were too 
infrequent to sort. The gates used for cell sorting are shown in Figure 37, 
below. We sorted the following populations: 
• Bulk naïve CD4 T cells (CD45RA+CCR7+CD27+CD95-) 
• Bulk central memory CD4 T cells (CD45RA-CCR7+CD27+CD95+/-) 
• Bulk effector CD4 T cells (CD45RA-CCR7-CD27+/-CD95+/-) 
• CFP10-specific naïve-like CD4 T cells 
(tetramer+CD45RA+CCR7+CD27+CD95-) 
• CFP10-specific central memory CD4 T cells (tetramer+CD45RA-
CCR7+CD27+CD95+/-) 





Figure 37: Sorting of CD4 T cell memory populations based on cell surface 
phenotypic marker expression. (A) Representative flow cytometry plots depicting 
placement of gates to select and sort the different CD4 T cell bulk memory 
populations (grey background), and the tetramer+ T cell populations (red). The grey 
gate selected the NL tetramer+ CD4 T cell population, the red indicates the gate 
utilised to sort central memory tetramer+ CD4 T cells and the blue gate effector 
tetramer+ CD4 T cells. (B) Flow cytometry plots indicating expression of the surface 
markers CD45RA, CCR7 and CD27. 
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5.4.4. Exclusion/inclusion criteria for samples from qRT-PCR 
It has been shown that many factors contribute to measurement error in qRT-
PCR. Technical errors as well as flaws in the experimental design add to 
variability within the data and have to be taken into account during data 
handling and interpretation. One of the key steps is identification of outlier 
samples, since inclusion of atypical samples may lead to data skewing and 
misinterpretation of results. To identify outliers in our data sets, we used the 
method described by Burns et al (Burns et al. 2005). 
 
Data generated from all experiments were analysed in the following manner. 
Firstly we sought to identify transcripts with consistent expression across all 
the different sorted T cell subsets, to allow identification of outlier data that did 
not follow the expected mRNA expression pattern of these transcripts.  We 
calculated the coefficient of variation (CV) of Ct values for all mRNA 
transcripts in all the samples before normalisation, and selected genes with a 
CV of 15% or less (Figure 38). The genes selected were B2M, TGFB1, CD4, 
LEF1, CD44 and STAT5B. IL4 was not included in this analysis, as no 
expression of IL4 was observed in any of the sorted samples. 
 
Figure 38: Analysis of the coefficient of variation (CV) of mRNA transcripts to allow 
for identification of transcript expression patterns, for outlier exclusion. The bar graph 
represents the CVs for 10 of the 96 most consistently expressed genes. Six of the 10 
genes shown had a CV below 15%. The red horizontal line depicts the cut off. Raw 
Ct values were used to calculate the CV. 
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We followed the method for exclusion of outliers based on RT-PCR data 
published by Burns et al (Burns et al. 2005). We then calculated the geometric 
mean of the Et (40-Ct) values for these 6 genes, for all the samples, and 
plotted on a box and whisker plot  (Figure 39). 
 
Figure 39: Determination of outlier samples. Distribution of the geometric mean of the 
Et (40-Ct) values of the 6 genes with a CV below 15% for all T cell sorts. The bold 
line represents the median and the box around the median represents the 
interquartile range. The whiskers extend out as far as the last data point that lies 
within the range of 1.5 times the IQR. Samples that lay below the lower or above the 
upper whisker were considered outliers, and excluded from the data analysis (n=13) 
(Burns et al. 2005). 
 
The whiskers extend out as far as the last data point that lies within the range, 
of 1.5 times the IQR.  All data points that lay above or below the whiskers 
were considered outliers and excluded from any further analysis (M. J. Burns 
et al. 2005). Outlier samples that were ultimately excluded are depicted in 
green on the heatmap in Figure 40, a supervised hierarchal clustering 
analysis. 
 
Because the samples from each sort were loaded as technical duplicates on 
the Fluidigm chip, Ct values from duplicates were averaged. Where one of the 
duplicates was excluded based on our exclusion/inclusion criteria, the 




Figure 40: Supervised hierarchal clustering of all 96 mRNA transcripts for all CD4 T cell sorts, depicting outlier data samples for ultimate 
exclusion. Samples shown in green were designated as outliers and excluded from further analysis. Samples shown in red were taken further 
for analysis. The histogram shows the distribution of the delta Et values for all the samples. The colour key designates delta Et values. The 6 
genes selected to determine outliers, are highlighted in red. 
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5.4.5. Confirmation of expression of transcripts of surface markers used for T 
cell memory subset sorting. 
To confirm that our cell sorting and transcriptional analysis methodology 
yielded expected results, we quantified mRNA expression of genes encoding 
the memory markers CCR7, CD27 and CD62L (SELL). Many groups have 
also used SELL (L-selectin/CD62L) to differentiate T cell memory subsets 
(Zhang et al. 2013). CCR7, CD27 and SELL mRNA transcript levels were 
higher in bulk naïve and central memory cells than in bulk effector CD4 T cells. 
CFP10-specific naïve-like CD4 T cells expressed similar mRNA transcript 
levels of these genes to bulk naïve T cells (Figure 41A). However, CFP10-
specific naïve-like CD4 T cells expressed significantly higher levels of these 
mRNA transcripts than CFP10-specific central memory and effector subsets 
(Figure 41B). These data confirmed that our sorting methods and 




Figure 41: CCR7, CD27 and SELL (encoding CD62L) mRNA transcript levels in 
sorted CD4 T cell memory populations. (A) mRNA transcript levels of the 
DRB1*04:01-CFP10(71-85) and DRB5*01:01-CFP10(51-65) tetramer+ naïve-like CD4 T 
cells, bulk naïve, central memory and effector memory CD4 T cells. (B) mRNA 
transcript levels of CFP10-specific naïve-like, central memory and effector CD4 T 
cells. Results from seven donors are expressed as delta Et values (normalised to 
B2M) in each sort of 30 cells. P-values were calculated using the Mann-Whitney test, 
after adjusting for multiple comparisons with the Benjamini Hochberg method. P 
values below 0.05 were considered significant. 
 
5.4.6. Naïve-like T cells have a transcriptional profile distinct from truly naïve 
cells. 
We sought to determine if naïve-like M.tb-specific CD4 T cells shared mRNA 
expression profiles with bulk naïve CD4 T cells. We performed unbiased 
clustering analyses of sorted DRB1*04:01-CFP10(71-85) and DRB5*01:01-
CFP10(51-65)  tetramer+ NL cells and bulk naïve, central memory and effector 
CD4 T cells from 7 donors. We identified 50 genes that were differentially 
expressed between the four T cell populations. CFP10-specific NL cells 
clustered together and away from the truly naïve cells. This suggests that the 
NL cells are more similar to each other than to truly naïve, central memory or 
effector CD4 T cells. Naïve-like cells clustered more closely with the bulk 




Figure 42: Unsupervised hierarchal clustering of transcriptional profiles of bulk CD4 T cell populations and antigen specific, DRB1*04:01-
CFP10(71-85) and DRB5*01:01-CFP10(51-65) tetramer+, naïve like CD4 T cells shown as delta Et values. Fifty genes were differentially expressed 
between antigen-specific naïve-like CD4 T cells (grey), bulk central memory CD4 T cells (red), bulk effector CD4 T cells (blue) and truly naïve 
bulk CD4 T cells (green). Heatmap rows = genes, columns = T cell population per sample.  
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To gain further insight into similarities or differences between NL cells and 
bulk naïve, central memory and effector CD4 T cells, we performed another 
unsupervised technique, principal component analysis (PCA). Tetramer 
stained CFP10-specific naïve-like cells did not cluster with the truly naïve CD4 
T and clustered away from bulk CD4 T cell populations (Figure 43). This 
further suggested that the CFP10-specific naïve-like T cells are very different 
to truly naïve T cells. When considering PC1, the CFP10-specific NL cells lie 
between central memory and effector cells, but PC2 suggests that the NL 
cells are also different to all the bulk subsets, although the differences are in 
different genes than those that separate truly naïve from central memory and 
effector CD4 T cells. 
 
Figure 43: Principal component analysis of the tetramer stained CFP10-specific 
naive-like CD4 T cells (grey), bulk central memory CD4 T cells (red), bulk effector 
CD4 T cells (blue) and truly naïve bulk CD4 T cells (green). 
 
In depth analysis of transcriptional profiles of these cell subsets showed 
particular patterns of gene expression. Firstly, seven chemokine receptors 
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were differentially expressed between CFP10-specific naïve-like CD4 T cells 
and bulk CD4 T cell populations. We observed higher expression of CCR4, 
CCR6 and CCR9 by CFP10-specific NL CD4 T cells compared with truly 
naïve bulk CD4 T cells, while a subset of CFP10-specific NL CD4 T cells 
expressed CCR2, CCR5 and CXCR6. The chemokine receptors CCR2 and 
CCR5 where not expressed by bulk naïve CD4 T cells. CCR7 was expressed 
at a lower level in CFP10-specific naïve-like cells compared with truly naïve 
bulk CD4 T cells, whereas CXCR6 expression levels were not different 
(Figure 44).  CFP10-specific NL CD4 T cells expressed significantly higher 
levels of CCR6 and CCR9 compared to bulk central memory CD4 T cells, 
lower levels of CXCR6, and similar levels of the other chemokine receptors.   
 
Chemokine receptor mRNA expression by CFP10-specific NL CD4 T cells 
was also distinct from effector CD4 T cells. NL cells expressed higher levels 
of CCR6; CCR7 and CCR9 transcripts compared with bulk effector CD4 T 
cells, but significantly lower levels of CCR2, CCR5 and CXCR6 transcripts 
(Figure 44). Interestingly, CCR4, a receptor for the chemokines MIP-1 and 
RANTES, was not significantly different between CFP10-specific NL cells and 




Figure 44: Chemokine receptor mRNA transcript levels in M.tb-specific NL and bulk 
memory CD4 T cell populations expressed as delta Et values. Each dot represents a 
sort of 30 cells from 7 LTBI volunteers. Results from seven donors are expressed as 
delta Et values (normalised to B2M) in each sort of 30 cells. P-values were 
calculated with the Mann-Whitney test, after correcting for multiple comparisons with 
the Benjamini Hochberg method with an FDR of 0.05 (q-value). P-values below 0.05 
were considered significant. 
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Eight mRNA transcripts encoding cytokine and cytokine receptors were 
differentially expressed between CFP10-specific NL CD4 T cells and bulk 
CD4 T cell populations. The mRNA transcript levels of IFN-γ, TNF-α, CCL5 
(RANTES), CXCL10 (IP-10) and IL2RB were significantly higher in CFP10-
specific NL CD4 T cells compared with truly naïve bulk CD4 T cells. However, 
LTB (TNF-C), IL2RG and IL7R were expressed at significantly lower levels in 
CFP10-specific naïve-like CD4 T cells (Figure 45). 
 
CFP10-specific NL CD4 T cells appeared to be adapted for effector functions, 
since mRNA transcript levels of IFN-γ, CCL5 and CXCL10 were higher 
compared with bulk central memory CD4 T cells. LTB (TNFC) and IL2RG 
were significantly lower in CFP10-specific naïve-like CD4 T cells. mRNA 
transcript levels of TNF-α, IL2RB and IL7R were not different between these 
two populations (Figure 45). 
 
The apparent effector characteristics of NL cells were further supported by the 
finding that mRNA transcript levels of IFN-γ, CCL5 and CXCL10 were not 
different to those expressed by effector cells. LTB and IL2RG did not follow 
this pattern; their mRNA levels were significantly lower in CFP10-specific NL 







Figure 45: Cytokine and cytokine receptor mRNA transcript levels in M.tb-specific NL 
and bulk memory CD4 T cell populations expressed as delta Et values. Each dot 
represents a sort of 30 cells from 7 LTBI volunteers. Results from seven donors are 
expressed as delta Et values (normalised to B2M) in each sort of 30 cells.  P-values 
were calculated with the Mann-Whitney test, after correcting for multiple comparisons 
with the Benjamini Hochberg method with an FDR of 0.05 (q-value). P-values below 
0.05 were considered significant. 
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The finding that CFP10-specific NL CD4 T cells expressed effector cytokines 
prompted us to investigate other effector molecules. The effector molecules 
Granulysin (GNLY), Granzyme A (GZMA) and B (GZMB), and Perforin 
(PRF1) mRNA transcript expression were higher in NL compared to bulk 
naïve and central memory CD4 T cells, but expressed at similar levels as 
effector cells. Granzyme K (GZMK) was the only molecule that was different 
between NL CD4 T cells and effector cells (Figure 46).  
 
 
Figure 46: Effector molecule mRNA transcript levels in M.tb-specific NL and bulk 
memory CD4 T cell populations expressed as delta Et values. Each dot represents a 
sort of 30 cells from 7 LTBI volunteers. Results from seven donors are expressed as 
delta Et values (normalised to B2M) in each sort of 30 cells. P-values were 
calculated with the Mann-Whitney test, after correcting for multiple comparisons with 
the Benjamini Hochberg method with an FDR of 0.05 (q-value). P-values below 0.05 
were considered significant. 
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Other mRNA transcripts levels (median and IQR) that were differentially 
expressed between the CD4 T cell subsets are listed in Table 35. 
 
Table 35. Differentially expressed gene transcripts in antigen-specific naïve-
like CD4 T cells and bulk CD4 T cell populations. Shown are the median and 
IQR for each population. Transcript levels more abundant in the CFP10-
specific naïve-like population compared with the other populations are 
highlighted in red. Transcript level less abundant in CFP10-specific naïve-like 
population than bulk T cell populations are highlighted in green. P-values 
were calculated with the Mann-Whitney test, after correcting for multiple 
comparisons with the Benjamini Hochberg method with an FDR of 0.05 (q-
value). P-values below 0.05 were considered significant. 
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5.3.7. CFP10-specific CD4 T cell transcriptional profiles 
Our finding that CFP10-specific naïve-like cells shared transcript 
characteristics with bulk effector cells was surprising. We also wanted to 
compare the transcriptional profile of CFP-10 specific NL CD4 T cell subsets 
with CFP10-specific central memory and effector CD4 T cells detected by 
HLA class II tetramer staining. We identified 22 genes that were differentially 
expressed between the three CFP10-specific T cell populations (Figure 47). 
Unsupervised hierarchical clustering, performed on expression data of these 
22 genes showed that these antigen-specific subsets sorted according to 
surface CCR7, CD27 and CD45RA marker expression, did not fall into 
discrete clusters  (Figure 47). 
 
 
Figure 47: Unsupervised hierarchal clustering of the transcriptional profile of CFP10-
specific, DRB1*04:01-CFP10(71-85) and DRB5*01:01-CFP10(51-65) tetramer+, naïve like, 
central memory and effector CD4 T cell populations shown as delta Et values. 
Twenty-two genes were differentially expressed between CFP10-specific naïve-like 
CD4 T cells (grey), central memory CD4 T cells (red) and effector CD4 T cells (blue). 
Heatmap rows = genes and columns = T cell population per sample.  
 
Some central memory cells clustered with NL CD4 T cells while others 
clustered with the effector CD4 T cell population. This suggested substantial 
heterogeneity within CFP10-specific CD4 T cells, even when cells are sub-
setted according to commonly used memory markers.  
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To investigate this further, we performed PCA. The PC1 and PC2 parameters 
defined in the PCA of the NL and bulk populations were applied to the 
analysis of the CFP10-specific NL, central memory and effector CD4 T cell 
populations. We reasoned that this analysis would allow interpretation of 
transcriptional signatures of CFP10-specific cells in relation to the bulk T cell 
populations. The CFP10-specific naïve-like CD4 T cell cluster overlapped 
somewhat with the CFP10-specific central memory population. CFP10-
specific central memory cells also overlapped with the CFP10-specific effector 
population (Figure 48). 
 
The CFP10-specific naïve-like and central memory cells had low PC2 values, 
which constituted the main factors differentiating them from bulk populations, 






Figure 48: Principal component analysis of the CFP10-specific naive-like, CFP10-
specific central memory and effector populations. Shown are the CFP-10 -specific 
naïve-like CD4 T cells (grey), the CFP-10 specific central memory CD4 T cells and 
the CFP-10 specific effector CD4 T cells (blue) overlaid over the bulk CD4 T cell 
populations, shown as shaded ellipses in the background. 
 
To gain a better understanding of how NL cells differed from central memory 
and effector cells, within the M.tb-specific compartment, we compared gene 
expression levels of cell trafficking molecules. Six chemokine receptors were 
significantly different between the CFP10-specific T cell populations. We 
observed no differences in expression CCR4, CCR5, CCR6 and CCR9 levels 
in CFP10-specific NL cells and central memory T cells, while a subset of NL 
cells did not express CCR5. However, the expression of these markers in NL 
cells was higher than in effector cells. CCR2 levels were higher in effector T 
cells when compared to NL cells, and only a subset of NL cells expressed 
detectable CCR2 mRNA. Transcript levels of CCR7, a marker for lymph node 
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trafficking, were higher in NL CD4 T cells when compared with central 
memory and effector CD4 T cells (Figure 49). 
 
This gene expression pattern of the cell trafficking molecules suggested that 
in CFP10-specific NL cells shared a similar expression profile with CFP10-




Figure 49: Chemokine receptor mRNA transcript levels in M.tb-specific naïve-like, 
central memory and effector CD4 T cell populations expressed as delta Et values. 
Each dot represents a sort of 30 cells from 7 LTBI volunteers. Results from seven 
donors are expressed as delta Et values (normalised to B2M) in each tetramer sort of 
30 cells. P-values were calculated with the Mann-Whitney test, after correcting for 
multiple comparisons with the Benjamini Hochberg method with an FDR of 0.05 (q-
value). P-values below 0.05 were considered significant. 
 
 
Furthermore, we did not observe any significant differences in the expression 
of transcription factor mRNA levels between the CFP10-specific naïve-like 
CD4 T cells and CFP10-specific central memory CD4 T cells (Figure 50). 
GATA3 and RORC transcript levels were higher in CFP10-specific effector 
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CD4 T cells, compared with CFP10-specific naïve-like CD4 T cells, while 
LEF1 was higher in CFP10-specific naïve-like CD4 T cells.  
 
GATA3 and RORC transcript levels were significantly higher in CFP10-
specific effector CD4 T cells, compared with CFP10-specific central memory 
CD4 T cells, while LEF1 was expressed at similar levels between the two 
populations (Figure 50). This data further suggested that CFP10-specific NL 
cells appear to display a transcriptional profile similar to CFP10-specific 
central memory cells rather than effector cells. 
 
 
Figure 50: Transcription factor mRNA transcript levels in M.tb-specific NL, central 
memory and effector CD4 T cell populations expressed as delta Et values. Each dot 
represents a sort of 30 cells from 7 LTBI volunteers. Results from seven donors are 
expressed as delta Et values (normalised to B2M) in each tetramer sort of 30 cells. 
P-values were calculated with the Mann-Whitney test, after correcting for multiple 
comparisons with the Benjamini Hochberg method with an FDR of 0.05 (q-value). P-
values below 0.05 were considered significant. 
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As the data suggested that CFP10-specific NL cells shared a transcriptional 
profile similar to that of central memory cells rather than effector cells, 
prompted us to investigate the expression of effector molecules and effector 
cytokines. The only effector molecule for which mRNA transcriptional levels 
were different between the CFP10-specific T cell populations was Granzyme 
K (GZMK). GZMK was expressed at significantly higher levels by antigen-
specific effector and central memory CD4 T cells compared with naïve-like 
CD4 T cells, many of which did not express detectable levels of GZMK. 
However, transcript levels of GZMK were not significantly different between 
CFP10-specific effector and central memory CD4 T cells (Figure 51). 
 
  
Figure 51: Granzyme K mRNA transcript levels in M.tb-specific NL, central memory 
and effector CD4 T cell populations expressed as delta Et values. Each dot 
represents a sort of 30 cells from 7 LTBI volunteers. Results from seven donors are 
expressed as delta Et values (normalised to B2M) in each tetramer sort of 30 cells. 
P-values were calculated with the Mann-Whitney test, after correcting for multiple 
comparisons with the Benjamini Hochberg method with an FDR of 0.05 (q-value). P-
values below 0.05 were considered significant. 
 
CFP10-specific naïve-like cells expressed significantly lower levels of the 
cytokine receptor, IL7R, than CFP10-specific central memory and effector 
CD4 T cell populations, while the latter expressed significantly higher levels of 
lL7R transcript, compared with the central memory population (Figure 52). 
 
IL12RB2 transcript levels were not different between CFP10-specific NL and 
CM CD4 T cell populations, and virtually no expression was observed in these 
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two populations. However, it was expressed at significantly higher levels in 
CFP10-specific effector CD4 T cells. 
 
 
Figure 52: Cytokine receptor mRNA transcript levels in M.tb-specific NL, central 
memory and effector CD4 T cell populations expressed as delta Et values. Each dot 
represents a sort of 30 cells from 7 LTBI volunteers. Results from seven donors are 
expressed as delta Et values (normalised to B2M) in each tetramer sort of 30 cells. 
P-values were calculated with the Mann-Whitney test, after correcting for multiple 
comparisons with the Benjamini Hochberg method with an FDR of 0.05 (q-value). P-
values below 0.05 were considered significant. 
 
Differences in mRNA transcript levels of other genes are shown in Table 36. 
Significant differences between CFP10-specific memory subsets were 
observed in genes involved in T cell activation and cell trafficking, as well as 
genes that were selected based on the Gattinoni et al., and Appay et al., gene 
lists. The data in Table 36, further suggests that CFP10-specific naïve-like 
CD4 T cells share a transcriptional profile with CFP10-specific central memory 
cells.  
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Table 36: Differentially expressed gene transcript levels in CFP10-specific 
naïve-like CD4 T cells compared with CFP10-specific central memory and 
effector CD4 T cells. Shown are the median and IQR for each population. 
Transcript levels more abundant in the CFP10-specific naïve-like population 
compared with the other populations are highlighted in red. Transcript level 
less abundant in CFP10-specific naïve-like population than other CFP10-
specific T cell populations are highlighted in green. Values shown in red, are 
significant differences observed between CFP10-specific effector and central 
memory T cells. P-values were calculated with the Mann-Whitney test, after 
correcting for multiple comparisons with the Benjamini Hochberg method with 
an FDR of 0.05 (q-value). P-values below 0.05 were considered significant. 
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5.5. Discussion 
In this chapter we characterised the transcriptional profile of CFP10-specific 
naïve-like CD4 T cells in natural M.tb infection. We hypothesised that CFP10-
specific naïve-like CD4 T cells had a transcriptional profile distinct from truly 
naive, bulk central memory, bulk effector as well as the CFP10-specific 
central memory and effector CD4 T cell populations.  We have showed that 
CFP10-specific naïve-like CD4 T cells: i) had a transcriptional profile distinct 
from truly naïve bulk CD4 T cells, ii) displayed a functional and trafficking 
molecule patterns similar to that of bulk effector CD4 T cells and iii) had a 
transcriptional profile similar to that of the CFP10-specific central memory T 
cell. 
 
We have shown that Ag85A-specific naïve-like CD4+ T cells were mostly 
CD95-negative, a hallmark marker for TSCM along with CCR7, CD27 and 
CD45RA expression, suggesting that these mycobacteria-specific cells are 
not TSCM cells (Gattinoni et al. 2011). Our experiments to determine if NL cells 
were TSCM cells were performed on limited numbers of cryopreserved PBMCs 
from MVA85A-vaccinated subjects. Since TSCM cells typically occur at very 
low frequencies in peripheral blood (Gattinoni et al. 2011), we cannot 
definitively rule out whether these cells exist in the mycobacteria-specific 
repertoire. By contrast, Ag85A-specific naïve-like CD4+ T cells were 
surprisingly abundant.  
 
The combination of T cell sorting by flow cytometry and multiplexed 
microfluidic qRT-PCR (Fluidigm) allows thorough interrogation of 
transcriptional profiles of rare cell subsets (Dominguez et al. 2013). We 
developed methodology to combine tetramer-stained cell sorting and 
microfluidic qRT-PCR, as well as data analysis and quality control measures 
to explore the transcriptional profile of M.tb-specific NL CD4 T cells. Patterns 
of mRNA expression of the phenotypic surface markers CCR7, SELL (CD62L) 
and CD27 confirmed that our methodology and analysis pipeline yielded 
expected results. We could not measure CD45RA transcriptional levels 
because this is an isoform of the CD45 protein. 
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We aimed to determine if CFP10-specific naïve-like CD4 T cells were distinct 
from truly naïve bulk CD4 T cells. We identified 50 genes that were 
differentially expressed between naïve and memory T cell populations. These 
genes included chemokine receptors, cytokines and cytokine receptors, 
inhibitory molecules, kinases involved in signaling, a co-stimulatory molecule, 
molecules involved in tissue homing, effector molecules and transcription 
factors. Nine of the 13 genes selected based on literature published by 
Gattinoni (Gattinoni et al. 2011) and Appay (Appay et al. 2007) were 
differentially expressed in these populations and mostly at higher levels in 
CFP10-specific naïve like CD4 T cells than in other bulk T cell populations.  
 
Several lines of evidence suggest that NL cells are not truly naïve cells. 
Unsupervised hierarchal clustering of the T cell populations showed that 
CFP10-specific CD4 T cells did not cluster with naïve bulk CD4 T cells, but 
rather clustered with bulk effector CD4 T cells. Principal component analysis 
confirmed this clustering behaviour, showing CFP10-specific CD4 T cells 
clustering alone, but within close proximity to bulk effector CD4 T cells. 
CFP10-specific naïve-like CD4 T cells displayed a transcriptional profile that 
resembled that of bulk effector CD4 T cells, expressing effector molecules 
and cytokines, suggesting that they may have effector function. High 
expression levels of chemokine receptors also suggest that CFP10-specific 
naïve-like CD4 T cells may have ability to rapidly traffic to tissues and play a 
role in inflammatory processes during M.tb infection. The high expression 
levels of cytokines and effector molecules observed further support this 
possible role in inflammation.  
 
Analysis of CFP10-specific naïve-like, central memory and effector 
populations identified 22 genes that were differentially expressed between the 
3 populations. These genes included chemokine receptors, transcription 
factors, an effector molecule, a co-stimulatory molecule, homing markers, a 
cytokine receptor, a kinase receptor and 5 of the genes selected based on the 
literature published by Gattinoni (Gattinoni et al. 2011), and Appay (Appay et 
al. 2007). Unsupervised hierarchal clustering showed that CFP10-specific 
naïve-like CD4 T cells clustered with CFP10-specific central memory CD4 T 
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cells rather than with CFP10-specific effector T cells.  Principal component 
analysis of the CFP10-specific population showed all three populations 
clustering closely together and with bulk effector CD4 T cells. CFP10-specific 
naïve-like CD4 T cells had transcriptional profiles similar to both CFP10-
specific central memory and effector memory cells. Interestingly, CFP10-
specific central memory cells also clustered with the bulk effector T cell 
population rather than with bulk central memory T cells. The amount of 
overlap observed in these memory subsets suggests a substantial degree of 
heterogeneity.   
 
Closer analysis of the CFP10-specific CD4 T cell populations showed 
heterogeneity within these populations. Unlike mRNA levels of CCR7, CD27 
and SELL (CD62L), which were homogeneously expressed in all cells of a 
given subset, levels of other transcripts, such as chemokine receptors, were 
very heterogeneous across multiple sorts of the same cell subset. This 
heterogeneity may be addressed by performing single cell sorting and 
transcriptional profiling in future. 
 
In addition, to delineate this naïve-like memory T cell population further, 
spectratyping of the complementary DNA (cDNA) across the TCR third 
complementary determining region (CDR3) region could generate information 
about the relative frequencies of different CDR3 length products. As various 
T-cell clones have different sequences or lengths of CDR3, analysis of the 
CDR3 could be used to determine the overall TCR repertoire diversity of this 
population (Ciupe et al. 2013; Pannetier et al. 1995). Furthermore, using an 
antigen-specific T cell control population, such as cells detected by CMV-
specific HLA class II tetramers would be important to interpret transcriptional 
profiles and in determining if our results reflect attributes of antigen-specific 
cells or M.tb-specific patterns. 
 
Further experiments are required to understand the functional properties of 
M.tb-specific naïve-like CD4 T cells. The observation that CFP10-specific NL 
cells express mRNAs encoding cytotoxic molecules and pro-inflammatory 
cytokines, similar to that of effector cells, suggest that these cells may have 
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effector functions. Future experiments should explore intracellular expression 
of these molecules by flow cytometry upon cell stimulation. Chemokine 
receptor cell surface expression should also be measured by flow cytometry. 
To determine how differentiated these cells really are, another option may be 
measurement of T cell telomere lengths, as highly differentiated cells have 
short telomeres when compared with naïve cells, or cells that have only 










Chapter 6. General conclusion 
 
6.1. Conclusion 
The objective of this thesis was to characterise M.tb-specific CD4 T cells after 
MVA85A vaccination and in natural, asymptomatic M.tb infection. Because it 
is not known exactly which CD4 T cell characteristics are important for 
protection, we aimed to assess T cell memory phenotype, homing marker 
expression, effector functions and proliferative capacity. We postulated that 
long-lived memory CD4 T cells with high proliferative capacity and the ability 
to home to the site of infection upon re-exposure to antigen may protect 
against TB, and that TB vaccines should aim to induce this phenotype of T 
cells. We chose to use HLA class II tetramers to avoid or minimise activation 
of lymphocytes and obtain a snap shot of the direct ex vivo phenotype of CD4 
T cells. To be able to achieve this aim, we first generated tetramer reagents. 
Using data from previously completed MVA85A vaccine trials, as well as 
healthy LTBI individuals, we were able to identify commonly recognised 
epitopes in the M.tb proteins, Ag85A, ESAT6 and CFP10 and determine their 
HLA restriction. The epitopes defined in these three antigens were then used 
to synthesise multiple tetramers of which 3 were selected for further studies in 
this thesis. Given the paucity of published HLA class II tetramers with highly 
specific T cell binding properties, this work should be of value to the field of 
mycobacterial immunology. 
 
Armed with these new detection tools, we identified and characterised Ag85A-
specific CD4 T cells after MVA85A vaccination. We showed that early after 
vaccination cells predominantly displayed an effector phenotype, that waned, 
and T cells reverted to either a naïve-like or central memory phenotype. The 
observed higher proportion of Ag85A-specific CD45RA-CCR7+ CD4 TCM cells 
rather than TE persisting up to one year after MVA85A vaccination, contradicts 
our previous finding in adolescents, which showed that antigen-specific T cells 
predominantly displayed a TE phenotype up to 2 months post-vaccination 
(Scriba et al. 2010). We recently completed a long-term follow-up study of 
MVA85A vaccinees (involving a cohort of adults, adolescents, children and 
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infants) and reported highly durable Ag85A-specific memory CD4 T cell 
responses 3-5 years post vaccination. We observed Ag85A-specific CD4 T 
cells with mixed central and effector memory phenotypes in these individuals 
(Tameris et al. 2014). These results highlight discordance between memory 
phenotypes and durability of antigen-specific immune responses, which 
require investigation. 
 
Another hypothesis is that induction of antigen-specific effector memory T 
cells that can readily traffic to the site of infection may afford immediate 
protection against M.tb by clearing the pathogen before it is able to replicate 
and establish persistent infection and disease (Hansen et al. 2011). This 
priming strategy may be effective against simian immunodeficiency virus (SIV) 
infection in non-human primates. Picker et al., have shown that use of a CMV-
based vaccine vector induced a persistent population of TEM that successfully 
controlled highly pathogenic SIV infection early after mucosal challenge 
(Hansen et al. 2011). This strategy may also have application in the field of TB 
vaccines. However, given the recent data that MVA85A-specific cells 
predominantly displayed an effector memory phenotype in infants (Tameris et 
al. 2014), and yet MVA85A did not provide evidence of efficacy against TB 
disease or M.tb infection, argues against this. There are many other possible 
reasons underlying the observed lack of efficacy in infants that may include 
route and/or age of administration, dose of the vaccine, the high rate of M.tb 
transmission in the trial population, or the magnitude, function and/or 
phenotype of the induced immune response. More research is required to 
understand T cell memory in mycobacterial infection. 
 
We showed that CLA expression by MVA85A-specific effector CD4 T cells 
was not mutually exclusive to expression of other T cell homing markers, such 
as !4, "7 or "1. This finding suggests that T cells primed after intradermal 
vaccination may not be confined to the skin since these cells expressed 
receptors for homing to other sites of inflammation as it was previously 
suggested (Kaufmann & McMichael 2005; Kantele et al. 1999; Walzl et al. 
2011; D. J. Campbell & Butcher 2002; Walrath & Silver 2010; J. A. Burns et 
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al. 2001). Regardless, our results suggest that CD4 T cell expression of 
homing markers may be more complex than previously acknowledged. 
Importantly, boosting immune responses in the skin, rather than in the 
respiratory tract, may lead to weaker and delayed T cell responses in the lung, 
following challenge with M.tb. Mice vaccinated intra-nasally with adenovirus 
expressing Ag85A (Ad85A), after a BCG subcutaneous prime, had lower 
mycobacterial burdens in their lungs, than mice given an intradermal boost 
with Ad85A, or mice vaccinated with BCG only (Forbes et al. 2008). This 
reduced bacterial burden was attributed to higher peripheral/splenic/lung 
antigen-specific T cell responses and lung-resident T cell responses prior to 
infection in intra-nasally vaccinated mice, compared with intra-dermally Ad35 
boosted mice (Forbes et al. 2008; Santosuosso et al. 2005). Collectively, 
these observations suggest that a vaccination route that mimics the natural 
entry portal of the pathogen may be more efficacious by inducing a tissue-
resident population of primed T cells.  
 
A limitation of our study of MVA85A induced CD4 T cells was that we could 
only use a single HLA class II tetramer to identify Ag85A-specific CD4 T cells.  
We cannot rule out that functional and phenotypic characteristics of CD4 T 
cells specific for other Ag85A epitopes may be different to the epitope we 
studied. Despite this, our work highlights the utility of HLA class II tetramers in 
detecting and characterising vaccine induced responses and how these 
powerful tools can be used to complement other functional assays. This work 
therefore adds to the understanding of vaccine induced T cell immunity. 
 
We observed a curious population of naïve-like antigen-specific CD4 T cells in 
MVA85A vaccinees, as described in Chapter 3. To gain a better 
understanding of this novel cell subset, we performed transcriptional profiling 
of sorted bulk and antigen-specific CD4 T cell populations. Interrogation of the 
gene expression profiles of M.tb-specific naïve-like CD4 T cells showed that 
CFP10-specific naïve-like CD4 T cells were distinct from truly naïve cells and 
that they were most similar to bulk effector cells. These CFP10-specific naïve-
like T cells expressed high levels of transcripts encoding chemokine receptors, 
cytotoxic molecules, as well as effector cytokines, further supporting their 
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close resemblance to effector cells. While previous studies had observed 
expression of effector cytokines upon stimulation of these cells (Kagina et al. 
2009; Caccamo et al. 2006; Tena-Coki et al. 2010; Soares et al. 2008), we 
were surprised to observe high mRNA expression levels of effector molecules 
directly ex vivo.  
While these observations require confirmation on a protein expression level, 
they raise interesting questions regarding functional potential of naïve-like 
cells and the regulation of these functions. The curious mRNA transcript 
patterns of naïve-like CD4 T cells could be due to programmed epigenetic 
modifications of DNA by either methylation or histone modifications, that 
modulate accessibility of genes for transcription (Youngblood et al. 2013). 
These mechanisms have recently been shown to modulate transcriptional 
activation of effector molecules through access restriction to chromatin by 
transcription factors and polymerases (Youngblood et al. 2013). This 
mechanism allows rapid recall of effector functions by having a pre-poised 
accessibility to effector genes and may explain why high transcript levels are 
present in unstimulated cells. It is tempting to speculate that the high levels of 
effector molecule transcript expression in naïve-like cells may be in line with 
this mechanism. However, such transcriptional control does not always 
translate into protein as many other post-transcriptional mechanisms are also 
involved (Youngblood et al. 2013). Differential protein expression of CCR7 
and CD62L on effector memory and central memory cells has also been 
attributed to transcriptional regulation of gene products from a subset of 
genes known as on-off-on genes. On-off-on genes are expressed in naïve 
cells and repressed in antigen-experienced cells. Their expression is 
postulated to be due to programming and regulating accessibility to the genes 
chromatin (Youngblood et al. 2013). Our analysis of CFP10-specific naïve-like, 
central memory and effector CD4 T cells showed that all three CFP10-specific 
populations clustered more closely with bulk effector cells, rather than with the 
respective bulk populations. This suggests that M.tb-specific CD4 T cells, 
irrespective of their surface expression patterns of CCR7, CD27 and CD45RA, 
appear similarly differentiated to bulk CD45RA-CCR7- effector T cells. The 
observed effector memory-like characteristics of M.tb-specific CD4 T cells 
may be due to constant re-exposure of the cells to M.tb, which is consistent 
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with the QFT-positive status of these individuals, suggesting persistent M.tb 
infection. Further, transmission rates of M.tb are extremely high in this 
endemic setting in South Africa. Although less likely than persisting M.tb 
infection driving effector responses, our observations may also reflect 
repeated re-exposure to M.tb (Verver et al. 2004). Finally, it is also possible 
that the highly differentiated M.tb-specific CD4 T cells may simply be a unique 
property of M.tb-specific cells. An important addition to future experiments 
would be inclusion of control tetramers bearing epitopes from other infections 
agents, such as influenza, EBV or CMV. Phenotypic and transcriptomic 
characteristics of CD4 T cells specific for cleared and chronic infections may 
aid interpretation of our results. Since the bulk memory CD4 T cell profile is a 
mixture of cells specific to other cleared and persistent infections, this subset 
is not an ideal comparator for our analyses. 
 
Our analyses of gene expression profiles have been highly informative and 
generated a number of hypotheses about the potential roles and functions of 
M.tb-specific NL T cells. With this in mind, we have proposed a number of 
further experiments to delineate the possible functions of these cells, as 
described in Chapter 5, section 5.5.  
 
Possibly the greatest caveat of the work described in this thesis is that the use 
of tetramers to study T cell populations restricts the breadth of antigen-
specific responses and HLA-allele coverage, and therefore only reflects a 
sub-population of the entire response to the antigen. When possible, it is 
recommended that multiple tetramers bearing multiple epitopes from the 
same antigen be utilised together, to gain a better reflection of a broader 
antigen-specific response. As recently shown, highly multiplexed HLA class II 
tetramer staining can be combined with mass cytometry (CyTOF) to achieve 
in-depth protein expression analysis on a single cell level (Newell et al. 2013). 
Since CyToF allows simultaneous analysis of up to 40 parameters per cell, 
this technology has enormous potential for exploring the complexity of 
immunity (Newell et al. 2012). This technology has been recently 




Finally, our work suggests that defining memory subsets using well-
established memory markers such as CD45RA, CCR7 to pigeon-hole M.tb-
specific CD4 T cells may not be appropriate, and does not reflect their 
functionality, as inferred from mRNA expression patterns and functional 
assays. Even in CD8 T cells, which have been the basis of most memory 
phenotype and functionality models, it is emerging that phenotype delineation 
using these markers does not always reflect the functions previously thought 
to correspond with memory phenotype (Appay et al. 2008). This phenotype-
based model, developed mainly while studying virus-specific CD8 T cells, 
appears to be even less applicable to CD4 T cells. While protein validation is 
required to back up our transcriptomic results, new markers, or new 
combinations of markers, are needed to meaningfully define CD4 T cell 
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